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Abstract 
Introduction. The ability to track cells in living organisms with sensitivity, accuracy and 
high spatial resolution would revolutionize the way we study disease. Reporter genes 
are valuable tools as they encode detectible products, allowing for “reporting” of viable 
cells that express them. Previously, a gene encoding Organic anion-transporting 
polypeptide 1a1 (Oatp1a1) was established as a magnetic resonance imaging (MRI) 
reporter based on its ability to take up the paramagnetic contrast agent gadolinium 
ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA). Our objective was 
to assess, characterize and further develop this system for whole-body tracking of cells 
in vivo. Methods. Cancer cells were engineered to synthetically express Oatp1a1, or 
Oatp1b3, a closely related human transporter protein. In our first study, T1-weighted 
images of Oatp1a1-expressing primary tumours in preclinical animals were acquired 
before and after administration of 0.1-mmol/kg Gd-EOB-DTPA at 3-Tesla. At endpoint, 
heterogenous contrast enhancement patterns within the primary tumour architecture 
were compared to whole-tumour fluorescent histology. In the next study, T1-weighted 
images of Oatp1b3-expressing primary tumours, and their spontaneous metastases to 
the lymph nodes and lungs, were acquired before and after administration of 1-mmol/kg 
Gd-EOB-DTPA at 3-Tesla. In the final study, the feasibility of Oatp1b3 as a 
photoacoustic reporter gene was assessed by acquiring full-spectrum near infrared 
photoacoustic images of primary tumours in preclinical animals before and after 
administration of 8-mg/kg indocyanine green. Results. We were able to demonstrate 
the feasibility of imaging cancer cells with Oatp1a1 at 3-Tesla and 0.1 mmol/kg Gd-
EOB-DTPA. Importantly, as primary tumours grew over time, heterogeneous contrast 
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enhancement patterns that emerged near-endpoint strongly correlated to viable cell 
distributions on whole-tumour histology. Oatp1b3 was also shown to operate as an MRI 
reporter gene at 3-Tesla, based on the same principle as Oatp1a1. Impressively, single 
lymph node metastases and the formation of micro-metastases in the lungs of 
preclinical animals were detected with Oatp1b3-MRI. Finally, we also demonstrated the 
ability of Oatp1b3 to operate as a photoacoustic reporter gene based on its ability to 
take up indocyanine green. Conclusion. The Oatp1 reporter gene system is a versatile 
imaging tool for spatiotemporal tracking of engineered cells in vivo with high sensitivity, 
high resolution, and 3-dimensional spatial information. 
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Summary for Lay Audience 
The ability to effectively detect a specific cell type, such as cancer cells, in the context of 
a larger, living biological organism would be useful for the study of medicine and, more 
broadly, for the life sciences. Though methods do exist to track cells non-invasively, the 
imaging is limited to superficial surfaces and/or sub-optimal resolution. Our work here 
tackles cellular imaging by focusing on magnetic resonance imaging (MRI) as a 
platform, allowing us to overcome several of these limitations. Unlike other imaging 
methods, MRI scanners produce highly detailed anatomical images and do not lose 
signal with increasing tissue depth. To image specific cells on MRI, we have developed 
a nanotechnology in the form of a protein that embeds itself on the surface of the cells 
we are interested in studying, and allows those cells to “pack” themselves with an MR 
imaging dye. Meanwhile, other cells do not have this capability. We test the 
effectiveness of this system for tracking cancer cells in preclinical animal models, and 
remarkably, it has allowed us to visualize the changing architecture of a primary tumour 
over time, as well as track the spread of cancer cells from the primary tumour to other 
parts of the body with high sensitivity and high resolution. This molecular technology 
can, in principle, be applied to any cell type, and paves the path for imaging various 
biological processes to better understand their mechanisms and develop new 
treatments for disease.  
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“Through countless generations, from the very beginning, the social 
subservience of women resulted naturally in the partial atrophy or at least 
the hereditary suspension of mental qualities which we now know the 
female sex to be endowed with no less than men… It is not in the shallow 
physical imitation of men that women will assert first their equality and later 
their superiority, but in the awakening of the intellect of women… The 
female mind has demonstrated a capacity for all the mental acquirements 
and achievements of men, and as generations ensue that capacity will be 
expanded; the average woman will be as well educated as the average 
man, and then better educated, for the dormant faculties of her brain will be 
stimulated to an activity that will be all the more intense and powerful 
because of centuries of repose.  Woman will ignore precedent and startle 
civilization with her progress.” 
 
- Nikola Tesla  
When Woman Is Boss 
January 30, 1926 
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CHAPTER 1 Introduction  
The overarching goal of this thesis is to develop the organic anion-transporting 
polypeptide 1 reporter gene system for non-invasive, longitudinal tracking of viable 
cancer cells in preclinical animal models. This introductory chapter provides an 
overview on known cancer mechanisms, clinical imaging methods, and preclinical 
approaches for studying cancer. Additionally, an overview of current methods in 
molecular imaging and in-depth background knowledge on the relevant modalities for 
this thesis, including bioluminescence imaging, magnetic resonance imaging, and 
photoacoustic imaging, will be provided. Background knowledge on organic anion-
transporting polypeptides is also discussed to provide a baseline for its development as 
a multimodality reporter gene.  
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1.1 Motivation and Overview  
Cancer is a heterogenous group of diseases involving abnormal cell growth with 
potential to invade and spread to other parts of the body. Cancerous, or malignant, 
tumours are distinct from benign tumours, by their ability to spread throughout the body. 
Each year, over 14 million new cases of cancer are diagnosed, and approximately 10 
million deaths result directly from cancer, comprising 15.7% of all annual deaths (1). 
Non-invasive imaging plays a critical role in the detection, staging, and monitoring of 
cancer in individual patients (2). The technologies used for this purpose encompass 
multiple modalities such as ultrasound (US), computed tomography (CT), magnetic 
resonance imaging (MRI), and positron emission tomography (PET). These 
technologies have also been applied for assessing cancer progression at the preclinical 
stage.  
“Precision Medicine”  (PM) increasingly shows greater promise than conventional 
“one-size-fits-all” traditional medicine with respect to patient outcomes, spurring the 
need for understanding the molecular features of cancer in individual patients, rather 
than its macroscopic features (3). Molecular imaging (MI) is a growing biomedical 
research discipline that enables the visualization, characterization, and quantification of 
biological processes taking place at both the cellular and subcellular levels within intact 
living subjects over time, including patients (4). As a small part of this larger effort, this 
thesis develops a reporter gene technology to image the viability of engineered cancer 
cells in preclinical animals at the primary tumour stage, as well as for noninvasive, 
longitudinal tracking of metastatic cancer cell dissemination throughout the entire body. 
Specifically, this thesis employs, characterizes and develops methods for using organic 
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anion-transporting polypeptide 1 (Oatp1) as a reporter gene for tracking of engineered 
cancer cells in vivo in preclinical animal models. We also discuss the potential utility of 
Oatp1 reporter genes for future use in clinical cell tracking studies. 
In Chapter 2, Oatp1a1 was investigated for longitudinal imaging of primary triple-
negative breast cancer tumours on magnetic resonance imaging (MRI) with concomitant 
enhancement of bioluminescence imaging (BLI) signals, and effectively demonstrated 
non-homogenous distributions of breast cancer cells within tumour masses. In Chapter 
3, Oatp1b3 was explored for tracking of metastasizing triple-negative breast cancer 
cells in preclinical animals on MRI, with simultaneous tracking of metastases with BLI. 
This collection of experiments demonstrated detection of the spread from primary 
orthotopic tumours to single lymph nodes via Oatp1b3-enhanced MRI, subsequent 
visualization of multi-lymph node spread, and finally detection of small metastatic lung 
lesions within the same animal over time.  
In Chapter 4, Oatp1b3 was additionally assessed for its ability to take up a 
fluorescent and photoacoustic contrast agent called indocyanine green (ICG), allowing 
for the establishment of Oatp1b3 as a photoacoustic reporter gene for rapid, cost-
effective imaging of engineered cells in localized tissues with concurrent high-contrast 
and resolution. Finally, Chapter 5 summarizes the conclusions and significance of this 
thesis, discusses its experimental limitations, and presents ideas for future work to build 
on the results presented in this thesis.  
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1.2 Modeling Cancer 
1.2.1 Cancer Trends  
In North America, one in every two women, and one in every three men 
will develop cancer in their lifetime (5). In general, when the cancer is caught 
when still confined to its tissue of origin, the main goal is to eradicate the tumour 
from the primary site and prevent distant metastasis via surgical resection, 
radiation, and/or systemic therapy (6). Prognosis is often hopeful at these stages, 
though notable exceptions exist (1, 7). At the primary site, the tumour has been 
demonstrated to comprise not only of cancer cells as one might expect. In fact, 
nonmalignant cells can account for approximately half of the tumour mass, in 
both primary and metastatic lesions (8) (Figure 1.1). These other components 
profoundly influence its progression and metastatic efficiency, and shape its 
therapeutic responses and resistance to treatment (9).  
Direct targeting of non-cancer cells within the tumour microenvironment 
(TME) has contributed to positive therapeutic outcomes (10-12). These TME 
components include vascular endothelial cells, tumour-associated adipocytes, 
fibroblasts, lymphocytes, neutrophils, and macrophages, secreted factors and 
extracellular matrix (ECM) proteins (13). Once the cancer metastasizes, curative 
treatment becomes less likely. Unfortunately, many patients present with distant 
metastatic spread at their initial diagnosis (14). At that juncture, the goal often 
becomes prolonging the life of the patient and symptom palliation (6). And while 
metastatic disease accounts for the vast majority of cancer-associated deaths, 
this process remains the least understood aspect of cancer biology (15).  
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Figure 1.1. The Tumour Microenvironment. The tumour microenvironment is a 
complex ecosystem of heterogeneous tumour cells, stromal cells, and a variety of 
immune cells residing in a network of dysregulated vasculature and collagen. Poor 
perfusion and densely-packed glycolytic tumour cells create pockets of reduced oxygen 
or hypoxia, low pH, poor nutrient availability, anti-inflammatory cytokines, chemokines, 
and accumulated metabolic by-products, such as lactate. Tumour-infiltrating immune 
cells of both the myeloid and lymphoid lineages are found within the TME. NK, natural 
killer. This figure was drawn by Nivin N. Nyström. 
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1.2.2 Preclinical Animal Models in Oncology 
Clinical research in oncology is largely limited to analytical or 
observational methods, for obvious ethical reasons, with therapy-focused clinical 
trials being the one exception to this rule. Preclinical animal models therefore 
offer an indispensable intermediate to clinical trials and reductionist in vitro 
research that fails to model the complexity of cancer progression at both early 
and late stages of the disease, including TME development and metastatic 
colonization (16). Preclinical animal models provide a platform to improve our 
understanding of underlying biological mechanisms in oncology, as well as a 
platform to test the initial efficacy of new treatment strategies, and have 
contributed to major breakthroughs, such as the first demonstration of immune 
checkpoint blockade (17).  
In 2016, approximately two-thirds of published studies in oncology 
employed preclinical animal models in their methods, and immunodeficient mice 
constitute the vast majority of animals in these studies (16). Immunodeficient 
mice are required for xenografting of human cancer cells in order to avoid cancer 
rejection; although models using mice reconstituted with components of the 
human immune system, so called “humanized” mouse models, are being 
developed (18). Syngeneic immunocompetent models also exist using mouse-
derived cell lines but these are less utilized for “proof-of-concept” imaging 
studies. The most common immunodeficient mouse strain used in oncology is 
the athymic nude mouse (57% of all studies), followed by the NOD scid gamma 
(NSG) mouse (24% of all studies).  
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Specifically, the athymic nude strain was generated from a spontaneous 
mutation of Foxn1, a transcription activator particularly important in thymic 
epithelium. This resulted in mice unable to develop their thymus gland, and in 
turn, a systemic depletion of T cells, and a decreased rejection rate of tumour cell 
engraftments relative to immunocompetent mice (19). Although their natural killer 
(NK) cell counts are low at birth, this metric increases with age, and their innate 
immunity remains intact. In contrast, NSG mice are far more immunodeficient 
than athymic nudes. Specifically, the NSG mouse model exhibits depletion of 
both T and B cells, a dysfunctional complement system, extremely low 
development of NK activity, and impaired innate immunity. As a result, NSG mice 
ultimately feature the highest tumour engraftment rates of all mouse strains and 
are highly permissive for metastasis (20).  
 
1.2.3 Cancer Cell Lines and Tumour Initiation  
There are different methods by which tumour growth can be initiated 
within a preclinical animal. These include environmentally-induced tumour 
models (6% of studies), genetically-engineered mouse models (24% of studies), 
and, most commonly, due to cost-effectiveness and time efficiency, cell 
implantation models (89% of studies) (16). This thesis focuses on cell 
implantation models of tumour initiation. Most studies using cell implantation 
methods for tumour initiation employ established cancer cell lines harvested from 
tumours in human patients or animals, that are subsequently propagated in vitro 
as a monolayer or in vivo as xenografts. The establishment of cell lines as a 
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scientific tool has an unfortunate history, clouded with racism and medical 
misconduct. The first cancer cell line, “HeLa,” was harvested in 1951 from 
Henrietta Lacks, an African-American cervical cancer patient from a poor 
socioeconomic background. Sampling of both her healthy tissue and cancer was 
performed, with the intention of culturing the specimens for laboratory research, 
without her knowledge or consent during her multiple visits to John Hopkins 
University (21). This was conducted despite the contemporary norm of obtaining 
consent at the time, which was propelled by the Nuremberg Code of 1947, and 
soon followed by the legal recognition and duty of “Informed Consent” in 1957 
(see Salgo v. Leland Stanford, Jr. University Board of Trustees) (22). 
It was another 30 years before the first widely-used breast cancer cell 
lines, the MD Anderson (MDA) series of cells, became established, which this 
thesis uses to model breast cancer in vivo (23). More recent breast cancer cell 
lines include the “SUM” series of cells derived from primary tumours, pleural 
effusions or various metastatic sites (24). Additionally, the murine-derived 4T1 
cell line established by Miller et al in 1983, which is also used in this thesis, was 
isolated from a triple negative breast cancer, and is a widely-used metastatic 
breast cancer model (25, 26). Since innate and adaptive immunity have been 
demonstrated to play important roles in tumour growth and metastasis, a murine-
derived breast cancer cell line, which can be grown in immunocompetent mice, 
represents an important tool for studying immune responses in cancer 
development (27, 28). Though there are known caveats to using any animal 
model (29, 30), cell lines remain powerful experimental tools. In many instances, 
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information generated from a study has translated to clinical benefit. For 
example, the discovery that anti-estrogens regulated growth of tamoxifen-
stimulated MCF-7 cells led to development and trials of fulvestrant (Faslodex®, 
AstraZeneca Pharmaceutical LP, Wilmington, DE, USA), that is now regularly 
recommended for treatment of recurrent ER-positive metastatic breast cancer in 
menopausal women (31-34). 
To establish a primary tumour with the cell implantation method, cells 
often are introduced ectopically, that is subcutaneously, or orthotopically, into the 
tissue that matches the tumour histotype. For breast cancer cells in mice, 
orthotopic implantation means a cell injection into one (or more) of four mammary 
fat pads. Orthotopic implantations of tumour cells have been extensively 
described to be superior with respect to modelling tumour microenvironmental 
interactions, therapeutic response and metastatic patterns, relative to ectopic 
implantations (35-40). After implantation, a host of cell types come together and 
actively interact with the implanted tumour cells to establish the TME. Depending 
on the immunocompetency of the mouse strain, these may include 
macrophages, fibroblasts, NK cells, neutrophils, decreases in local pH, and 
remodeling of the ECM (41).  
 
1.2.4 Established Mechanisms of Metastasis 
Metastasis accounts for about 90% of cancer related deaths (15). Though 
drastic improvements to survival have been shown for cancer at early stages, 
randomized clinical trials over a 30-year period have largely failed to show 
 10 
sustained increases in survival for patients with metastatic disease (42). To 
target metastatic disease, a better understanding of the metastatic process is 
warranted, and this represents a major area of investigation for various cancer 
types. The dissemination of cancer cells from primary tumours and subsequent 
seeding of new tumour colonies into distant tissue involves a multi-step process 
known as the invasion-metastasis cascade (15) (Figure 1.2). Before the 
metastatic process can begin, the primary TME, that encompasses the tumour 
cells and the stroma in which they grow as well as the interactions between these 
two compartments, is established at the primary site (43).  
The first step of the invasion-metastasis cascade is (1) dissociation of a 
single cancer cell from the primary tumour through epithelial-to-mesenchymal 
transition (EMT) or a collective of cancer cells in which some “leader cells” have 
undergone mesenchymal transition but carry epithelial-type cargo cancer cells 
along with them. The dissociated tumour cells infiltrate into the surrounding 
stroma and invade and migrate through the basement membrane supporting the 
endothelium of local blood and/or lymphatic vessels as the second step of the 
invasion-metastasis cascade called (2) invasion. It is worth noting that spread of 
tumour cells to nearby lymph nodes is an early and common event in patients, 
and the lymphatic vasculature is therefore considered as an important route of 
metastatic spread. It has been proposed that entry of cancer cells into the 
lymphatic vasculature might be facilitated by the higher permeability of lymphatic 
vessels relative to blood vessels and/or by the absence of a complete basement 
membrane barrier (44). Yet, the relative frequencies at which distal organ 
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metastasis occurs directly via lymphatics, or directly through the bloodstream, or 
indirectly from the lymphatic system to the bloodstream and then to the organ, 
are not fully understood.  
 Next, (3) intravasation occurs, whereby the dissociated tumour cells 
enter the hematogenous and/or lymphagenous vasculature after having 
successfully crossed through the extracellular matrix (ECM). In blood circulation, 
the tumour cells are referred to as circulating tumour cells (CTCs). In this phase, 
the bloodstream represents a hostile environment for CTCs, exposing them to 
rapid clearance by natural killer cells or fragmentation due to the physical 
stresses encountered in transit through the circulation. The dissociated tumour 
cells are distributed to remote organs by blood or lymphatic flow and actively 
leave the vasculature via (4) extravasation, at which point they are referred to 
as disseminated tumour cells (DTCs). Having traveled far from the primary 
tumour, DTCs find themselves in a new microenvironment devoid of familiar 
stromal cells, growth factors, and ECM constituents that previously sustained the 
viability of their predecessors in the primary site (45). DTCs may reside within 
their newfound organ in a non-proliferative state for many months or even years 
in a phase known as (5) dormancy. Finally, the growth of an overt metastatic 
colony represents the concluding and most deadly phase in the malignant 
progression of a tumour. 
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Figure 1.2. The Invasion-Metastasis Cascade. (1) Epithelial to mesenchymal 
transition (EMT) results in dissociation of the breast cancer cell from the primary 
tumour. (2) Invasion of the dissociated tumour cell through the extracellular matrix 
(ECM) and basement membrane of the primary site. (3) Intravasation of the dissociated 
tumour cell into the bloodstream, or alternatively, into the lymphatic system. At this 
point, the dissociated tumour cell is deemed to be a circulating tumour cell, CTC. (4) 
Extravasation of the CTC from the bloodstream into the target tissue such as the lungs, 
at which point, the tumour cell is called a disseminated tumour cell (DTC). (5) The DTC 
remains in a non-proliferative state at the metastatic site for some time, a phase called 
dormancy, and may or may not enter a proliferative state at a later time. This figure was 
drawn by Nivin N. Nyström. 
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1.2.5 Modeling Metastatic Disease 
Metastasis accounts for about 90% of cancer-related deaths (15). Yet, 
approximately 75% of studies employing preclinical animal models focus only on 
the primary tumour and do not include the study of metastasis (16). Even more, 
investigators in these studies largely use rudimentary measurements such as 
primary tumour growth curves and tumour mass as study readouts to estimate 
therapeutic response (16). In fact, many preclinical studies are limited to simple 
end point readouts such as tumour weight, tumour volume or survival. While 
these are clinically important parameters, end point readouts neglect the 
temporal kinetics of tumour growth and metastatic progression. It is therefore 
unsurprising that survival rates for patients diagnosed with metastatic disease 
have not improved for breast cancer (42), as well as several other types of 
cancer (46, 47). The low success rate of clinical trials in oncology warrant a 
change in the approach taken to identify and assess new therapies (48).  
To model metastatic disease in preclinical animal models, cells can be 
injected via the intravenous, intracardiac, or intrasplenic routes to generate 
reliable metastases within lung, brain, or liver tissue, respectively (49). These are 
referred to as experimental metastasis models because they recapitulate 
metastatic colonization but circumvent the primary disease. The most 
comprehensive way to study the entire metastatic cascade in preclinical animal 
models is orthotopic tumour cell implantation to induce the development of a 
primary tumour followed by spontaneous cancer cell metastasis to other parts of 
the body (16). These spontaneous metastasis models recapitulate the entire 
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invasion-metastasis cascade for more precise modeling of tumour progression. 
However, spontaneous models are used much less often than experimental 
metastasis models due to a longer experimental timeline, and unpredictable 
outcomes (49). For instance, it is difficult to determine, exactly and absolutely, 
where the metastasizing cells colonize and patterns may differ from mouse to 
mouse. In summary, preclinical evaluation of metastasis is challenging, but 
necessary to expand knowledge on the metastatic process and test therapies 
targeting metastatic disease.  
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1.3 Molecular Imaging 
1.3.1 Imaging Cancer in Patients 
Imaging technologies play a critical role in the diagnosis of cancer. While 
primary diagnostic tools include ultrasound (US) and computed tomography (CT), 
other modalities such as magnetic resonance imaging (MRI) and positron 
emission tomography (PET) have seen increasing use and have overall 
demonstrated better detection and staging of disease (50). For example, PET 
imaging of prostate-specific membrane antigen (PSMA) for prostate cancer 
staging shows increased specificity and sensitivity compared to standard imaging 
protocols, enabling personalized treatment planning and improved outcomes 
(51). And while US-guided prostate biopsy exhibits true positive detection rates 
of 10–19%, this increases to 59% for multiparametric MRI-guided biopsies (52).  
Imaging is also playing an increasingly important role in monitoring 
treatment delivery and treatment response (53). For instance, imaging therapy 
response in gastrointestinal stromal cancer patients with 2-deoxy-2-[18F]-
fluoroglucose (18F-FDG) PET allowed for determination of patient response 
status only 8 days after the start of treatment, compared to 8 weeks for CT, 
thereby offering the opportunity to provide salvage therapies for non-responders 
before the cancer has a chance to progress (54). Though costs of providing 
advanced imaging technologies for cancer diagnosis, staging and monitoring 
have deterred widespread utility, their usage is cost-effective with respect to life-
year gains, and have been shown to offset costs via rapid determination of 
effective personalized treatments (55, 56). 
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1.3.2 Molecular Imaging of Cancer 
Clinical imaging for abnormalities at the macroscopic scale is sensitive but 
unspecific (57). To address these limitations, the motivation for molecular 
imaging (MI) is to translate highly informative in vitro and ex vivo bioassays to an 
in vivo or in situ setting, an approach which has strong roots in nuclear medicine 
but is rapidly emerging in other modalities (58). While in vitro and ex vivo 
techniques provide valuable insight into innerworkings of cells and biochemistry 
of disease, they are limited by an inability to provide spatiotemporal information 
over entire intact organisms, making it difficult to appreciate the “full picture” of 
disease states and/or biochemical processes.  
Additionally, the need to remove a tissue sample from its natural 
environment and process it renders results not accurate of true in vivo 
physiological conditions. Further, destruction or irreversible processing of tissue 
makes each sample useful for a small number of in vitro protocols, which may 
limit the information that could possibly be extracted per sample. Finally, the 
need to euthanize animals for ex vivo protocols makes longitudinal studies of the 
same animal impossible, and creates issues with respect to both increased costs 
and inter-subject variability (59).  
To visualize, quantify, and monitor cell populations over time, one of three 
approaches may be taken: 1) development of an imaging probe that targets 
biomarkers on cells and/or pathways of interest, 2) pre-loading cells of interest 
with a contrast agent and subsequently introducing them into the biological 
system, and 3) engineering cells with a reporter gene in vitro or ex vivo and 
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subsequently introducing them into the biological system, or engineering them 
with a reporter gene in situ. Each of these methods has its strengths and 
limitations, which will be discussed in detail in Sections 1.3.3, 1.3.4, and 1.3.5, 
respectively.  
Further, each of these methods can be employed on various imaging 
modalities. Likewise, each of these modalities also presents with its own set of 
strengths and disadvantages, and its effective application depends greatly on the 
details of the disease and/or biochemical process of interest. The relevant 
imaging modalities for this thesis, which include bioluminescence imaging, 
magnetic resonance imaging, and photoacoustic imaging, will be thoroughly 
reviewed in Sections 1.4, 1.5, and 1.6, respectively.  
 
1.3.3 Targeted Molecular Probes 
The development of targeted molecular probes is perhaps the most 
obvious approach for MI. These include a broad range of categories, including 
small molecules, peptides, aptamers, relatively high-molecular-weight antibodies, 
engineered protein fragments, and nanoparticles. Each type of agent falls within 
a different size range and thus possesses distinct pharmacokinetic and binding 
properties (59). In general, the objective of a molecular probe is to effectively 
target a specific biomarker in situ and generate significant signal above 
background for detection and image generation. In general, there are two main 
mechanisms by which a targeted probe may function: 1) probes that bind specific 
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receptors, transporters, or ion channels, (60) and 2) probes that enable imaging 
of metabolism, enzymatic activity, and/or transport (61).  
The main advantage of targeted molecular probes is the ease of their 
translation into human patients, relative to all other MI approaches, once safety 
and effectiveness has been demonstrated. Their limitation, however, is the time 
and expense required to create a new molecular probe for each biological marker 
(62). Additionally, the targeting mechanism of the probe may activate or inhibit its 
target, which may cause undesired effects on the biochemical process being 
studied, especially if binding is irreversible, although this is less of a concern for 
modalities requiring biologically-negligible probe concentrations like PET (63).  
On the other hand, probes that target metabolism, enzymatic activity, 
and/or transport such as hyperpolarized carbon-13 pyruvate for MRI and 18F-
FDG for PET can be used to image a generic process, e.g. all cancers exhibit 
increased pyruvate to lactate metabolism due to the Warburg effect, but this does 
not allow for identification of specific molecular biomarkers for each individual 
cancer patient (64). Further, specificity may be limited because other non-related 
pathologies e.g. non-oncogenic inflammation, can exhibit similar changes in 
metabolism (65); however, new metabolic probes for hyperpolarized carbon-13 
MRI are being developed for increased cellular specificity (66-68).  
 
1.3.4 Ex Vivo Cellular Loading 
Cells can also be tracked by direct labelling via in vitro or ex vivo 
incubation with a contrast agent prior to their introduction or re-introduction into 
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the biological system, respectively.  Examples of ex vivo cell loading approaches 
include indium-111 for imaging of white blood cells in patients with PET (69), 
iron-oxide nanoparticles for MRI of cancer cells in preclinical animal models (70), 
and gold nanoparticles for PAI (71) and/or CT (72). This approach allows for 
sensitive and specific determination of the location of labelled cells for a limited 
time after their introduction into the body (73).  
While cellular loading is clinically relevant for immune cells in patients, it is 
limited to preclinical animal models for tracking of diseased cells, e.g. it is 
unethical to (re-)introduce labelled cancer cells into a patient. After their 
introduction into the biological system, the number of contrast agent molecules 
per cell declines over time due to its diffusion out of the cell and/or dilution due to 
cell division (74). This is a significant limitation for tracking proliferative cancer 
cells in preclinical animal models, such as during the initial establishment of a 
primary tumour, prior to their spontaneous spread to other parts of the animal.  
On the other hand, some groups have taken advantage of the “dilution-
with-division” effect in cellular loading and used this method to study the 
dormancy phase of cancer cells in experimental metastasis models (75, 76). 
Some cells types are not extensively proliferative, like stem cells, and these have 
been monitored using iron oxide nanoparticles and MRI with success (77). A 
second limitation of cellular loading is that the contrast agent molecules can also 
be engulfed by other cells once the initially loaded cells have died, e.g. 
macrophages can ingest particles via phagocytosis, thereby generating false 
positive signals in absence of the cells of interest (74). These limitations for in 
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vitro or ex vivo labelling of cells, largely restrict the timeframe in which cells of 
interest can be accurately detected and identified using in vitro or ex vivo direct 
labelling (78). Further, considerations must be taken with the effects of foreign 
particles packed into cells on normal cellular function. Ideally, the contrast agent 
used for labelling would remain inert, but this is not always the case. For 
example, cancer cells labelled in vitro with iron oxide nanoparticles and 
subsequently introduced into preclinical animal models exhibited reduced rates of 
growth due to pro-inflammatory effects caused by the labelling agent (79). 
 
1.3.5 Reporter Genes  
Reporter genes are functional pieces of deoxyribonucleic acid (DNA) that 
encode detectable proteins. Unlike traditional contrast agents, they can be fused 
to a gene of interest at the DNA-level to track the protein product across time and 
space at sub-cellular resolutions, or alternatively, the reporter can be placed 
under equivalent regulatory control to the gene of interest to indirectly track its 
spatiotemporal expression at the supra-cellular level. Green fluorescent protein, 
pioneered by Drs. Osamu Shimomura, Martin Chalfie and Roger Y. Tsien, 
became so widely used in biomedical research that it was subject of the 2008 
Nobel Prize in Chemistry. The means by which scientists employ reporter genes 
can become quite complex to provide detailed information on highly specialized 
processes, e.g. determination of stem cell differentiation status (80), resonance 
transfer methods for detection of protein-protein interactions (81, 82), genetic 
circuitry to image cell-cell interactions (83), fluorescent barcoding of cells to track 
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cellular ancestry (84), but ultimately, reporter genes are used as a protein-based 
detection mechanism to track and monitor the fates of live cells in tissues. 
Recently, reporter genes have become of particular interest for development and 
clinical management of gene and adoptive cell therapies in patients, which 
represents a revolutionary form of treatment for a number of diseases (85-88).  
Reporter genes and other genetic material can be introduced into cells in 
a number of ways (89). In this thesis, the primary method of delivering genetic 
material to the cell is through the utilization of lentiviruses, a technique first 
described by Dr. Didier Trono’s group at the Salk Institute in 1996 (90). Lentiviral 
vector systems typically consist of three separate plasmids: the packaging, 
envelope, and transfer plasmids. Briefly, the packaging plasmid includes a set of 
genes, including gag and pol that encode the major structural polyprotein 
required for assembly of the viral capsid, and the reverse transcriptase required 
for the integration of the genetic material of the virus into the host genome (91). 
The envelope plasmid includes the env gene, which ultimately encodes the viral 
spike protein, important in dictating the tropism of the virus (92). Finally, the 
transfer plasmid encodes the transgene of interest, flanked by viral long terminal 
repeats (LTRs) that facilitate viral packaging and host genome integration (93). 
Following co-transfection of these plasmids, packaging cells such as the 293T 
cell line release transgene-containing lentiviral particles into the media, which 
could then be collected for experimental use. 
In MI, reporter genes overcome several limitations presented by targeted 
probes and cellular loading approaches, and as a result, have increasingly been 
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utilized in the literature at the preclinical stage (94). Once a reporter gene is 
established to work in one cell type, it can generally be used as a universal tool 
to track any gene of interest, unlike targeted probes that need to be newly 
designed for each biomarker. If scientists opt to integrate the reporter gene into 
the genome of a target cell, its DNA sequence then replicates with cell division; 
thus, its expression and subsequent detection depends only on the genetic 
regulation employed in the study, independent of cell division. Importantly, after 
the engineered cell dies, the DNA encoding the reporter is destroyed and its 
contrast mechanism cannot be transferred to bystander and/or phagocytic cells, 
unlike contrast agents used for cellular loading.  
However, reporter gene contrast mechanisms also do present with some 
shortcomings. For example, reporter genes have decreased sensitivity relative to 
ex vivo cellular loading approaches (59). Additionally, while reporter genes are 
highly useful for tracking protein entities in vivo, tracking of non-protein small 
molecules in the body with genetically-encoded reporters becomes complicated 
and is better suited for targeted probe approaches (95). Nonetheless, since 
green fluorescent protein was first established, reporters for various modalities 
have been developed, including bioluminescence imaging (96-100), 
photoacoustic imaging (101), positron emission tomography (102-104), magnetic 
resonance imaging (105-110), and ultrasound (111). Traditionally, cells would be 
engineered in vitro or ex vivo, similar to cellular loading, but new methods are 
emerging for genetic engineering of target cells in situ (112-114).  
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1.3.6 Multimodality Imaging 
It is important to recognize that all molecular imaging modalities have 
advantages as well as inherent limitations. Multimodality imaging allows 
researchers to combine different imaging datasets to gain a more complete 
understanding of the biology being studied. The most widespread application of 
multimodality imaging is the integration of PET, which allows for sensitive 
detection of probe activity, with computed tomography that provides detailed 
anatomical images of internal structures, thereby allowing clinicians and 
researchers to determine the three-dimensional (3D) locations of radiotracers 
(115). Within the last decade, PET/MRI has been increasingly commissioned at 
research centres, to combine functional information from PET, with structural and 
additional functional information from MRI for ultimate high sensitivity, high 
specificity, and high resolution molecular imaging (116).  
Beyond PET, researchers are combining other modalities and molecular 
imaging approaches at the preclinical stage to better understand disease 
pathogenesis in terms of the interplay between different cell types, to identify 
putative mechanisms of disease and/or to evaluate the efficacy of new candidate 
treatments. For example, in studying the biology of cancer cell dormancy, a 
phenomenon that is increasingly being recognized as a hallmark of metastatic 
disease (117), Parkins et al. combined cellular loading of iron oxide nanoparticles 
for MRI with BLI of luciferase expression to detect viable cancer cells arrested 
into the brains of mice after systemic administration (118). Iron oxide 
nanoparticles allowed for high resolution 3D imaging of single cells with detailed 
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anatomical context, but provided no information on the viability of the cancer 
cells; i.e. hypointense signals on MRI may be stemming from uncleared particles 
even after cancer cell death or, alternatively, from microglia that have engulfed 
the nanoparticles as well as other unrelated sources of reduced MRI signal. 
Adding BLI to their protocol allowed for viability measurements of engineered 
cancer cells within brains of mice, confirming the presence of live cancer cells. 
Other studies have utilized various combinations of modalities, which ultimately 
serve to clarify or further experimental findings (119, 120). In the development of 
Oatp1 as a reporter gene in this thesis, complementary modalities are used in 
combination primarily to confirm reporter gene activity in vivo, e.g. 
bioluminescence as a reference for reporter gene activity on MRI, ultrasound with 
photoacoustics for anatomical context. The sections below introduce the imaging 
modalities relevant to this thesis and include detailed discussions on established 
reporter genes for each modality. 
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1.4 Bioluminescence Imaging 
1.4.1 Reporter Gene Development 
Bioluminescence is a specific form of chemiluminescence whereby light is 
produced and emitted from biological organisms. This process occurs widely in 
marine vertebrates and invertebrates, as well as in some fungi, microorganisms, 
including some bioluminescent bacteria, and terrestrial arthropods such as 
fireflies (121). The principal reaction in bioluminescence involves the oxidation of 
a molecule called the “luciferin” via an enzyme, called the “luciferase.” The 
luciferase may require other cofactors, such as calcium or magnesium ions, 
and/or the energy-carrying molecule adenosine triphosphate (ATP), in order to 
perform the oxidation (Equation 1.1).  
 
Equation 1.1. Biological oxidation of D-luciferin by firefly luciferase.  
D-luciferin + ATP + O2 + Mg2+ → Oxyluciferin + AMP + CO2 + PPi + h# 
 
In firefly luciferase, the oxygen of the C4 carboxyl end group on luciferin 
acts as a strong nucleophile and attacks the electrophilic phosphorous in the α-
position within ATP in an SN2 displacement (122). Inorganic pyrophosphate (PPi) 
is removed as the leaving group, resulting in an enzyme-bound intermediate, 
luciferyl-adenylate (123). The acidity of the C4 carbon is increased in its new 
bond to AMP, allowing for its deprotonation, and carbanion formation (124). At 
this step, the carbanion, as a nucleophile, will then tend to attack molecular 
oxygen, thus generating a high-energy intermediate, the luciferin dioxetanone 
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(125, 126). Finally, dioxetanone spontaneously decarboxylates to form 
oxyluciferin (127). The resulting molecule, oxyluciferin, is in a singlet excited 
state, and its decay to the ground state releases a photon (128). Throughout the 
reaction, the Mg2+ shields the negative charges and influences the conformation 
of the phosphate groups (129).  
In the laboratory, luciferase-based systems are used as reporter genes for 
biomedical research purposes. Work on luciferase as a reporter gene system first 
began in 1982 when Belas et al. isolated and expressed luciferase genes from 
marine bacteria in E. coli (130). The most widely used luciferase reporter gene 
today, firefly luciferase, was first cloned and expressed in E. coli by De Wet et al. 
in 1985 (131), expressed in mammalian cells just two years later in 1987 by 
Keller et al. (132), and used to image cells of interest in mammalian hosts in 
1995 by Contag et al. (133).  
 
1.4.2 In Vivo Image Generation 
Current methods to generate bioluminescence imaging data with live 
animals first involves generation of stable Firefly luciferase-expressing cells and 
subsequent implantation of these cells into animals. The animal would then 
typically receive intraperitoneal administration of D-luciferin, after which, the 
substrate diffuses into surrounding organs and, thereafter, is carried away by 
capillary blood or lymph within those tissues. Evidence suggests that D-luciferin 
diffuses slowly and passively across cell membranes to enter the cytoplasm 
where the luciferase protein would be present within engineered cells (134). A 
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broad spectral distribution of light peaked at a wavelength of 560 nm is emitted 
following relaxation of excited oxyluciferin to its ground state (135). Light 
emission from constitutively expressed luciferase is proportional to tumour cell 
burden, and photon emission increases as the cell population multiplies (136).  
Kinetic PET studies with radiolabeled 14C-D-luciferin revealed generally 
low brain uptake likely due to presence of the blood brain barrier, high intestinal 
uptake due to the intraperitoneal route of injection, and predominant renal 
excretion of the luciferase substrate (137-139). Depending on the model, the 
signal from in vivo bioluminescence generally peaks 10 to 15 minutes post-
administration of D-luciferin, after which signals plateau and eventually drop as 
the substrate is renally excreted. The bioluminescent reaction between the 
luciferase enzyme and its substrate produces low-intensity light that ordinarily 
cannot be seen with the human eye or by conventional microscopy (121).  
A specialized imaging detector is required, especially when imaging cells 
within preclinical animal models, as light scattering and light attenuation from 
surrounding tissues further obscure the spatial location of the signal source. The 
most common system for imaging bioluminescence in vivo comprises of a light-
tight imaging chamber into which the anesthetized subjects are placed onto a 
heated stage. A bright-field photograph from the top of the black chamber is first 
taken of the subject as a spatial reference, after which a sensitive charged-
coupled device (CCD) camera is used to detect and spatially localize the 
bioluminescent photons. The CCD is super-cooled to approximately -90°C to 
minimize thermal noise and increase exposure times, thereby increasing its 
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ability to detect very low levels of light (140). The units of measurement for 
bioluminescence signals can include counts measured in photons (p), total flux 
(p/s), or average radiance (p/s/cm2/sr). Total flux is generally used to calculate 
total tumour burden for an animal, whereas average radiance can be utilized to 
measure individual bioluminescence signals from a specific region of interest 
(141).  
 
1.4.3 Applications for Cancer Research 
There are several advantages of bioluminescence imaging that make it a 
useful modality for cancer research. Before bioluminescence imaging was 
established, the default method by which preclinical scientists could dynamically 
track tumour progression was with simple readouts such as caliper 
measurements, which are not feasible for measuring tumour growth or metastatic 
burden in deep tissues. More extensive measurements could be made 
posthumously, by either staining tissue for cancer cell markers or by imaging 
histology with confocal microscopy for fluorescent reporter gene expression. 
These histological methods, require extensive and time-consuming tissue 
preparation and provide information only at endpoint. Further, this preparation 
meant that only ex vivo tissues could be observed, giving a static picture of gene 
expression and/or cellular location, with the exception of translucent, non-
mammalian model organisms e.g. C. elegans, D. rerio (142).  
For longitudinal imaging in mammalian models with these previous 
methods, studies needed to overcome inherent inter-subject variability at each 
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timepoint. Thus, large numbers of animals would need to represent different 
timepoints for a methodical understanding of the biological phenomenon being 
studied. However, bioluminescence imaging allows for whole-body imaging 
without euthanasia, offering a tool to longitudinally track the protein and/or cell of 
interest in an individual animal over time, which greatly reduces the number of 
animals needed to understand a hypothesis or effect (143). In addition, 
mammalian systems do not naturally produce bioluminescence signals, so 
luciferase-expressing cells in preclinical animal models generate sensitive 
imaging data due to an inherently high contrast-to-background ratio. 
Bioluminescent imaging has therefore become a critical tool in preclinical 
oncology research. In recent years, the luciferase reporter gene has been used 
to track the expression of specific oncoproteins (144-147), model metastatic 
progression (148-150), and assess the delivery, biodistribution, and/or efficacy of 
new candidate therapies (151-153). 
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Figure 1.3. Bioluminescence Imaging of Preclinical Animal Models. 
Bioluminescence imaging measurements in counts (photons) of 2×105 luciferase-
expressing MDA-MB-435 cells immediately (A,C) or 33 days (B,D) after injection into 
the left (A,B) or right (C,D) ventricle. A 120-second acquisition was taken for Day 0 
images (A,C); Day 33 images required only a 10-second duration (B,D). This figure was 
acquired from Zinn et al. (154).  
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1.4.4 Limitations of Bioluminescence Imaging  
The ultimate goal of molecular imaging for cancer research is to detect 
cancer-associated molecular events as they occur within a biological system. 
Bioluminescence imaging provides a unique platform to track these events with 
high sensitivity and robustness, but light attenuation and light scattering from 
surrounding tissues limit the depth of detection and resolution of imaging, making 
it difficult to determine the precise location of the source of signal (155). A small 
number of superficial cells and a large number of deep-seated cells generate 
similar signals, which is particularly problematic when researching metastatic 
spread in preclinical animal models. A photograph or X-ray image overlayed on 
bioluminescence data, as is de rigueur on current imaging systems, can only 
qualitatively approximate the possible source location. Additionally, tissue 
scattering of bright sources of light emitted from larger tumours adjacent to 
weaker regions of light emission i.e. smaller metastases, may obscure the 
presence of smaller tumours or metastases in bioluminescence imaging, which 
may only become apparent during histological evaluation if the corresponding 
tissue is sampled (156).  
Furthermore, imaging of larger animal models, and even humans, would 
be challenging as light attenuation from surrounding tissues would completely 
obscure any signals deeper than a few centimeters within the body of the subject 
(157). New image acquisition systems offering bioluminescence tomography 
have recently been developed, to generate multi-projection datasets overlayed 
onto CT images, but the long acquisition times and increased costs of these 
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systems counter some of the original benefits of bioluminescence imaging – its 
high throughput and cost-effectiveness (158). Complicating factors also exist with 
respect to the biochemical effects of luciferase expression on the biological 
system being studied; during imaging, ATP-dependent luciferases become a 
significant metabolic burden, and have been demonstrated to decrease ATP 
availability by a factor of two (159), which may have effects on the ability of the 
tumour to grow and progress. Along the same lines, metastasis has been shown 
to be seriously debilitated in murine breast cancer models when cells are 
engineered with luciferase, all things being equal (160). Reporter gene design 
requires relative inertness, and while its expression may not seriously alter the 
parameters of the study, the undesired effects of synthetic luciferase activity on 
the biological system should be acknowledged to some extent.  
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1.5 Magnetic Resonance Imaging  
1.5.1 Magnetic Resonance Imaging in Medicine  
Magnetic resonance imaging (MRI) is a versatile technology used to non-
invasively acquire an increasing variety of imaging data. In addition to anatomy, 
images of physiological processes of the body can also be achieved (65). Proton 
(¹H) MRI, which represents the vast majority of scans acquired, and the imaging 
performed in this thesis, is largely used to identify disease on a macroscopic 
scale, such as a solid tumour. MRI also has potential for detection of events at 
the molecular scale, with high resolution 3-dimensional spatial information and 
surrounding anatomical context. The following sections provide a brief overview 
of the fundamental processes involved with generating a proton image. The 
information below is obtained from a combination of sources: Magnetic 
Resonance Imaging: Physical Principles and Sequence Design, Second Edition 
(2014), MRI from Picture to Proton, Third Edition (2017), and MRIquestions.com 
(2020), unless otherwise referenced.  
 
1.5.2 Nuclear Magnetic Resonance  
MRI was originally known as NMRI, “nuclear magnetic resonance 
imaging,” but the adjective, "nuclear" was dropped to avoid negative 
connotations wrongly associated with radiation exposure (161). Atomic nuclei 
possess an intrinsic property known as spin angular momentum (I, kg·m2·s−1) 
that interacts with electromagnetic fields. The particle is not actually spinning. 
Rather, like mass, spin is a fundamental property and does not arise from more 
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basic mechanisms. Spin angular momentum is quantized into integer or half-
integer units e.g. ¹H has I = ½. Only nuclei with non-zero spins (I ≠ 0) can interact 
with electromagnetic fields and precess around the axis of an applied external 
magnetic field. The magnetic moment, &⃑ (A⋅m2) quantifying the interaction of the 
nuclei with this field is given by Equation 1.2. 
 
Equation 1.2. The gyromagnetic ratio of an atomic species.  
&⃑ = * ∙ ,⃑ 
 
The proportionality constant, * is known as the gyromagnetic ratio, which is 
unique for every nuclear isotope (Table 1.1). The nuclear magnetic dipole 
moment experiences a torque in the external magnetic field, -! which causes the 
dipole moment to precess around the field direction at a specific frequency 
known as the Larmor frequency, .! (Equation 1.2). 
 
Equation 1.3. The Larmor Equation.  
.! = * ∙ -! 
 
When an animal or human is placed in the scanner, the distribution of cones of 
precession of the ensemble of spins becomes skewed towards the field direction, 
resulting in a net longitudinal equilibrium magnetization. This longitudinal 
magnetization is manipulated by application of additional alternating magnetic 
fields producing signal for magnetic resonance imaging. 
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Table 1.1. Gyromagnetic Ratios of Various Atomic Species. Nuclei and their 
corresponding gyromagnetic ratio, measured in MHz/T. Note that some species have 
negative gyromagnetic ratios, which results in an opposite precession direction.  
 
 
 
 
 
 
 
 
Nucleus "
#$ (MHz⋅T
−1) 
1H 42.58 
2H 6.536 
3H 45.42 
3He −32.43 
7Li 16.55 
13C 10.71 
14N 3.077 
15N −4.316 
17O −5.772 
19F 40.05 
23Na 11.26 
27Al 11.10 
29Si −8.465 
31P 17.24 
57Fe 1.382 
63Cu 11.31 
67Zn 2.669 
129Xe −11.78 
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 We can see from Table 1.1 that among common nuclear isotopes, ¹H has 
the highest gyromagnetic ratio, dictating that it has the highest precession 
frequency and, as a result, is the most “MR visible” nucleus. The Larmor 
equation also dictates that larger magnetic fields generate higher precessional 
frequencies. In a 1.5T field, the resonance frequency of ¹H would be (42.58 
MHz/T) ∙ (1.5T) = 63.87 MHz. At 3.0T, the resonance frequency would be twice 
as large, or 127.74 MHz. For MRI, the net magnetization (/00⃑ ) is a useful term to 
describe the vector sum of individual spins, ,⃑ obtained from millions of nuclei 
placed in an external field. /00⃑  can be displaced from its equilibrium state (/00⃑ !) 
along the direction defined by -!through the application of a radiofrequency (RF) 
pulse, -%. This alternating magnetic field oscillates in a plane transverse to the 
static field at the Larmor frequency of the nuclei of interest e.g. ¹H. The 
application of -% produces a torque on /00⃑ !causing it to be tipped into the 
transverse plane and precess at the Larmor frequency around the external field. 
Following the RF excitation, the net magnetization returns to its equilibrium state 
according to the longitudinal (T1) and transverse (T2) relaxation times (Figure 
1.4). The T1 relaxation time (and its inverse rate, R1) characterizes the re-growth 
of 1/00⃑ 2 along the direction of the B0 field. This occurs through the transfer of 
energy from the excited nuclei to the lattice and is called spin-lattice relaxation for 
this reason. The T2 relaxation time (and its inverse rate, R2), referred to as spin-
spin relaxation, characterizes the exponential decay of the excited magnetization, 
/&' within the transverse plane through transfer of energy between spins.  
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Figure 1.4. Transverse Decay and Longitudinal Restoration. When the net 
magnetization (/00⃑ !) is tipped by a 90° radiofrequency pulse away from the magnetic field 
direction (3̂), the longitudinal magnetization, /( is completely transferred to the 
transverse (xy) plane, where the resulting transverse magnetization (/&') precesses at 
the Larmor frequency (.!), about the axis of the external magnetic field (z). /( regrows 
as a simple exponential with time constant T1. On the /( graph, it corresponds to the 
time required for /( to grow to approximately 63% (1 − 1/e) of its final value (/!). 
Similarly, the transverse relaxation time T2 represents the time required for /& or /' to 
decay to approximately 37% (1/e) of their initial maximum values. This image was 
adapted from MRIquestions.com, courtesy of Dr. Allen D. Elster.  
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1.5.3 Generating Image Contrast  
A linear magnetic field z-gradient is imposed along each Cartesian axis to 
spatially encode signals from every voxel in the MR imaging matrix. These 
gradients are many orders of magnitude smaller than the main field and are used 
to modify the frequency and phase of proton spins as a function of spatial 
position. That is, spatial encoding is achieved by assigning a unique phase and 
frequency to each location of the imaging volume. A series of instructions known 
as a “pulse sequence” is used to synchronize the RF excitation of /00⃑ ! and 
manipulate the gradient fields at specified time intervals.  
After RF excitation, the transverse magnetization, /&' induces a voltage 
in the RF coil, which is digitized and stored as the MR signal. MR signals arise 
from multiple voxels recorded all at once, each containing different tissues with 
different proton densities and relaxation times. The resulting total MR imaging 
data is thus the sum of many sinusoidal frequencies near the Larmor frequency 
with different phases, whose amplitudes rise or fall as a result of T2 effects and 
magnetic field inhomogeneities. Fourier transform methods are applied to the MR 
imaging data to sort out the frequency components and accumulated phases for 
reconstruction of the physical image.  
 
1.5.4 Contrast in Images  
Imaging parameters such as time-to-repetition (TR), time-to-echo (TE) and 
flip or excitation angle (5) can be specifically chosen to highlight different 
physical properties of tissues within the imaging volume related to their relaxation 
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properties, which makes them more conspicuous. For example, using 
parameters to produce T1-weighted images, tissues with short T1 values such as 
fat appear bright since they magnetize quickly while those with a long T1 like 
water or air appear dark. Contrast in T2-weighted images depends on the rate of 
dephasing (spin-spin relaxation) in a particular voxel following an RF excitation. 
In T2-weighted images, tissues with a long T2, like cerebrospinal fluid, appear 
bright, while tissues with a short T2, such as fat, appear dark (Table 1.2).  
Paramagnetic agents such as gadolinium (Gd)- and manganese (Mn)-
based contrast agents (GBCAs, MBCAs, respectively) are not directly observed 
on MR images, but rather, enhance the relaxation of surrounding protons, 
effectively shortening the T1 value of the tissue in which it accumulates, resulting 
in hyperintense volumes on T1-weighted images. The paramagnetic susceptibility 
of these elements is proportional to the number of unpaired electrons they 
possess e.g. seven for Gd. However, the ionic radius of free Gd+3 mimics that of 
Ca+2, and this chemical mimicry is cause for toxicity. Free gadolinium becomes a 
competitive inhibitor in processes that depend on Ca+2, including voltage-gated 
calcium channels and the activity of many vital enzymes. All GBCAs therefore 
require a ligand to chelate the free ion. This thesis specifically applies a clinically 
approved contrast agent, gadolinium ethoxybenzyl diethylene triamine 
pentaacetic acid (Gd-EOB-DTPA), known as Primovist, (Bayer, Inc.) as a probe 
for the development of a magnetic resonance imaging reporter gene. 
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Tissue T1 Time (ms) T2 Time (ms) 
Water/CSF 3700 - 4000 2000 
Gray Matter 1331 - 1485 80 - 96 
White Matter 832 - 923 70 - 110 
Muscle 898 - 1249 29 - 34 
Liver 745 - 809 31 - 34 
Fat 382 - 391 68 - 87 
 
Table 1.2. Relaxation Times of Common Tissues at 3 Tesla. Spin-lattice relaxation 
(T1) times, and spin-spin relaxation (T2) times, in milliseconds of various human tissues 
at 3 Tesla (162).  
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1.5.5 Reporter Genes for Magnetic Resonance Imaging 
Reporter genes for MRI include a diverse group of protein-based 
mechanisms through which contrast is enhanced. These can be separated into 
different classes based on the type of contrast produced: 1) negative contrast on 
1H MRI (106, 163-166), 2) positive contrast on 1H MRI (110, 167), 3) 
hyperpolarization-based reporters (168, 169), 4) diffusion-weighted reporters 
(169, 170), and those based on 5) chemical exchange saturation transfer (CEST) 
(105, 168). Perhaps the most widely investigated class of MR reporter genes are 
those that generate negative contrast (hypointense signal), based on the 
principle of iron sequestration. High concentrations of iron cause magnetic 
susceptibility changes in tissues that, in turn, increase their effective spin-spin 
relaxation i.e. decrease T2*.  
Negative contrast reporter genes include the iron storage molecule ferritin 
(163), the transferrin receptor (TfR) (164), the bacterial iron transporter magA 
(165), and the tyrosinase enzyme that produces iron-chelating melanin (166). 
Although negative contrast reporter genes have been demonstrated for various 
cancer-related applications, e.g. detection of dendritic cell migration to lymph 
nodes (171), presence of cancer cells in lymph nodes (172), regions of limited or 
no contrast already exist throughout the body at various major sites, making it 
difficult to definitively identify the location of engineered cells with accuracy and 
precision without serious reliance on pre-contrast images acquired at the start of 
the study.  
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Positive contrast mechanisms overcome this limitation by instead 
increasing the spin-lattice relation of tissues, or in other words decreasing T1, 
thereby causing increased local image intensity. Additionally, most of these 
positive contrast mechanisms depend on the administration of an agent for 
contrast enhancement, allowing for comparison of pre- and post-contrast images 
for increased conspicuity. Positive contrast reporter genes include the β-
galactosidase enzyme capable of cleaving a caged synthetic Gd3+ probe (110), a 
divalent metal transporter capable of taking up Mn2+ (167), and an organic anion-
transporting polypeptide transporter capable of taking up chelated Gd (173). This 
thesis focuses on the development of organic anion-transporting polypeptides as 
multimodality reporter genes that facilitate cancer cell tracking with magnetic 
resonance and photoacoustic imaging, with concomitant enhancement of 
bioluminescence signals in luciferase-expressing cells. 
 
1.5.6 Organic Anion-Transporting Polypeptides 
Organic anion-transporting polypeptides (Oatp) represent a large family of 
multispecific transporter proteins, differentially expressed on various mammalian 
tissues, including the kidneys, the liver, the heart, the brain, and the testis (174). 
Physiologically, they play a role in mediating the uptake of various compounds, 
including bile acids and steroid conjugates (175). Their presence in the body, 
however, have made them an important factor to consider in the design and 
development of several xenobiotics e.g. statins, some antibiotics, and anticancer 
drugs (176). Though the exact mechanism of Oatp-mediated transport remains 
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controversial, it is well established that transport is ATP- and sodium-
independent. The driving force for its transport remains an active area of 
research in both pharmacology and hepatology. With respect to imaging, human 
Oatp1b1 and Oatp1b3 are exploited for detection of liver lesions with MRI using a 
clinical contrast agent, gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic 
acid (Gd-EOB-DTPA), whose trade name is Primovist (Bayer, Inc) (177). Healthy 
liver cells expressing Oatp1b1 and Oatp1b3 are capable of taking up Gd-EOB-
DTPA and appear bright on MRI after its administration. Diseased regions of the 
liver (e.g. hepatocellular carcinoma cells or fibrosis) do not express these 
transporters and are unable to take up Gd-EOB-DTPA, and appear hypointense 
relative to regions of healthy liver.  
Motivated by this mechanism, work on Oatp reporter gene development 
began by scientists at the University of Cambridge who established rat-derived 
Oatp1a1 as an MR reporter gene, based on its ability to transport Gd-EOB-DTPA 
into expressing cells (173). As the Gd concentration increases within engineered 
cells following injection of the contrast agent, the Gd interacts with the water 
protons in the intracellular environment, increasing the spin-lattice relaxation rate 
of those protons, which in turn, increases the signal intensity from those voxels 
on T1-weighted MR images. Longitudinal in vivo imaging has determined the 
optimal time to image is approximately 5 hours after administration of the 
contrast agent. At this time interval, most nonspecific (extracellular) contrast is 
cleared from the body and only cells engineered to express Oatp1 retain the 
agent, thereby increasing the image contrast for those cells with up to a 7.8-fold 
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in vivo signal enhancement at 7 Tesla following an injection of 2-mmol/kg Gd-
EOB-DTPA in mice. Contrast enhancement in the Oatp1a1-expressing 
xenografts returned to baseline levels by 60 hours (Figure 1.5). Since this initial 
publication, however, very little further research has been undertaken to develop 
this technology for gene and/or cell tracking applications. The unique 
combination of advantages presented by this reporter gene, which include its 
employment of a clinical probe as well as its reversibility, dose-dependent 
expression, positive contrast, and multimodal capabilities, warranted further 
study into its development as a reporter gene for whole-body tracking of 
engineered cells.  
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Figure 1.5. Magnetic Resonance Imaging of Oatp1 Expression In Vivo. (A) T1-
weighted images before (0) and 5, 10, 25, 50, and 80 hours after intravenous injection 
of Gd-EOB-DTPA, of a representative animal bearing 293T xenografts. Control 
xenograft (left flank) expressed luciferase and the xenografts on the right flank 
expressed luciferase and Oatp1. (B) Xenograft relaxation rates (R1) before (0) and 
following intravenous injection of Gd-EOB-DTPA (0.664 mmoles/kg) were significantly 
greater compared with controls [*P < 0.001, **P < 0.0001, n = 5 (n = 4 at 107 h)]. (C) R1 
increased in control and Oatp1-expressing xenografts after repeated intravenous 
injection with Gd-EOB-DTPA (0.664 mmoles/kg), following washout of the original dose 
in A/B and injection and washout of Gd-DTPA. This figure was acquired from Patrick et 
al. (173).  
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1.6 Photoacoustic Imaging  
1.6.1 Basic Principles  
Light in the visible portion of the spectrum is highly scattered by tissues. 
Methods that attempt to form images from light passing through tissue fall into 
two categories: ballistic (minimally scattered) microscopy e.g. fluorescence 
microscopy, and diffuse (multi-scattered) imaging e.g. bioluminescence imaging. 
The former provides fine resolution but with a shallow imaging depth in tissue, up 
to approximately 1 mm, as defined by the optical diffusion limit (178). When 
incident photons reach this depth, most have undergone tens of scattering 
events, which randomize the photon paths and inhibit effective optical focusing 
and image formation. On the other hand, diffuse optical imaging can probe 
centimeters into tissue but with limited spatial resolution, equivalent to about one-
third the imaging depth (179). Randomized paths of the diffuse photons render 
the image reconstruction difficult. It remains a challenge for conventional optical 
imaging to attain fine spatial resolution at depths beyond the optical diffusion 
limit. 
Photoacoustic imaging (PAI), or optoacoustic imaging, is a hybrid imaging 
modality based on acoustic detection of optically-excited sources, thereby 
combining the advantages of optical contrast specificity with the spatial resolution 
of ultrasound (180). In the photoacoustic effect, endogenous molecules such as 
de-oxyhemoglobin and oxyhemoglobin, or exogenous contrast agents, are 
excited by nanosecond-pulsed laser beams and rapidly convert a fraction of that 
energy into heat during relaxation. This heat energy leads to a transient 
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thermoelastic expansion, resulting in the emission of ultrasonic waves that can 
be detected with ultrasound transducers to produce images. Photoacoustic 
imaging side steps the optical diffusion limit by exploiting low acoustic scattering 
in tissue, about three orders of magnitude less than optical scattering in tissue 
per unit path length (181). By exciting different molecules at different optical 
wavelengths, photoacoustic imaging reveals rich optical contrasts according to 
chemical composition, and provides inherently background-free detection 
because the photoacoustic amplitude is proportional to the optical absorption and 
quantum yield of the target molecules (182). In relation to other optical modalities 
(e.g., fluorescence imaging), photoacoustic imaging has the capability of 
improved resolution and increased depth of imaging (Figure 1.6).  
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Figure 1.6. Imaging Resolution vs Imaging Depth of Optical or Optic-based 
Modalities. Comparison of the performance of photoacoustic imaging with that of 
optical and ultrasonic modalities, with respect to their imaging depth and spatial 
resolution. PAM, photoacoustic microscopy; PACT, photoacoustic computed 
tomography; US, ultrasound imaging. Figure was acquired from Brunker et al. (101).  
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1.6.2 Applications for Cancer Research 
Photoacoustic imaging is a relatively nascent modality, first demonstrated 
in the late 1990s (183-185) and recent refinements have led to broad 
applications in biology and medicine. Major preclinical applications include 
imaging of angiogenesis, microcirculation, tumour microenvironments, drug 
response, biomarkers, and gene activities (186), while initial clinical applications 
include melanoma cancer imaging, gastrointestinal tract endoscopy, 
intravascular catheter imaging, neonatal brain imaging, breast and prostate 
cancer detection, sentinel lymph node needle guidance, imaging of early 
chemotherapy response, in vivo label-free histology, blood perfusion imaging, 
blood oxygenation imaging, and tissue metabolism imaging (186-188).  
 
1.6.3 Photoacoustic Reporter Genes  
Though the field of photoacoustic imaging is relatively new, the small 
number of endogenous contrast sources within biological tissues, and the ability 
to acquire real-time co-registered anatomical images with ultrasound, has 
spurred rapid development of several reporter genes for gene and/or cell tracking 
on photoacoustic imaging. Photoacoustic reporter genes can be classified as 
either direct or indirect, depending on whether the protein encoded is the source 
of contrast, or whether the protein instead processes an injected agent that, in 
turn, generates the contrast (101). Briefly, photoacoustic reporter genes with 
direct mechanisms include fluorescent, nonfluorescent/chromoprotein, and 
photoswitchable reporter genes. On the other hand, indirect mechanisms have 
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so far consisted of enzymatic proteins, including tyrosinase, β-galactosidase, and 
the VioA-E operon. Of these, tyrosinase and β-galactosidase have been more 
widely employed. Human-derived tyrosinase is responsible for the rate limiting 
step in the melanin synthesis pathway, that is, the oxidation of tyrosine to 
dopaquinone (189). Specifically, melanin exhibits a broad extinction coefficient 
spectrum, that spans the visible to near-infrared wavelength region and 
possesses a relatively low quantum yield, allowing for its detection on 
photoacoustic imaging (190, 191). The β-galactosidase reporter, encoded by the 
bacterial-derived LacZ gene, is naturally responsible for lactose metabolism, but 
is more widely known for its role in a chromogenic complementation assay, 
whereby the colourless lactose analog 5-bromo-4-chloro-3-indolyl-β-D-
galactoside probe, known as X-gal, is cleaved, thereby yielding a stable dark 
blue product (192). In 2007, β-galactosidase was demonstrated as the first 
photoacoustic reporter gene for in vivo imaging, with significant contrast-to-noise 
at 650 nm wavelengths (193). Indirect mechanisms of genetically-encoded 
photoacoustic contrast present with several advantages over direct mechanisms, 
but primarily offer signal amplification, allowing for increased sensitivity for gene 
and/or cell tracking (194). Interestingly, both tyrosinase and β-galactosidase have 
also been previously established as MR reporter genes, thereby allowing for 
multi-modality molecular imaging for in vivo gene and/or cell tracking (195).  
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1.7 Purpose of Thesis  
1.7.1 Rationale  
The reporter gene approach for in vivo molecular imaging has significant 
potential for cell tracking applications in preclinical research and clinical 
medicine. Specifically, the ability of the Oatp1 reporter gene to transport and 
concentrate specific clinical contrast agents within engineered cells, could allow 
for sensitive, high resolution imaging in 3D, with positive contrast with several 
imaging modalities. The overall objective of the work presented in this thesis is to 
develop and assess new methods of reporter gene imaging for tracking of 
engineered cancer cells in preclinical mouse models.  
 
1.7.2 Hypothesis 
In its development and assessment of Oatp1 as a multimodality reporter gene 
for in vivo molecular imaging, this thesis is testing three primary hypotheses: 
 
1. Rat-derived Oatp1a1 will facilitate longitudinal imaging of viable cancer 
cell distributions within primary tumours on MRI at 3 Tesla, based on its in 
vivo ability to transport Gd-EOB-DTPA into cells.  
2. Human-derived Oatp1b3 will allow for longitudinal, whole-body imaging of 
spontaneous cancer cell metastasis on MRI at 3 Tesla, based on its ability 
to take up Gd-EOB-DTPA in vivo.  
3. Human-derived Oatp1b3 can be utilized as a photoacoustic imaging 
reporter gene, for detection of viable cancer cells, based on its ability to 
take up indocyanine green in vivo.  
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1.7.3 Overview of Studies  
In our initial research, we strove to build on the seminal work first reported 
in PNAS, which established rat-derived Oatp1a1 as an MRI reporter gene using 
the paramagnetic contrast agent, Gd-EOB-DTPA (173). We wanted to extend 
this work by establishing the feasibility of using Oatp1a1 at clinical doses of Gd-
EOB-DTPA and a clinical field strength of 3 Tesla. In Chapter 2, we 
demonstrated for the first time that Oatp1a1 is able to provide high resolution, 3D 
information on the distribution of viable cancer cells in primary tumours, at clinical 
contrast agent dose and field strength. Importantly, we validated the local 
contrast enhancement exhibited on MRI with quantitative histology. This chapter 
has been peer-reviewed and accepted for publication as: Nyström NN, Hamilton 
AM, Xia W, Liu S, Scholl TJ, Ronald JA. “Longitudinal Visualization of Viable 
Cancer Cell Intratumoral Distribution in Mouse Models Using Oatp1a1-Enhanced 
Magnetic Resonance Imaging.” Investigative Radiology. 2019 May; 54(5): 302-
311. DOI: 10.1097/RLI.000000000 0000542. In Chapter 3, we worked with 
human-derived Oatp1b3, a closely-related transporter to the rat-derived Oatp1a1, 
and worked to establish its potential future use in humans as a clinical-grade 
reporter gene. This research validated that Oatp1b3, like Oatp1a1, can also 
transport Gd-EOB-DTPA with a significant efficiency for MR imaging. Importantly, 
we further demonstrated that Oatp1b3 facilitates sensitive imaging of 
spontaneous metastasis in preclinical mouse models at the single lymph node, 
multi-lymph node, and distant organ metastatic stages on MRI at 3 Tesla. 
Chapter 3 is currently in preparation as a manuscript for submission to peer-
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review. In Chapter 4, our research was focused on expanding the Oatp1 imaging 
reporter gene “toolkit” beyond MR imaging to include photoacoustic imaging. This 
extension offers potential for cost-effective, 3D imaging at tissue depths of 
several centimeters. Here, we first demonstrated in in vitro experiments that 
Oatp1b3 will transport indocyanine green resulting in increased signal-to-noise 
ratios for both fluorescence and photoacoustic imaging. Using in vivo 
fluorescence imaging, we determined the optimal imaging timepoint after 
administration of indocyanine green to be 24 hours post-intraperitoneal injection. 
And finally, we established in a murine breast cancer model that in vivo 
photoacoustic imaging can readily detect Oatp1b3-engineered cancer cells after 
injection of indocyanine green. This chapter has been peer-reviewed and 
accepted for publication as: NN Nyström, LCM Yip, JJL Carson, TJ Scholl, JA 
Ronald. “Development of a Human Photoacoustic Imaging Reporter Gene Using 
the Clinical Dye Indocyanine Green.” Radiology: Imaging Cancer 1 (2), e190035. 
DOI: 10.1148/rycan.201919 0035.  
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CHAPTER 2 Intratumoral Distribution of Viable Cancer Cells over Time 
Rationale. Multimodality reporter gene imaging provides valuable, non-invasive 
information on the fate of engineered cell populations. To complement magnetic 
resonance imaging (MRI) measures of tumour volume and 2-dimensional reporter-
based optical measures of cell viability, reporter-based MRI may offer 3-dimensional 
information on the distribution of viable cancer cells in deep tissues. Methods. Here, we 
engineered human and murine triple-negative breast cancer cells with lentivirus 
encoding tdTomato and firefly luciferase for fluorescence imaging and bioluminescence 
imaging (BLI). A subset of these cells was additionally engineered with lentivirus 
encoding organic anion transporting polypeptide 1a1 (Oatp1a1) for MRI. Oatp1a1 
operates by transporting gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid 
(Gd-EOB-DTPA) into cells, and it concomitantly improves BLI substrate uptake. After 
orthotopic implantation of engineered cells expressing or not expressing Oatp1a1, 
longitudinal fluorescence imaging, BLI, and 3-Tesla MRI were performed. Results. 
Oatp1a1-expressing tumours displayed significantly increased BLI signals relative to 
control tumours at all time points (p<0.05). On MRI, post-Gd-EOB-DTPA T1-weighted 
images of Oatp1a1-expressing tumours exhibited significantly increased contrast-to-
noise ratios compared with control tumours and pre-contrast images (p<0.05). At 
endpoint, tumours expressing Oatp1a1 displayed intratumoral MR signal heterogeneity 
not present at earlier time points. Pixel-based analysis of matched in vivo MR and ex 
vivo fluorescence microscopy images revealed a strong, positive correlation between 
MR intensity and tdTomato intensity for Oatp1a1-expressing tumours (p<0.05), but not 
control tumours. Conclusions. These results characterize Oatp1a1 as a sensitive, 
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quantitative, positive contrast MRI reporter gene for 3-dimensional assessment of viable 
cancer cell intratumoral distribution and concomitant BLI enhancement. This 
multimodality reporter gene system can provide new insights into the influence of viable 
cancer cell intratumoral distribution on tumour progression and metastasis, as well as 
improved assessments of anticancer therapies. 
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2.1 Introduction 
 Fluorescent reporter genes have provided valuable insight towards the 
understanding of molecular processes occurring in cancer, from the role of regulatory 
RNA (1, 2), to new knowledge on cancer stem cells (3), and the intercellular interactions 
involved in metastasis (4). Although fluorescence imaging (FLI) produces excellent 
resolution, it is restricted to superficial tissue depth due to light scattering in deep tissues. 
Bioluminescence imaging (BLI) allows for sensitive whole-body imaging of luciferase-
engineered cells in preclinical animal models with increased detection depth compared 
to FLI but presents data with low two-dimensional resolution and minimal anatomic 
information. Similar to FLI, BLI still suffers from light scattering, often preventing 
researchers from pinpointing precise locations of reporter gene expression in deep 
tissues. Additionally, light attenuation by surrounding tissues may fully impede the 
detection of weaker signals from deeply-located and/or smaller populations of engineered 
cells (5). Multimodality imaging can ameliorate inherent limitations present in a single 
imaging modality (6-8). For example, reporter genes for magnetic resonance imaging 
(MRI) would provide the high resolution, 3-dimensional and quantitative information 
needed to complement data provided by more affordable and time-efficient optical 
modalities such as FLI and BLI. Hence, development of a multimodality FLI/BLI/MRI 
reporter system could be used to provide a more complete picture of the cellular and 
molecular changes occurring in vivo over time, including its use in studying longitudinal 
cancer progression and treatment response in preclinical animal models. 
 In recent years, MRI reporter gene development has largely focused on negative 
contrast technologies based on iron-accumulating proteins such as ferritin heavy chain 
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(FTH) and the transferrin receptor (TfR) (9). However, negative contrast in tumour 
microenvironments can be the result of other processes such as hemorrhage, thereby 
generating uncertainty in the source of the loss of contrast on MRI (10). Moreover, regions 
of low signal naturally exist in MR images throughout the body (e.g., lungs). Alternatively, 
positive contrast MRI reporter genes are also being developed (11-13). Recently, a 
member of the organic anion-transporting polypeptide (OATP) family of proteins, namely 
Oatp1a1 (slco1a1, slc21a1, slc21a3, oatp1, OATP-1), has been established as a positive 
contrast MRI reporter gene based on its ability to take up a clinically-approved, liver-
specific paramagnetic contrast agent called gadolinium ethoxybenzyl diethylenetriamine 
pentaacetic acid (Gd-EOB-DTPA; Primovist/Eovist, Bayer-Schering Pharma, Berlin, 
Germany) (14). Gd-EOB-DTPA-enhanced MRI performed on high-field 7-Tesla and 9.4-
Tesla scanners showed contrast enhancement of Oatp1a1-expressing xenografts in mice 
following administration of high Gd-EOB-DTPA doses (approximately 25-fold greater than 
clinical doses) (14). An added advantage of this system is that Oatp1a1 co-expression 
with firefly luciferase also increased BLI signal generation in engineered cells through 
increased intracellular uptake of the luciferase substrate D-luciferin (15). Further 
development and characterization of Oatp1a1 as an MRI reporter gene with concomitant 
BLI enhancement would allow for its widespread use in longitudinal imaging studies of 
preclinical cancer models, as well as clinical MRI applications such as tracking of gene- 
or cell-based therapies.  
 Here, we established a multimodality reporter gene system composed of two 
distinct lentiviruses: the first lentivirus was built to co-express the fluorescence reporter 
tdTomato (tdT) with the BLI reporter human codon-optimized firefly luciferase (FLuc2); 
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and the second encoded the fluorescence reporter zsGreen1 (zsG) co-expressed with 
Oatp1a1. Human and murine triple negative breast cancer (TNBC) cells were engineered 
with this system and imaged both in vitro and in vivo. Following cell implantation, 
orthotopic TNBC tumours in mice were longitudinally imaged for three weeks with BLI 
and MRI using a clinical 3-Tesla MRI scanner. Each week, pre-contrast MRI was 
performed on mice, followed by administration of Gd-EOB-DTPA (0.1 mmol/kg) at a dose 
deemed safe for use in humans (16) and post-contrast MRI. Significant MRI and BLI 
enhancement of Oatp1a1-expressing tumours was observed relative to control tumours. 
Moreover, as tumour growth progressed, Oatp1a1-based high-resolution, 3-dimensional 
MRI revealed intratumoral heterogeneity in signal enhancement, with enhanced MR 
regions containing viable fluorescent TNBC cells according to ex vivo microscopic 
analysis, and non-enhanced MR regions composed of necrotic tissue, hemorrhage, 
and/or non-fluorescent cells. Our studies highlight the utility of this tri-modality reporter 
gene system for tracking the fate of viable cancer cells over time using complementary 
imaging modalities. We posit that this imaging approach will have significant impact for 
improved monitoring of viable cancer cell growth across a broad range of preclinical solid 
tumour models. 
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2.2 Materials and Methods  
2.2.1 Lentiviral Construction and Production  
Third generation packaging and envelope-expression plasmids 
pMDLg/pRRE, pRSV-Rev, and pMD2.G were obtained (gifts from Didier Trono; 
Addgene plasmids #12251, #12253, and #12259, respectively), in addition to a 
third-generation lentiviral transfer vector encoding tdT and firefly luciferase (FLuc) 
separated by a P2A self-cleaving peptide sequence (pUltra-Chili-Luc; gift from 
Malcolm Moore; Addgene plasmid #48688).  All cloning was performed using In-
Fusion HD Cloning (Takara Bio USA, Inc.). In the pUltra-Chili-Luc vector, we first 
replaced FLuc with FLuc2 and then replaced the Ubiquitin C promoter with a 
human elongation factor 1 alpha promoter (pEF1α) obtained from the pSelect-Zeo-
SEAP Vector (Cat. psetz-seap, InvivoGen). This latter transfer vector was called 
pEF1α-tdT/FLuc2. The resultant transfer vector was further cloned, using the same 
protocol described above, to replace tdTomato with the zsGreen1 fluorescence 
reporter gene (zsG) sequence, obtained from the pLVX-ZsGreen1-N1 Vector (Cat. 
632565, Takara Bio USA, Inc.), generating an intermediary pEF1α-zsG/FLuc2 
transfer plasmid. The LV-PGK-SO plasmid co-expressing mStrawberry- and 
Oatp1a1 (14) was kindly provided by Dr. Kevin Brindle (University of Cambridge). 
The E2A-Oatp1a1 sequence was amplified and cloned, as described above, 
replacing the P2A-FLuc2 sequence within pEF1α-zsG/FLuc2 to obtain a pEF1α-
zsG/Oatp1a1 lentiviral transfer plasmid. To produce pEF1α-tdT/FLuc2 and pEF1α-
zsG/Oatp1a1 lentiviruses, the packaging, envelope and one of the transfer 
plasmids were co-transfected into human embryonic kidney (HEK 293T) cells 
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using Lipofectamine 3000 (ThermoFisher Scientific) according to the 
manufacturer’s lentiviral production protocol. Lentivirus-containing supernatants 
were harvested 24h and 48h post transfection, filtered through a 0.45-μm filter, 
and stored at -80°C prior to use. 
 
2.2.2 Cell Culture and Stable Cell Generation 
Human embryonic kidney cells (HEK 293T), human TNBC cells (MDA-MB-
231), and murine TNBC cells (4T1) were obtained from a commercial supplier 
(American Type Culture Collection; ATCC) and cultured in Dulbecco's Modified 
Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum at 37°C and 
5% CO2. All cells were routinely verified as free of mycoplasma contamination 
using the MycoAlert mycoplasma detection kit (Lonza Group). For stable cell 
generation, MDA-MB-231 and 4T1 cells were first transduced with pEF1α-
tdT/FLuc2 lentivirus overnight in the presence of 4- to 8- μg/mL polybrene. 
Transduced cells were washed, collected, and tdT-positive cells were sorted using 
a FACSAria III fluorescence-activated cell sorter (BD Biosciences), thereby 
generating luciferase-expressing cells. These luciferase-expressing cells were 
expanded, and a subset of this population was additionally transduced with pEF1α-
zsG/Oatp1a1 lentivirus and zsG-positive cells were sorted. The resulting 
population will be referred to as luciferase/Oatp1a1-expressing cells. During 
sorting for zsG, cells were also sorted for tdTomato fluorescence intensity that was 
equivalent to the original luciferase-expressing cells to maintain equivalent 
luciferase expression. Fluorescence intensity of expanded cell populations was 
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evaluated via flow cytometry using a FACSCanto flow cytometer (BD Biosciences). 
Fluorescence was analyzed using FlowJo software (FlowJo LLC) to validate 
luciferase- and luciferase/Oatp1a1-expressing cells had matched tdT fluorescence 
signal (i.e., matched FLuc2 expression), and sorted and validated cells were 
utilized for all experiments. 
 
2.2.3 Immunofluorescence Staining  
Luciferase- and luciferase/Oatp1a1-expressing cells were grown on glass 
coverslips, rinsed with PBS, and fixed with 4% paraformaldehyde (PFA) for 10 
minutes. Cells were then permeabilized via 0.02% Tween 20 (Sigma-Aldrich) for 
20 minutes, incubated overnight at 4°C with rabbit anti-OATP1A1 primary antibody 
(20 µg/ml, LS-C113034, LifeSpan BioSciences Inc.), followed by incubation with 
goat anti-rabbit AlexaFluor 647-conjugated secondary antibodies for two hours at 
room temperature (1:500 dilution, ab150079, Abcam). Coverslips were 
counterstained with DAPI, mounted, and imaged using a LSM Meta 510 
microscope (Zeiss).  
 
2.2.4 Proliferation Assays  
Non-transduced, luciferase-, and luciferase/Oatp1a1-expressing cells 
(5×104) were seeded in 96-well plates and cell proliferation was evaluated using a 
tetrazolium salt (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 
MTT) assay. Optical absorbance measurements at 590 nm were made on a 
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spectrophotometer at 0h, 24h and 48h post initial seeding. Measures at 24h and 
48h were normalized to seeding values obtained at 0h to evaluate cell proliferation.  
 
2.2.5 In Vitro Luciferase Assays  
Total intracellular luciferase activity was measured on cell lysates using the 
Dual-Luciferase Reporter Assay System (E1910, Promega). Light production in 
relative light units (RLU) was measured on a GloMax 20/20 Luminometer 
(Promega) after mixing of 10 μL of lysate and 5 μL of LARII substrate. Protein 
concentrations were calculated using a Pierce BCA Protein Assay Kit for 
normalization of light production (ThermoFisher Scientific). For BLI of intact cells, 
1×105 cells/well were seeded in 6-well plates and grown for 3 days, after which 
0.15 mg/ml D-luciferin was added to each well, and plates were imaged on an IVIS 
Lumina XRMS In Vivo Imaging System (PerkinElmer). Following BLI, cells from 
each well were harvested and protein concentrations were measured using a 
Pierce BCA Protein Assay Kit. Average radiance values in photons/s/cm2/sr were 
measured from each well using the software LivingImage (PerkinElmer) and 
normalized to protein levels as a surrogate measure of cell number. 
 
2.2.6 In Vitro Magnetic Resonance Imaging 
Non-transduced, luciferase-, and luciferase/Oatp1a1-expressing cells 
(2×106) were seeded in T-175 flasks and grown for 3 days. Cells were incubated 
with media containing 1.6-mM Gd-EOB-DTPA or with media containing an 
equivalent volume of PBS for 90 minutes at 37°C and 5% CO2. Cells were then 
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washed 3 times with PBS, trypsinized and pelleted in 0.2-mL tubes, and placed 
into a 2% agarose phantom mold that was incubated in a 37°C chamber for two 
hours to mimic body temperature. MRI was performed on a 3-T GE clinical MR 
scanner (General Electric Healthcare Discovery MR750 3.0 T, Milwaukee WI, 
U.S.A.) and a 3.5-cm diameter birdcage RF coil (Morris Instruments, Ottawa, ON, 
Canada). A fast spin echo inversion recovery (FSE-IR) pulse sequence was used 
with the following parameters: field of view (FOV) = 256´256, repetition time (TR) 
= 5000 ms, echo time (TE) = 19.1 ms, echo train length (ETL) = 4, number of 
excitations (NEX) = 1, receiver bandwidth (rBW) = 12.50 MHz, inversion times (TI) 
= 50, 100, 125, 150, 175, 200, 250, 350, 500, 750, 1000, 1500, 2000, 2500, 3000, 
in-plane resolution = 0.27 mm2, slice thickness = 2.0 mm, scan time = 5 min and 
25 s per inversion time. Spin-lattice relaxation rates (R1) were determined by non-
linear least-squares fitting (MATLAB, MathWorks, Natick, Massachusetts, United 
States) of signal intensities across the series of variable inversion time images on 
a pixel by pixel basis. The most common inversion recovery equation presented in 
the literature is as follows:  
! = # ∙ (1 − 2)!	
#$
#! 	+ 	)!
#%
#! ) 
 
Here, !  represents the acquired signal, and #  is the proportionality 
constant, which depends on the specific coil used, the main magnetic field, the 
proton density, and the temperature, amongst other factors (17). However, two 
practical obstacles exist that render this equation impractical for real-world 
applications: first, a perfect 180° pulse is never truly achieved, and second, the 
signal is not acquired immediately after the RF pulse (18). In practice, these real-
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world limitations produce a different behavior at -. = 	0  and -. = 	∞  than 
predicted theoretical outputs dictated by the equation above. To address these 
limitations, and assuming -1 ≫ -. , the equation above was adjusted to the 
following:  
! = 3&& − (3&& −3') ∙ )
"#$ #!%  
  
Here, if -. = 	0 , then ! = 	−3'  where 3'  is simply the first value of the 
inversion recovery curve, independent of the final, steady state magnetization 3&&. 
Additionally, if -. = 	∞, then ! = 	3&&. Finally, we use the absolute value of this last 
equation because the DICOM images acquired provided magnitude (non-phase) 
information:  
! = 43&& −	(3&& −3') ∙ )
"#$ #!% 4 
 
The zero-crossing point, the -. at which point ! = 0, is extrapolated from 
the data and the 1( of each pixel can be determined via the following 
relationship: 
1( = ln 2 -.)*++7  
 
2.2.7 Orthotopic Tumour Model  
Animals were cared for in accordance with the standards of the Canadian 
Council on Animal Care, and experiments were undertaken with an approved 
protocol of the University of Western Ontario’s Council on Animal Care (AUP 2016-
026). One million luciferase- (n=4) or luciferase/Oatp1a1-expressing (n=5) MDA-
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MB-231 cells, or 0.3×106 luciferase- (n=5) or luciferase/Oatp1a1-expressing (n=5) 
4T1 cells were implanted orthotopically into the right fourth mammary fat pad of 
immunocompromised (Nu/Foxn1-nu) female mice (Charles River). Fluorescence 
imaging for tdTomato, BLI for luciferase with or without co-expression of Oatp1a1, 
and Gd-EOB-DTPA enhanced MRI for Oatp1a1 was performed on mice according 
to the imaging timelines specified below. Non-specific Gd-DTPA-enhanced MRI 
was also performed on mice bearing luciferase-expressing tumours (n=2) or 
luciferase/Oatp1a1-expressing tumours (n=2) at endpoint.  
 
2.2.8 In Vivo Fluorescence and Bioluminescence Imaging 
FLI and BLI were performed on an IVIS Lumina XRMS In Vivo Imaging 
System (PerkinElmer). For MDA-MB-231 mice, FLI and BLI was performed on 
days 0, 4, 8, 12, and 16 after cell implantation. For 4T1 mice, FLI and BLI was 
performed on days 0, 4 and 8 after cell implantation. Mice were anesthetized with 
1-2% isoflurane using a nose cone attached to an activated carbon charcoal filter 
for passive scavenging. FLI for tdTomato was performed using 554-nm excitation 
and 581-nm emission filters. Images were acquired with a 0.15-s exposure time. 
Mice were then administered 150 μL of 30-mg/mL D-luciferin intraperitoneally and 
BLI images with 0.15-s exposure times were captured every 30 s for 30 minutes. 
Regions of interest (ROIs) were manually drawn around tumour borders using 
LivingImage software (PerkinElmer) to measure fluorescence radiance efficiency 
(µW/cm2).  The ROI of the tdTomato fluorescence image for each mouse on each 
day was then overlayed onto the corresponding BLI image, that was acquired 
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subsequently, to measure bioluminescent average radiance (p/s/cm2/sr). The ratio 
of BLI average radiance to fluorescence radiance efficiency, which we called 
normalized radiance in accordance with previous literature (19), was then 
calculated for each tumour on each day.  
 
2.2.9 In Vivo Magnetic Resonance Imaging  
Scans were performed on a 3-T GE clinical MR scanner (General Electric 
Healthcare Discovery MR750 3.0 T, Milwaukee WI, U.S.A.) using a custom-built 
gradient insert and a bespoke 5-cm-diameter solenoidal radiofrequency coil. For 
MDA-MB-231 mice, MRI was performed on days 7, 9, 14, 16, 21, and 23 after cell 
implantation.  4T1 mice were imaged on days 7 and 9. Mice were anesthetized 
with 1-2% isoflurane using a nose cone attached to an activated carbon charcoal 
filter for passive scavenging. T1-weighted images were acquired using a Spoiled 
Gradient Recalled Acquisition in Steady State (SPGR) pulse sequence using the 
following parameters: FOV = 50mm, TR = 15.8 ms, TE = 10.5 ms, rBW = 31.25 
MHz, ETL = 4, Frequency and Phase 500×500, Flip Angle: 60°, NEX = 1, v 100-
µm isotropic voxels, scan time = approximately 22-24 minutes per mouse 
(dependent on mouse size). Pre-contrast images were acquired approximately 48 
hours prior to post-Gd-EOB-DTPA imaging, on days 7, 14, and 21. For post-Gd-
EOB-DTPA imaging on days 9, 16, and 23, mice were administered 0.1 mmol/kg 
Gd-EOB-DTPA via the tail vein and imaged on MRI 5 hours post-injection. (See 
timeline in Supplementary Figure 1.) Additionally, mice bearing luciferase- (n=2) 
and luciferase/Oatp1a1-expressing (n=2) MDA-MB-231 tumours at endpoint were 
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administered 0.1 mmol/kg gadolinium-diethylenetriamine pentaacetic acid (Gd-
DTPA; Magnevist, Bayer-Schering Pharma, Berlin, Germany) and imaged 10 
minutes post-injection using the scanning parameters described above. Following 
imaging, whole-tumours were manually segmented in three-dimensions using ITK-
SNAP software and contrast-to-noise ratios relative to hind-leg muscle in all 
images were calculated (20). 
 
2.2.10 Histology  
Following in vivo experiments, mice were sacrificed via isoflurane overdose, 
perfused with 4% PFA through the left heart ventricle and tumours were excised 
from mammary fat pads. Tumours were then frozen in OCT medium (Sakura 
Finetek) and 10-µm frozen sections were collected. Whole-tumour microscopy 
images of tdTomato fluorescence were taken using an EVOS FL Auto 2 Imaging 
System (Invitrogen) prior to hematoxylin/eosin (H&E) staining of the same and/or 
adjacent histology sections and subsequent imaging with the same microscope. 
For pixel-by-pixel analysis of MRI intensity to tdTomato fluorescence intensity, 
fluorescence microscopy images of whole-tumours were converted to the 
Neuroimaging Informatics Technology Initiative (NIfTI) data format (21). A blinded 
participant matched fluorescence microscopy images to a corresponding Gd-EOB-
DTPA-enhanced MRI image plane for a luciferase- and luciferase/Oatp1a1 mouse, 
and utilized a 15-fiducial system per image set on 3D Slicer (Version 4.31, Surgical 
Planning Laboratory, Brigham & Women's Hospital Boston MA, U.S.A.) to perform 
a non-rigid image registration using with a custom software plugin (22). Following 
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registration, fluorescence microscopy and Gd-EOB-DTPA-enhanced MR images 
of each tumour were imported into MATLAB, overlayed, and MR intensity and 
fluorescence intensity were each binned into 256 values. Pixels with zero-values 
for MR intensity and/or tdTomato fluorescence intensity were excluded from the 
analysis. Once MR intensity and fluorescence intensity were obtained for each 
pixel, the mean fluorescence intensity for each MR intensity bin was then 
calculated. MR intensity bins with fewer than 100 pixels were excluded from the 
analysis to eliminate bins with insufficient sampling numbers for meaningful 
calculations. 
 
2.2.11 Statistics 
Unpaired two-tailed t tests were performed using Graphpad Prism software 
(Version 7.00 for Mac OS X, GraphPad Software Inc., La Jolla California USA, 
www.graphpad.com) for cell characterization and luciferase studies. Two-way 
Analysis of Variance (ANOVA) and Tukey’s post-hoc multiple comparisons were 
performed for MRI results. For pixel-by-pixel MRI-to-fluorescence image analysis, 
Pearson correlation tests were performed. For all tests, a nominal p-value less 
than 0.05 was considered statistically significant.  
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2.3 Results 
2.3.1 Lentiviral expression of reporter genes in human and murine TNBC cells 
Lentiviral transfer plasmids encoding pEF1a-tdT/FLuc2 and pEF1a-
zsG/Oatp1a1 were successfully engineered and utilized to produce lentiviral 
vectors (Figure 2.1A). Human (MDA-MB-231) and murine (4T1) TNBC cell lines 
were transduced with pEF1a-tdT/FLuc2 lentivirus and subsequently sorted for 
tdTomato fluorescence with >95% purity to obtain luciferase-expressing cells. 
Following sorting and expansion, a subset of luciferase-expressing cells was 
transduced a second time with pEF1a-zsG/Oatp1a1 lentivirus and sorted again for 
zsGreen1 fluorescence with >95% purity whilst also matching the tdTomato 
intensity to that of the original luciferase-expressing cells (Figure 2.1B). OATP1A1 
immunostaining confirmed absence of Oatp1a1 expression in luciferase-
expressing cells, whereas positive OATP1A1 staining was present in cells double 
transduced with the pEF1a-zsG/Oatp1a1 lentivirus (Figure 2.1C), hereafter 
referred to as luciferase/Oatp1a1-expressing cells. Proliferation assays showed no 
difference in growth rates between non-transduced cells, luciferase-expressing 
cells, and luciferase/Oatp1a1-expressing cells for both human and murine TNBC 
cell lines. 
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Figure 2.1. Lentiviral Engineering of Triple-Negative Breast Cancer Cells with a 
Multimodality Reporter Gene System. A, Reporter gene constructs for co-expression 
of tdT and human codon-optimized firefly luciferase (luciferase), and zsG and organic 
anion-transporting polypeptide 1a1 (Oatp1a1). B, Histograms of 4T1 cells engineered 
with the reporter gene constructs and fluorescence-activated cell sorted for tdT and zsG 
fluorescence. C, Anti-Oatp1a1 immunofluorescence staining of MDA-MB-231 cells 
engineered with tdT/luciferase lentivirus alone (Luciferase Control) or additionally 
engineered with zsG/Oatp1a1 lentivirus (Luciferase OATP1A1). Scale bar = 20 μm. 
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2.3.2 Increased BLI signal and Gd-EOB-DTPA-enhanced MRI contrast of TNBC cells 
co-expressing luciferase/Oatp1a1 
To first compare luciferase activity across engineered cells excluding any 
contribution from OATP1A1, cell lysates were prepared and luciferase activity 
assays exhibited no significant difference in intracellular luciferase activity between 
luciferase- and luciferase/Oatp1a1-expressing cells (n=3 per group). By contrast, 
for cells with intact membranes, where OATP1A1 functions, MDA-MB-231 cells 
co-expressing luciferase and Oatp1a1 exhibited a significant 5.5-fold increase in 
BLI signal (4.072 ± 0.145 ×1011 p/s/cm2/sr/μg) relative to cells expressing 
luciferase alone (7.432 ± 0.515 ×1010 p/s/cm2/sr/μg) (n=3, p<0.05; Figure 2.2A-
B). Similarly, 4T1 cells co-expressing luciferase and Oatp1a1 exhibited a 
significant 2.6-fold increase in BLI signal (4.091 ± 0.383 ×107 p/s/cm2/sr/μg) 
relative to cells expressing luciferase alone (1.603 ± 0.068 ×107 p/s/cm2/sr/μg) 
(n=3, p<0.05).  
Next, non-transduced, luciferase-, and luciferase/Oatp1a1-expressing cells 
were incubated with or without Gd-EOB-DTPA (1.6 mM) for 90 minutes, washed 
thoroughly, and pelleted before being placed into an agarose cell phantom (Figure 
2.2C-D). Inversion recovery MRI of the phantom was performed at 3T and 37°C, 
and spin-lattice relaxation rate (R1) maps were generated. In the absence of Gd-
EOB-DTPA, neither MDA-MB-231 (Figure 2.2C-D), nor 4T1 cells, displayed 
differences in R1 rates between non-transduced and transduced genotypes. 
Further, control non-transduced and luciferase-expressing cells treated with Gd-
EOB-DTPA did not exhibit differences in R1 rates relative to untreated controls or 
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to each other. Exclusively, cells engineered to express Oatp1a1 exhibited 
significantly increased R1 rate following Gd-EOB-DTPA incubation compared to all 
other conditions. MDA-MB-231 cells co-expressing Oatp1a1 demonstrated a 
significant 3.7-fold increase in R1 rate following treatment with Gd-EOB-DTPA 
(2.898 ± 0.484 s-1) relative to luciferase-expressing MDA-MB-231 cells (0.848 ± 
0.011 s-1) (n=3, p<0.01; Figure 2.2C-D). 4T1 cells co-expressing Oatp1a1 
demonstrated a 16.1-fold increase in R1 rate following incubation with Gd-EOB-
DTPA (14.325 ± 6.01 s-1) relative to luciferase-expressing 4T1 cells (0.859 ± 0.023 
s-1) (n=3, p<0.01).  
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Figure 2.2. In Vitro Functional Characterization of Triple-Negative Breast Cancer 
Cells Engineered with Reporter Genes. (A) Representative well plate of non 
transduced, luciferase- (Luciferase Control), and luciferase/Oatp1a1-expressing 
(Luciferase OATP1A1) MDA-MB-231 cells imaged following administration of 1 μL of 150 
mg/mL D-Luciferin. (B) Normalized average radiance (p/s/cm2/sr/μg) of MDA-MB-231 
cells following administration of 1 μL of 150 mg/mL D-Luciferin (n=3, *p<0.05). (C) Spin-
lattice relaxation map of representative phantom containing cell pellets of MDA-MB-231 
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cells either treated or untreated with 1.6 mM Gd-EOB-DTPA as follows: 1 treated non-
transduced, 2 untreated non-transduced, 3 treated Luciferase Control, 4 untreated 
Luciferase Control, 5 treated Luciferase OATP1A1, 6 untreated Luciferase  OATP1A1. 
(D) Spin-lattice relaxation rates (s-1) of engineered and non-engineered MDA-MB-231 
cells either treated or untreated with 1.6 mM Gd-EOB-DTPA (n=3, *p<0.05). Error bars 
indicate standard deviation. 
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2.3.3 Oatp1a1 expression increases in vivo BLI and MRI signal of orthotopic TNBC 
tumours over time 
Immunocompromised female mice were implanted with luciferase- or 
luciferase/Oatp1a1-expressing cells into the fourth mammary fat pad to generate 
orthotopic tumours for longitudinal FLI, BLI, and MRI. tdTomato FLI was performed 
to obtain relative measures of the total number of viable cells within each tumour 
in order to normalize BLI signals across time. As a result, average radiance 
measures (p/s/cm2/sr) from BLI images were normalized to fluorescence efficiency 
measures (μW/cm2) in FLI images to obtain measures of normalized radiance. 
Luciferase/Oatp1a1-expressing MDA-MB-231 tumours that had near-equivalent 
FLI signals displayed higher BLI signals than luciferase-expressing tumours 
without Oatp1a1 (Figure 2.3A). At each time point, MDA-MB-231 tumours 
expressing both luciferase and Oatp1a1 (n=5) exhibited significantly increased 
normalized radiance, relative to tumours expressing luciferase alone (n=4; p<0.05) 
(Figure 2.3B-C). Similarly, 4T1 tumours expressing both luciferase and Oatp1a1 
(n=5) also exhibited significantly increased normalized radiance relative to 
luciferase-expressing tumours not expressing Oatp1a1, averaging a 2.9-fold 
increase in normalized radiance (n=5; p<0.05). Collectively, pooled imaging data 
across all time points for MDA-MB-231 tumours were significantly higher for 
tumours co-expressing Oatp1a1 compared to tumours without, averaging a 4.0-
fold increase in normalized radiance.  
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Figure 2.3. In Vivo Bioluminescence Enhancement via Oatp1a1. (A) Representative 
fluorescence (top panel) and bioluminescence (bottom panel) images of mice bearing 
MDA-MB-231 luciferase-expressing tumours (left; Luciferase Control) or MDA-MB-231 
luciferase/Oatp1a1-expressing tumours (right; Luciferase OATP1A1). (B) tdTomato 
fluorescence efficiency (μW/cm2) of MDA-MB-231 tumours over time. (C) Normalized 
radiance (no units) of MDA-MB-231 tumours over time (*p<0.05). Error bars indicate 
standard deviation. 
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Next, we performed Gd-EOB-DTPA-enhanced MRI of these mice on a 3 
Tesla MRI scanner. Pre-contrast images of MDA-MB-231 tumours (Figure 2.4A 
and 2.4C) and 4T1 tumours exhibited no difference in CNR between luciferase 
and luciferase/Oatp1a1 tumours across all time points. Conversely, following 
administration of Gd-EOB-DTPA, luciferase/Oatp1a1 tumours showed significantly 
elevated CNR across all time points compared to all other conditions (p<0.05; 
Figure 2.4B, 2.4D, 2.4E). Mice bearing 4T1 tumours imaged at days 7 and 9 after 
cell implantation showed a significant 2.6-fold increase in CNR after Gd-EOB-
DTPA administration in mice bearing luciferase/Oatp1a1 tumours relative to 
luciferase-expressing tumours (n=5; p<0.05). Collectively, pooled data across all 
time points showed a significant 2.2-fold average increase in CNR for 
luciferase/Oatp1a1 MDA-MB-231 tumours (n=5) post-contrast images relative to 
luciferase tumours (n=4; p<0.05). Contrast enhancement consistently returned to 
baseline levels within 5 days following administration of Gd-EOB-DTPA (Figure 
2.4E).  
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Figure 2.4. In Vivo MR Signal Enhancement via Oatp1a1. Representative T1-weighted 
3-dimensional reconstruction of mouse bearing luciferase-expressing MDA-MB-231 
tumour (Luciferase Control) at Day 7 (A) before and (B) 5-hours following administration 
of 0.1-mmol/kg Gd-EOB-DTPA at Day 9. Representative T1-weighted 3-dimensional 
reconstruction of mouse bearing luciferase/Oatp1a1-expressing MDA-MB-231 tumour 
(Luciferase OATP1A1) at Day 7 (C) before and (D) 5-hours following administration of 
0.1-mmol/kg Gd-EOB-DTPA at Day 9. (E) Mean contrast-to-noise ratios (CNR) of MDA-
MB-231 tumours over time (*p<0.05, ****p<0.0001). Error bars indicate standard 
deviation. 
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2.3.4 Bright regions in Gd-EOB-DTPA-enhanced MR images of Oatp1a1-expressing 
tumours correspond to areas of viable cancer cells in matched histological sections 
Upon sacrifice, tumours were harvested and whole-tumour sections were 
imaged for tdTomato fluorescence, followed by H&E staining (Figure 2.5). 
Luciferase tumours did not display contrast enhancement and/or any patterns of 
heterogeneity in post-Gd-EOB-DTPA images (Figure 2.5A). By comparison, as in 
Figure 2.4, luciferase/Oatp1a1 tumours imaged following Gd-EOB-DTPA (0.1 
mmol/kg) administration were brighter than in pre-contrast images, and in some 
tumours (n=2), both enhancing and non-enhancing regions were notable (Figure 
2.5E). Qualitatively, enhancing regions on Gd-EOB-DTPA-enhanced MRI of 
luciferase/Oatp1a1 tumours corresponded to regions of increased tdTomato 
fluorescence intensity on matched and co-registered confocal microscopy images 
(Figure 2.5H), whereas non-enhancing regions corresponded to areas that either 
lacked tdTomato fluorescence or displaying overtly bright fluorescence, which 
were subsequently shown to be either acellular, necrotic regions (no fluorescence) 
or hemorrhagic regions (autofluorescence) on H&E stained sections, respectively 
(Figure 2.5G). For mice in Figure 2.5, MR images approximately 10 minutes post-
administration of Gd-DTPA (0.1 mmol/kg) were acquired to compare contrast-
enhancement distribution patterns to that with Oatp1a1-based Gd-EOB-DTPA 
enhancement (Figure 2.5B and 2.5F). In Gd-DTPA-enhanced images, control 
tumours did display heterogeneous contrast enhancement (Figure 2.5B, yellow 
contour), with enhancing regions identified to be largely lacking tdTomato 
fluorescence and acellular according to histology (Figure 2.5C-D). Importantly, 
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maximum contrast enhancement within Oatp1a1-expressing tumours is acquired 
5-hours following administration of Gd-EOB-DTPA (12), once non-specific contrast 
enhancement has already cleared, as demonstrated by the absence of 
enhancement on MRI in the central region of the tumour evidently occupied by a 
hemorrhagic core (Figure 2.5G).   
For quantitative pixel-by-pixel analysis, post-Gd-EOB-DTPA MR images 
and whole-tumour tdTomato fluorescence microscopy images of a luciferase- and 
luciferase/Oatp1a1-expressing tumour were successfully co-registered 
(Figure2.6). Using the exclusion criteria described in the methods, 0.86% of pixels 
were eliminated from the analysis of the control luciferase tumour (99.14% pixels 
analyzed), and 0.72% of pixels from the luciferase/Oatp1a1-expressing tumour 
image analysis were eliminated (99.28% pixels analyzed). Fluorescence intensity 
of the luciferase/Oatp1a1-expressing tumour exhibited a non-zero background 
signal (Sbackground = 28.8) as well as a point of saturation in the fluorescence signal 
(Ssaturation= 53.3); linear regression analysis was thus performed within these limits. 
The luciferase/Oatp1a1-expressing tumour exhibited a significant strong, positive 
correlation between MR intensity on in vivo Gd-EOB-DTPA-enhanced images and 
tdTomato fluorescence intensity on ex vivo histology, with a goodness-of-fit (R2) 
coefficient of 0.9821 (n=18,368 pixels, p<0.0001) (Figure 2.6A-C). The control 
luciferase-expressing tumour did not exhibit any significant correlation between 
MR intensity and fluorescence intensity, with a goodness-of-fit (R2) coefficient of 
0.1992 (n=17,270 pixels, p=0.17) (Figure 2.6D-F).  
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Figure 2.5. In Vivo Magnetic Resonance Imaging of TNBC Tumours with 
Corresponding Histology. Luciferase-expressing MDA-MB-231 tumour (Luciferase 
Control) (A) on Day 23, 5-hours following administration of 0.1-mmol/kg Gd-EOB-DTPA; 
(B) on Day 25, approximately 10 minutes following administration of 0.1-mmol/kg Gd-
DTPA; along with corresponding (C) H&E staining and (D) tdTomato fluorescence 
microscopy. Note that this is the same tumour presented in Figure 4A-B. MDA-MB-231 
tumour co-expressing luciferase and Oatp1a1 (Luciferase OATP1A1) (E) on Day 23, 5-
hours following administration of 0.1-mmol/kg Gd-EOB-DTPA; (F) on Day 25, 
approximately 10 minutes following administration of 0.1-mmol/kg Gd-DTPA; along with 
corresponding (G) H&E staining and (H) tdTomato fluorescence microscopy. Note that 
this same tumour is presented in Figure 4C-D at an earlier timepoint. Yellow contours and 
arrows indicate comparative features of interest. NT, non-transduced cells. NC, necrotic 
core hemorrhaging, which is autofluorescent in the tdTomato image.  
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Figure 2.6. Pixelwise Analysis of In Vivo MR Intensity to Ex Vivo Fluorescence 
Intensity of TNBC Tumours Engineered with Reporter Genes. (A) T1-weighted image 
of MDA-MB-231 tumour co-expressing luciferase and Oatp1a1 (Luciferase OATP1A1) 5-
hours following administration of 0.1-mmol/kg Gd-EOB-DTPA acquired on Day 23. (B) 
Corresponding tdTomato fluorescence microscopy of same tumour, and (C) MR intensity 
vs fluorescence intensity correlation plot (R2=0.9821, p<0.0001, n=18,368 pixels). (D) T1-
weighted image of luciferase-expressing MDA-MB-231 tumour (Luciferase Control) 5-
hours following administration of 0.1-mmol/kg Gd-EOB-DTPA acquired on Day 23. (E) 
Corresponding tdTomato fluorescence microscopy of same tumour, and (F) MR intensity 
vs fluorescence intensity correlation plot (R2=0.03967, p=0.1701, n=17,270 pixels) 
(*p<0.05).   
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2.4 Discussion 
In this study, we present a robust approach for sensitive in vivo 
multimodality tracking of viable engineered cancer cells based on Oatp1a1-
mediated BLI and MRI contrast agent uptake. This integrated system enables time-
efficient, low cost BLI for 2D monitoring of cancer cell viability, as well as 3D 
intratumoural cell viability measures with Gd-EOB-DTPA-enhanced MRI that is not 
provided by traditional MRI techniques (Figures 2.4 and 2.5). Gd-EOB-DTPA-
enhancing regions of T1-weighted images of Oatp1a1-expressing tumours 
matched remarkably well with areas of viable cancer cells in matched histological 
images (Figure 2.5), which was further validated via pixel-by-pixel correlational 
analysis (Figure 2.6). The resulting strong, positive correlation between in vivo 
MRI intensity and ex vivo fluorescence intensity reveals a quantitative ability of 
Oatp1a1-dependent MRI to convey surrogate information on viable cancer cell 
distributions and densities within tumours. These tools therefore provide the ability 
to obtain important tumour characteristics for a better understanding of tumour 
architecture over time (23-25) and would be valuable for evaluating the efficacy of 
candidate therapies in the future.  
Arguments can be made on the benefits of reporter genes operating on 
other modalities, particularly positron emission tomography (PET), such as the 
mutant herpes simplex virus type 1 thymidine kinase (HSV1-sr39tk), which offers 
relatively high SNR with respect to the trace amounts of contrast agent 
administered into the biological system (26-28). However, the spatial resolution of 
PET signals from reporter genes (~1 mm) are relatively poor compared to MRI 
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(~100 μm in-plane) (29). The strength and utility of MRI lies in its ability to generate 
highly resolved anatomical information in 3-dimensions. Reporter genes operating 
on MRI can contribute a unique advantage to this modality by providing information 
on precise locations of viable, specific engineered cell populations. However, many 
established MRI reporter genes, such as those that operate through iron-
sequestration, generate undesirable negative contrast that can spread beyond 
precise locations of where the iron resides (i.e., a blooming artifact), obscuring 
underlying anatomy. Negative contrast in tumour microenvironments can be 
produced through other processes such as hemorrhage, thereby causing 
uncertainty in the source of the signal (10). Additionally, negative contrast already 
exists at major sites of oncogenesis and metastasis such as the lungs, hindering 
the ability to image ectopic negative contrast within important regions of the body 
(30). Iron-sequestering reporter genes have also been reported to alter phenotype 
and differentiation patterns in therapeutic cells, likely due to their physiologically 
central role in iron homeostasis and protection from oxidative stress (31). Positive 
contrast reporter genes for MRI have also been described in the literature. The 
most established class comprises of lysine-rich proteins capable of chemical 
exchange saturation transfer (CEST), affording the unique ability to toggle between 
detection and silencing of CEST signals through selective radiofrequency (RF) 
pulses (12). The Oatp1a1 system operates via an entirely different contrast 
mechanism relative to CEST, which opens potential to track two different cell 
populations, or different genetic information within a single cell population, by using 
both CEST and Oatp1a1 positive-contrast reporters within the same study.  
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Gd-EOB-DTPA and Oatp1a1 as a positive contrast probe-reporter system 
offers a unique combination of advantages, which include physiological 
compatibility, specificity in contrast enhancement, reversibility, as well as 
mammalian-origin. With respect to physiological compatibility, Oatp1a1 is 
biologically derived from a liver transporter protein that takes up bile acids (BAs) 
and specific exogenous drugs for further metabolism and/or clearance by the liver; 
in itself, the protein has not been reported to exhibit enzymatic or physiologically-
central activity, though studies describing effects of altered Oatp1a1 expression 
are very limited in number (32, 33). In our study, we did not find any quantitative 
differences in cell proliferation, or qualitative observations in morphology that 
distinguished Oatp1a1-expressing cells from their parental lines, supporting the 
notion that physiological effects are negligible as a result of its synthetic 
expression, though more studies are needed and are being pursued. Thus, 
biological imaging studies can be performed using Oatp1a1 with little concern over 
any confounding effects. It is important to caution, however, that candidate 
therapies should be tested in vitro for specific uptake by Oatp1a1 prior to 
performing a full preclinical animal study. Unanticipated uptake of a drug by 
Oatp1a1 may result in its concentration within the tumour and, thus, a pronounced 
therapeutic effect may be observed that would not have occurred in the absence 
of Oatp1a1 expression. For example, methotrexate has been shown to be taken 
up specifically by a human transporter, Oatp1b3, that overlaps in function with rat 
Oatp1a1, while other anti-tumour drugs such as tyrosine kinase inhibitors exhibit 
no uptake through this transporter (34).  
 
114 
The Gd-EOB-DTPA and Oatp1a1 system additionally provides the benefits 
of specificity in contrast enhancement and reversibility. Traditional contrast-
enhanced MRI methods for measuring tumour response to therapy in preclinical 
animal models are largely based on blood-pooling contrast agents such as Gd-
DTPA. Though these agents offer powerful means to detect cancerous lesions, 
they fall short in conveying information pertaining to the distribution of viable 
cancer cells within the enhancing mass. For example, reduction in tumour size as 
measured by Gd-DTPA-enhanced MRI may be caused by eradication of non-
cancerous volumes by the candidate therapy, thereby generating false positive 
treatment outcomes in preclinical animal studies. This is plausible when 
considering that it is difficult to differentiate between important, antagonistic 
parameters on Gd-DTPA-enhanced MRI, such as tumour recurrence and 
treatment necrosis (35), or vasogenic edema and infiltrative tumour (36). With 
Oatp1a1, images are acquired prior to and 5 hours post administration of Gd-EOB-
DTPA, long after any non-specific contrast enhancement is cleared, allowing for a 
comparison of the two images for detection of engineered cancer cells with high 
specificity. Further, the contrast enhancement returns to baseline approximately 
40 hours post-administration of Gd-EOB-DTPA, as the contrast agent washes out 
(14), demonstrating its reversibility, unlike other genetically-encoded reporters 
such as ferritin heavy chain for example, which exhibits signal persistence for more 
than seven days following inactivation of an established inducible promoter driving 
its expression (37). It is important to note, however, that these timepoints for 
maximal tumour CNR and washout kinetics of Gd-EOB-DTPA by Oatp1a1-
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expressing cells are based on previous publications (12) and have not been 
verified in our study. The point of maximum contrast agent retention and contrast 
agent washout may differ between different engineered cell types and will also 
likely depend on the site of implantation. We do show that tumour CNR 
enhancement of Oatp1a1-expressing mammary fat pad tumours does return to 
pre-contrast baseline levels five days after Gd-EOB-DTPA administration (Figure 
4E). Further, Oatp1a1-expressing tumours were imaged immediately following Gd-
DTPA administration (n=2) two days following Gd-EOB-DTPA imaging (Figure 
2.5F), where CNR in non-dynamic contrast enhancing regions was observed to be 
similar to baseline (i.e. pre-contrast) values. Though only anecdotal, this finding 
supports previous reports that Gd-EOB-DTPA contrast enhancement within 
Oatp1a1-expressing cells returns to baseline approximately two days post-
administration (14).  
In comparison to previous studies using high-field scanners and relatively 
high Gd-EOB-DTPA doses (14), we demonstrate the feasibility of the system using 
a 3-Tesla scanner and Gd-EOB-DTPA doses (0.1 mmol/kg) that, while 
approximately 4-fold the traditional dose (0.025 mmol/kg) used in the clinic, was 
deemed safe for patients who do not have renal impairments (16, 38). Doses up 
to 0.5 mmol/kg have also been used in patients (39). Recent work has been 
performed on a human transporter that overlaps in function with rat-derived 
Oatp1a1, namely Oatp1b3, where xenografts engineered to express Oatp1b3 
showed contrast enhancement following administration of Gd-EOB-DTPA using a 
7-Tesla scanner (40). This human variant may mitigate immunogenicity concerns 
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over introducing a non-human protein into human cells for clinical translation or 
when performing imaging of patient-derived tumour xenografts in humanized mice 
(41). Future work should also evaluate the utility of rat (i.e., Oatp1a1) and mouse 
(i.e., Oatp1 (42)) transporter proteins for performing longitudinal MRI of cancer cell 
viability in immunocompetent rat and mouse models, respectively. Such advances 
could help alleviate the use of immunogenic reporters such as GFP and luciferases 
for monitoring tumour progression in syngeneic immunocompetent experimental 
models or transgenic models.  
This technology could also be applied to monitor oncotherapies in real-time, 
including the viability and location of engineered therapeutic cells targeting 
cancerous tissue (43-45), and for tracking the activation of gene-based therapies 
directed toward cancers (46-50). In conclusion, the promising sensitivity, 
specificity, positive contrast, reversibility, high resolution, and 3D spatial 
information generated by this multimodality reporter gene system warrant the 
application of Oatp1a1 to uncover new dynamic insights about how tumours 
develop and respond to therapies through simultaneous fluorescence, 
bioluminescence, and magnetic resonance imaging. 
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CHAPTER 3 Whole-Body, Sensitive Visualization of Spontaneous Metastasis in 
Mice using the Oatp1b3 MRI Reporter System 
Rationale. Metastasis is the leading cause of cancer-related deaths. However, 75% of 
preclinical cancer studies do not examine metastasis, focusing only on primary tumour 
growth, in part due to a lack of technologies for accurate quantification of metastatic 
spread over time. To better understand the metastatic process and advance our ability 
to test therapies targeting metastatic disease, tools for accurate spatiotemporal 
quantification of metastasis are needed. Our objective was to assess Oatp1b3 for 
whole-body in vivo tracking of cancer cells in a spontaneous metastasis model. 
Methods. Breast cancer cells were engineered with lentivirus to express luciferase for 
bioluminescence imaging (BLI). A subset of these cells was additionally engineered to 
co-express Oatp1b3 for MRI. Luciferase control (Luc-CTL) or luciferase/Oatp1b3 (Luc-
1B3) cells were implanted into the 4th mammary fat pad of female mice. BLI and T1-
weighted 3T-MRI was performed before and after 1-mmol/kg Gd-EOB-DTPA injection. 
Results. Macro-metastases (>1mm3) located at axillary lymph nodes exhibited 
significantly increased MR signal intensity in Luc-1B3 mice on post-contrast images 
relative to pre-contrast images, and to Luc-CTL mice both pre- and post-contrast (n=3, 
p<0.0001). Importantly, numerous micro-metastases (<1mm3) were detected throughout 
lungs of Luc-1B3 mice on post-contrast MRI, which were not detected in corresponding 
pre-contrast MRI, with BLI, nor on post-contrast images of Luc-CTL mice. Analyzing 
mean signal intensity and volume of individual foci (N=60 across 3 mice) demonstrated 
that lesions around 0.01 mm3, correlating to ~104 cells, could be detected. A Luc-1B3 
cohort (n=7) was imaged over time, and metastasis was first detected at the ipsilateral 
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axillary lymph node, with significantly increased MR signal intensity relative to 
surrounding muscle tissue (p<0.0001). Follow-up MRI at 20-days post-implantation 
revealed tumor growth at the initial ipsilateral axillary lymph node lesion, as well as 
subsequent metastases at other loci, including the contralateral axillary and ipsilateral 
brachial lymph nodes. These subsequent metastases were not at all detectable with 
BLI. Conclusions. BLI provides whole-body information on locations of engineered 
cells, but smaller populations can go undetected. Oatp1b3-MRI mitigates these 
limitations for effective tracking of metastatic spread. We show that this reporter can 
dynamically track the metastatic process at its earliest stages, including small single 
lymph node lesions. At late stages, we demonstrate its superiority over BLI to track 
cancer spread to multiple lymph nodes and other organs such as the lungs. Oatp1b3 
fulfills a long-standing gap in our ability to accurately study metastatic disease over 
time, and offers a path towards deep-tissue tracking of any Oatp1b3-engineered cell 
type with combined high resolution, sensitivity, 3D spatial information, and surrounding 
anatomical context. 
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3.1 Introduction 
Metastatic disease is responsible for over 90% of cancer-related 
mortalities (1). Preclinical animal models provide an essential platform for the 
study of metastasis, intermediate to reductionist in vitro research and clinical 
investigations. Yet, approximately 75% of preclinical animal studies do not 
investigate metastasis to any extent, and instead focus only on primary tumour 
models. This is often due to a lack of technologies for sensitive longitudinal 
quantification of metastatic spread (2). Bioluminescence imaging (BLI) is 
frequently used for assessing metastatic burden because of its high throughput 
and sensitivity; however, assessing total burden with BLI, particularly in 
spontaneous metastasis models, remains challenging due to light scatter and 
attenuation by surrounding tissues (3). Small superficial lesions cannot be readily 
differentiated from larger lesions in deep tissues, and light from large superficial 
tumors complicates detection of deeper lesions. To address these limitations, 
preclinical oncology studies focused on examining metastatic disease have 
supplemented BLI observations with parallel methods, such as multi-modality 
imaging (4-6) and/or ex vivo analysis of whole-body or whole-organ systems (7, 
8). For example, BLI has been paired with tissue clearing protocols, light-sheet 
microscopy and computational methods for sensitive imaging of metastatic cells 
at endpoint (9). In contrast, sensitive, high resolution, 3-dimensional dynamic 
tracking of metastatic spread in alive animals remains an elusive goal (10).  
To better understand the metastatic process and advance our ability to 
test therapies targeting metastatic disease, tools for accurate spatiotemporal 
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quantification of metastasis are needed. As a modality, magnetic resonance 
imaging (MRI) uniquely provides versatile, high resolution, 3-dimentional spatial 
information, with surrounding anatomical context. Further, MRI is the standard of 
care for detection and monitoring of cancer and many other diseases. Contrast-
enhanced MRI can be used to visualize tumours due to leaky vasculature, 
however small tumours often go undetected with these methods. The use of 
reporter genes to enhance the conspicuity of engineered cancer cells may 
improve our ability to track these cells dynamically. Several MRI reporter genes 
have been developed including those providing either positive (11, 12) or 
negative (13-16) contrast on proton-MRI, diffusion-weighted MRI (17), chemical-
exchange saturation transfer MRI (18), or hyperpolarized MRI (19, 20). Despite 
these efforts, MRI reporter genes have often been overlooked in cancer cell 
tracking applications due to a perception that they provide limited imaging 
sensitivity, i.e. labelled metastatic lesions would have to be quite large before 
enough signal is generated for detection (21). Recent development of Organic 
Anion-Transporting Polypeptide 1 (Oatp1) has demonstrated the possibility for 
sensitive, positive contrast MRI of engineered cells (22-24). Specifically, Oatp1 
encodes expression of a transporter on the surface of cells that is capable of 
taking up the paramagnetic contrast agent gadolinium ethoxybenzyl diethylene 
triamine pentaacetic acid (Gd-EOB-DTPA), thereby generating positive contrast 
on T1-weighted images. Although previous studies have focused on primary 
tumour models, optimization of experimental parameters including contrast agent 
concentration, field strength and choice of pulse sequence could facilitate 
 129 
sensitive whole-body in vivo detection of metastasizing cells. The objective of this 
study therefore was to evaluate the use of whole-body MRI to track Oatp1b3-
expressing cancer cells in a spontaneous murine breast cancer metastasis 
model. The ability to track spontaneously metastasizing cancer cells in preclinical 
animal models in real-time, with sensitivity, high resolution, and 3-dimentional 
spatial information could offer new insights into complex metastatic mechanisms, 
and provide a new approach towards assessing the efficacy of candidate 
therapies for treatment of metastatic disease.  
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3.2 Materials and Methods 
3.2.1. Lentiviral Construction and Production  
Lentiviral transfer plasmids co-encoding tdTomato fluorescent protein with 
firefly luciferase 2 (25), and zsGreen fluorescent protein with Oatp1b3 (26) were 
previously cloned. The cDNA for Organic anion transporting polypeptide 1b1 
(Oatp1b1) was acquired from the hOATP1B1/SLCO1B1 VersaClone cDNA 
Vector (Cat. RDC1113, R&D Systems, Minneapolis, Minnesota, United States). A 
lentiviral transfer plasmid co-encoding zsGreen with Oatp1b1 was cloned using 
the In-Fusion HD Cloning kit (Takara Bio USA Inc, Madison, Wisconsin, United 
States). Third-generation packaging and envelope-expression plasmids 
(pMDLg/pRRE, pRSV-Rev, and pMD2.G, Addgene plasmids: #12251, #12253, 
and #12259, respectively; gifts from Didier Trono) were co-transfected with each 
of the three transfer plasmids (tdTomato/Luciferase, zsGreen/Oatp1b1, 
zsGreen/Oatp1b3) into human embryonic kidney (HEK 293T) cells using 
Lipofectamine 3000 according to the manufacturer’s lentiviral production protocol 
(Thermo Fisher Scientific Inc., Waltham, Massachusetts, United States). 
Lentivirus-containing supernatants were harvested 24h and 48h post 
transfection, filtered through a 0.45-μm filter, and used immediately for 
transductions.  
 
3.2.2. Cell Culture and Stable Cell Generation 
Human embryonic kidney (HEK 293T) and human triple negative breast 
cancer cells (MDA-MB-231) were obtained from a commercial supplier (American 
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Type Culture Collection, Manassas, Virginia, United States) and cultured in 
Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal 
bovine serum at 37°C and 5% CO2. All cells were routinely verified as free of 
mycoplasma contamination using the MycoAlert mycoplasma detection kit 
(Lonza Group, Basel, Switzerland). MDA-MB-231 cells were first transduced with 
lentivirus co-encoding tdTomato and Firefly Luciferase, and fluorescence-
activated cell sorting was performed to sort for tdTomato-positive cells using a 
FACSAria III cell sorter (BD Biosciences, Mississauga, Ontario, Canada). The 
sorted cells were expanded and transduced again with lentivirus co-encoding 
zsGreen with either Oatp1b1 or Oatp1b3 and fluorescence-activated cell sorting 
was performed to select for tdTomato and zsGreen double-positive cells using 
equivalent intensity-gating for each colour. Sorted cells, hereon referred to as 
either Luc-CTL, Luc-1B1 or Luc-1B3 cells, were utilized for all experiments.   
 
3.2.3. In Vitro Bioluminescence Imaging 
Luciferase- and Oatp1b3-expressing cells were seeded into 24-well plates 
with the following numbers of cells per well: 1x106, 5x105, 3x105, 1x105, and 
5x104. Immediately after seeding, 0.15 mg/ml D-luciferin was added to each well, 
and plates were imaged on an IVIS Lumina XRMS In Vivo Imaging System 
(PerkinElmer, Waltham, Massachusetts, United States). Average radiance values 
in photons/s/cm2/sr were measured from each well using LivingImage software 
(PerkinElmer, Waltham, Massachusetts, United States). 
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3.2.4. Western Blot 
A million Luc-CTL, Luc-1B1 or Luc-1B3 cells were washed three times in 
PBS and incubated with 200-µL 4°C RIPA buffer and protease inhibitors for 30 
minutes. Lysates were collected and sonicated with five 5.0-s 40 kHz bursts 
before being centrifuged at 13,000G for 20 minutes at 4°C. Supernatants were 
collected, quantified and 40 µg of protein from each sample was loaded into an 
acrylamide gel composed of a 4.0% stacking layer buffered at pH 6.8 and a 15% 
separation layer buffered at pH 8.8. Gel electrophoresis was performed for 20 
minutes at 90V and 1 hour at 110V. Protein was transferred to a nitrocellulose 
membrane for 7.5 minutes via the iBlot™ 2 Gel Transfer Device (IB21001, 
Thermo Fisher Scientific, Waltham, Massachusetts, United States) and blocked 
with 0.05% Tween-20, 3% BSA solution for 30 minutes. Rabbit anti-Oatp1b3 
antibody (1:1000 dilution, ab139120, Abcam, Cambridge, United Kingdom) was 
added and incubated overnight at 4°C. The blot was washed 3x with 0.05% 
Tween-20 solution for 10 minutes and Goat anti-Rabbit 790-nm antibody 
(1:10,000 dilution, A11369, Thermo Fisher Scientific, Waltham, Massachusetts, 
United States) was added for 45 minutes at room temperature. The blot was 
washed again 3x with 0.05% Tween-20 solution for 10 minutes and imaged on 
the Odyssey CLx Imaging System (LI-COR Biosciences, Lincoln, Nebraska, 
United States).  
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3.2.5. In Vitro Magnetic Resonance Imaging 
Luciferase- and Oatp1b3-expressing cells (1×106) were seeded in 
individual15-cm dishes and grown for 3 days. Cells were incubated with media 
containing 1.6-mM Gd-EOB-DTPA or 1.6-mM Gd-DTPA (control) for 60 minutes 
at 37°C and 5% CO2. In a separate experiment, cells were also incubated with 
media containing 16-mM Gd-EOB-DTPA or 16-mM Gd-DTPA (control) for 60 
minutes at 37°C and 5% CO2. Cells were subsequently washed 3 times with PBS, 
trypsinized and pelleted in 0.2-mL tubes. MRI was performed on a 3-T GE clinical 
MR scanner (General Electric Healthcare Discovery MR750 3.0 T, Milwaukee, 
Wisconsin, United States) using a 3.5-cm-diameter birdcage RF coil (Morris 
Instruments, Ottawa, Ontario, Canada). Imaging data were acquired at 19.5°C with 
a fast spin echo inversion recovery (FSE-IR) pulse sequence using the following 
parameters: Matrix size = 256´256, repetition time (TR) = 5000 ms, echo time (TE) 
= 19.1 ms, echo train length (ETL) = 4, number of excitations (NEX) = 1, receiver 
bandwidth (rBW) = 12.50 kHz, inversion times (TI) = 20, 35, 50, 100, 125, 150, 
175, 200, 250, 350, 500, 750, 1000, 1500, 2000, 2500, 3000, in-plane resolution = 
0.2x0.2 mm2, slice thickness = 2.0 mm, acquisition time = 5 min and 25 s (per 
inversion time). Spin-lattice relaxation rates (R1) were determined by non-linear 
least-squares fitting (MATLAB, MathWorks, Natick, Massachusetts, United States) 
of signal intensities across the series of variable inversion time images on a pixel 
by pixel basis. The most common inversion recovery equation presented in the 
literature is as follows:  
! = # ∙ (1 − 2)!	
#$
#! 	+ 	)!
#%
#! ) 
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Here, ! represents the acquired signal, and # is the proportionality constant, 
which depends on the specific coil used, the main magnetic field, the proton 
density, and the temperature, amongst other factors (27). However, two practical 
obstacles exist that render this equation impractical for real-world applications: 
first, a perfect 180° pulse is never truly achieved, and second, the signal is not 
acquired immediately after the RF pulse (28). In practice, these real-world 
limitations produce a different behavior at -. = 	0 and -. = 	∞ than predicted 
theoretical outputs dictated by the equation above. To address these limitations, 
and assuming -1 ≫ -., the equation above was adjusted to the following:  
! = 3&& − (3&& −3') ∙ )
"#$ #!%  
  
Here, if -. = 	0, then ! = 	−3' where 3' is simply the first value of the 
inversion recovery curve, independent of the final, steady state magnetization 3&&. 
Additionally, if -. = 	∞, then ! = 	3&&. Finally, we use the absolute value of this last 
equation because the DICOM images acquired provided magnitude (non-phase) 
information:  
! = 43&& −	(3&& −3') ∙ )
"#$ #!% 4 
 
The zero-crossing point, the -. at which point ! = 0, is extrapolated from 
the data and the 1( of each pixel can be determined via the following 
relationship: 
1( = ln 2 -.)*++7  
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3.2.6. Spontaneous Metastasis Model 
Animals were cared for in accordance with the standards of the Canadian 
Council on Animal Care, and experiments were undertaken with an approved 
protocol of the University of Western Ontario’s Council on Animal Care (AUP 
2016-026). Luc-CTL or Luc-1B3 cells (3×105) were implanted into the left 4th 
mammary fat pad of female nod scid gamma mice (Jackson Laboratory, Bar 
Harbor, Maine, United States). BLI was performed after 150-mg/kg D-luciferin 
injection. T1-weighted 3T-MRI was performed before and 5h post 1-mmol/kg Gd-
EOB-DTPA injection. Detectability of widespread metastases was evaluated by 
imaging Luc-CTL and Luc-1B3 mice (n=3 each) 30 days after cell implantation. 
Subsequently, a second Luc-1B3 cohort (n=7) was imaged over time until 
endpoint (up to Day 24) to assess ability to monitor metastasis dynamically. 
 
3.2.7. In Vivo Bioluminescence Imaging 
Bioluminescence imaging was performed on an IVIS Lumina XRMS In 
Vivo Imaging System (PerkinElmer). Mice were anesthetized with 1-2% 
isoflurane using a nose cone attached to an activated carbon charcoal filter for 
passive scavenging, and administered 150 μL of 30-mg/mL D-luciferin 
intraperitoneally. Whole-body bioluminescent images were acquired with 
repeated 1.0-s exposure times every minute for approximately 15 minutes. Once 
the maximum signal plateaued, the lower half of the mouse i.e. location of 
primary tumour, was shielded with opaque black cloth and the front limbs of the 
mice were taped down to fully expose the surface area of the thoracic region. 
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The field-of-view was adjusted to fit the upper body of the mouse and an image 
was captured with a 5-minute exposure time to detect spontaneous metastases. 
Regions-of-interest (ROIs) were manually drawn around primary tumour borders 
using LivingImage software (PerkinElmer, Waltham, Massachusetts, United 
States) to measure bioluminescent average radiance (p/s/cm2/sr). For analysis of 
spontaneous metastases, ROIs were automatically generated with LivingImage 
software (PerkinElmer, Waltham, Massachusetts, United States).   
 
3.2.8. In Vivo Magnetic Resonance Imaging 
Scans were performed on a 3-T GE clinical MR scanner (General Electric 
Healthcare Discovery MR750 3.0 T, Milwaukee, Wisconsin, United States) using 
a custom-built gradient insert and a bespoke 5-cm-diameter solenoidal 
radiofrequency coil. Mice were anesthetized with 1-2% isoflurane using a nose 
cone attached to an activated carbon charcoal filter for passive scavenging. T1-
weighted images were acquired using a 2D Spoiled Gradient Recalled 
Acquisition in Steady State (SPGR) pulse sequence using the following 
parameters: FOV = 40mm, TR = 15.8 ms, TE = 10.5 ms, rBW = 31.25 kHz, ETL 
= 4, Matrix size 400×400, Flip Angle: 60°, NEX = 3, v = 0.1-µm3 isotropic voxels, 
scan time = approximately 20 minutes per mouse, dependent on mouse size. 
Volumes-of-interest (VOIs) were manually delineated around metastatic lesions 
in post-contrast images using both ITK-SNAP (29) and Horos Project software 
(horosproject.org, Nimble Co LLC d/b/a Purview, Annapolis, Maryland, United 
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States). VOIs were manually segmented to acquire measures of signal intensity 
on both pre-contrast and post-contrast images.  
 
3.2.9. Statistics 
Analysis of Variance (ANOVA) and Tukey’s post-hoc multiple comparisons 
were performed for all MRI results. For all tests, a nominal p-value less than 0.05 
was considered statistically significant. 
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3.3 Results  
 
3.3.1 Lentiviral-mediated integration of reporter genes in cancer cells 
Lentiviral transfer plasmids encoding pEF1a-tdTomato/Luciferase, pEF1a-
zsGreen/Oatp1b1, and pEF1a-zsGreen/Oatp1b3, each separated by self-cleaving 
2A peptide sequences, were successfully cloned and utilized to produce lentiviral 
vectors (Figure 3.1B, 3.1C). A human triple-negative breast cancer cell line (MDA-
MB-231) was transduced with pEF1a-tdTomato/Luciferase lentivirus and 
subsequently sorted for tdTomato fluorescence with >95% purity to obtain 
luciferase-expressing control cells, hereafter referred to as Luc-CTL cells. 
Following sorting and expansion, a subset of Luc-CTL cells was transduced a 
second time with either zsGreen/Oatp1b1 or pEF1a-zsGreen/Oatp1b3 lentivirus 
and sorted again for zsGreen fluorescence with >95% purity whilst also matching 
the tdTomato intensity to that of the sorted Luc-CTL cells. These resulting cell lines 
are hereafter referred to as Luc-1B1 and Luc-1B3 cells, respectively. In vitro 
bioluminescence imaging demonstrated a significant linear correlation with cell 
number for both Luc-CTL (R2=0.9916) and Luc-1B3 (R2=0.9893) with slopes that 
were not considerably different between cell lines (Figure 3.1D, 3.1E). Immuno-
blotting for OATP1B3 protein confirmed absence of Oatp1b3 expression in both 
Luc-CTL and Luc-1B1 cells, whereas bands correlating with the molecular weight 
of glycosylated (100 kDa) and unmodified (77 kDa) OATP1B3 protein (30) were 
observed in the lane containing lysates from Luc-1B3 cells (Figure 3.1F). Non-
specific bands across all cell types were observed at about 65 kDa and 72 kDa.  
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Figure 3.1. Imaging Principle and In Vitro Reporter Gene Expression. A, Illustration 
of the Oatp1b3 reporter gene mechanism. Cells engineered to express Oatp1b3 encode 
a transporter capable of taking up Gd-EOB-DTPA, a paramagnetic agent that interacts 
with proton spins to increase the spin-lattice relaxation rate of the intracellular 
environment, which in turn, allows those cells to exhibit increased signal intensity on T1-
weighted magnetic resonance images. B, Reporter gene cassette constitutively 
encoding tdTomato and firefly luciferase. C, Reporter gene cassette constitutively 
expressing zsGreen and Oatp1b3. D, Bioluminescence radiance (p/s/cm2/sr) of various 
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numbers of MDA-MB-231 cells per well expressing luciferase (Luc-CTL) or co-
expressing luciferase and Oatp1b3 (Luc-1B3). E, Quantification of average radiance 
(p/s/cm2/sr) of wells containing various numbers of Luc-CTL or Luc-1B3 cells. F, 
Western blot of cells expressing luciferase (Luc-CTL), co-expressing luciferase and 
Oatp1b1 (Luc-1B1, a closely related transporter), or co-expressing luciferase and 
Oatp1b3 (Luc-1B3).  
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3.3.2 Increased spin-lattice relaxation rates of cells expressing Oatp1b3  
Luc-CTL cells treated with low and high doses of Gd-DTPA did not exhibit 
significant differences in R1 rates (0.5827 ± 0.04658, 0.7464 ± 0.009090 s-1, 
respectively) to Luc-CTL cells treated with low and high doses of Gd-EOB-DTPA 
(0.6166 ± 0.05755, 0.7568 ± 0.03942 s-1, respectively), nor to Luc-1B3 cells treated 
with low and high doses of Gd-DTPA (0.5821 ± 0.04658, 0.7494 ± 0.1061 s-1) 
(Figure 3.2). Only Luc-1B3 cells incubated with low and high Gd-EOB-DTPA 
doses exhibited significantly increased R1 rates compared to all other conditions 
(1.320 ± 0.2229, 3.797 ± 0.1353 s-1) (n=3, p<0.05). 
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Figure 3.2. Spin-lattice Relaxation Rates of Oatp1b3-engineered cells at 3 Tesla. A, 
Map of spin-lattice relaxation rates (Hz) for MDA-MB-231 cells expressing luciferase (Luc-
CTL) or co-expressing luciferase and Oatp1b3 (Luc-1B3) treated with 1.6 mM of either 
Gd-DTPA (control probe) or Gd-EOB-DTPA. B, Map of spin-lattice relaxation rates (Hz) 
for MDA-MB-231 cells expressing luciferase (Luc-CTL) or co-expressing luciferase and 
Oatp1b3 (Luc-1B3) treated with 16 mM of either Gd-DTPA (control probe) or Gd-EOB-
DTPA. C) Quantification of spin-lattice relaxation (R1) rates (Hz) at 3 Tesla of cells treated 
with either Gd-DTPA or Gd-EOB-DTPA (n=3, ***p<0.001, ****p<0.0001).  
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3.3.3 Increased contrast enhancement of macro-metastatic lesions, and detection of 
micro-metastatic lesions with Oatp1b3 
Macro-metastases (>1mm3) located at axillary lymph node regions 
exhibited significantly increased MR signal intensity in Luc-1B3 mice on post-
contrast images (4631 ± 968.6 arbitrary units, a.u.) relative to pre-contrast 
images (766.7 ± 234.7 a.u.), and to Luc-CTL mice both pre- (840.1 ± 122.2 a.u.) 
and post-contrast (1058 ± 198.0 a.u.) (n=3 mice per group, p<0.0001) (Figure 
3.3A, 3.3B). Importantly, numerous micro-metastases (<1mm3) were detected 
throughout lungs of Luc-1B3 mice on post-contrast MRI, which were not detected 
in corresponding pre-contrast MRI, with BLI, nor on post-contrast images of Luc-
CTL mice. It was particularly surprising that micro-metastases could be detected 
in the lungs, because motion artifacts from breathing and susceptibility artifacts 
from the air-tissue interface were anticipated to present a serious challenge to 
imaging lung micro-metastases on MRI. Analyzing mean signal intensity and 
volume of individual foci (N=60 across 3 mice) demonstrated that several lesions 
as small as ~0.01 mm3 could be detected on Day 30 post-implantation of the 
primary tumour (Figure 3.3C). The smallest volume that demonstrated mean 
intensity (3332 a.u.) considerably above the mean intensity of lungs in control 
animals (236.08 ± 172.9 a.u.), was measured at 0.0043 mm3, but a more 
reproducible minimal volume of detection was highlighted by a cluster of lesions 
(N=7) around 0.01 mm3. 
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Figure 3.3. Bioluminescence Imaging and Magnetic Resonance Imaging at 3 Tesla 
of Spontaneous Metastases. A, Bioluminescence imaging (BLI, p/s/cm2/sr) and 
magnetic resonance imaging (MRI) of mice burdened with MDA-MB-231 cells 
engineered to express luciferase (Luc-CTL) or co-express luciferase and Oatp1b3 (Luc-
1B3). Magnetic resonance imaging was acquired pre- and 5 hours post-administration 
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of 1-mm/kg Gd-EOB-DTPA. Maximum intensity projections are also shown. B, Mean 
signal intensity (a.u.) of macro-metastases composed of MDA-MB-231 cells engineered 
to express luciferase (Luc-CTL) or co-express luciferase and Oatp1b3 (Luc-1B3) before 
and 5 hours after administration of 1-mmol/kg Gd-EOB-DTPA (n=3, p<0.05). C, Mean 
signal intensity (a.u.) and volume (mm3) of individual micro-metastatic lesions (<1mm3) 
5 hours after administration of 1-mm/kg Gd-EOB-DTPA, colored according to mouse 
identity (n=3, ****p<0.0001).  
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3.3.4 Oatp1b3 allows for longitudinal tracking of engineered cells spontaneously 
metastasizing through the lymph nodes and to the lungs 
In the Luc-1B3 cohort imaged across three weeks, metastases were first 
detected via BLI and MRI at the ipsilateral axillary lymph node on average 11 ± 
1.3 days after cell implantation into the left-bearing 4th mammary fat pad, with 
significantly increased MR signal intensity (2903 ± 616.6 a.u.) relative to 
surrounding muscle tissue (1123 ± 110.4 a.u.) (n=7, p<0.0001) (Figure 3.4A). 
Five out of 7 mice displayed significant lymph node MRI enhancement within 24 
hours following first detection of BLI signal in that region. The remaining two mice 
showed MR signal enhancement up to two days before BLI signal detection. 
Follow-up MRI at subsequent days revealed continued tumor growth at the initial 
ipsilateral axillary lymph node lesion (Figure 3.4B), as well as subsequent 
metastases at other loci, including the contralateral axillary lymph node (Figure 
3.4C) and ipsilateral brachial lymph node (Figure 3.4D). Finally, lung micro-
metastases began to appear on MRI approximately 26 days post-implantation of 
the primary tumor cells (Figure 3.4E). Mice were sacrificed at this point due to 
ulceration of the primary tumour (out of field-of-view in the images). Note that 
although the initial metastatic lesion in the ipsilateral axillary lymph node was 
detectible on BLI, subsequent metastatic lesions that formed afterward could be 
detected via Oatp1b3-MRI but could not be resolved on BLI. This was due to 
excessive light scatter from the much larger first lesions. Eventually, once the 
second-stage lesions grew to substantial cell numbers, the lesion could be 
detected on BLI (Figure 3.4E). However, at this point, several third-stage 
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metastases forming in the lungs of the animals, detectible on Oatp1b3-MRI, were 
far too small relative to the bilateral lymph node lesions surrounding them for 
detection on BLI (Figure 3.4E).  
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Figure 3.4. Longitudinal Tracking of Spontaneously Metastasizing Cancer Cells 
via Bioluminescence Imaging and Magnetic Resonance Imaging at 3 Tesla. 
Representative bioluminescence images (BLI, p/s/cm2/sr) and magnetic resonance 
images (MRI) at 3T of female nod scid gamma mice (n=7) after implantation of MDA-
MB-231 cells into the left-bearing 4th mammary fat pad on Day 10 (A), Day 15 (B), Day 
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20 (C), Day 23 (D), and Day 26 (E). MIP, maximal intensity projection. Scale bar, 5 mm. 
E, Quantification of mean signal intensity (a.u.) of initial ipsilateral axillary lymph node 
lesions (Days 10-13) and mean signal intensity (a.u.) of surrounding muscle tissue on 
MRI (n=7, ****p<0.0001).  
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3.4 Discussion 
Preclinical animal models provide an invaluable platform to improve our 
understanding of the mechanisms of metastasis and test candidate anti-
metastatic therapies under controlled conditions. However, sensitive and 
quantitative preclinical assessment of metastatic disease with a high degree of 
accuracy is a significant challenge. Compared with traditional contrast agents, 
reporter genes offer critical information on cell viability, and do not require the 
presence of biomarkers to be specific to the cells of interest, as in triple-negative 
breast cancer. Fluorescence reporter genes generate unparalleled sensitivity and 
resolution but are largely limited to superficial surfaces and ex vivo histological 
examination. Although the resolution of fluorescent imaging is excellent, 
assessment of metastases based on histology is labor-intensive and the quality 
of the output data depends highly on the extent of tissue sampling, e.g. 
measurements across numerous slices composing entire organs versus 
measurements from just a few slices, as well as the reproducibility of the staining 
approach. To overcome the intensiveness of the process and sampling bias, the 
last decade has seen a surge of tissue clearing methods that render large 
biological samples transparent and allow unprecedented three-dimensional views 
of large volumes of tissue with and advanced optical microscopy (31). However, 
a major drawback of this approach, as with histology, is that only a single 
timepoint can be acquired of an individual animal, which in turn, would require 
large numbers of animals to generate effective conclusions for a study (32). This 
is a particularly serious issue when working with spontaneous metastasis models 
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that exhibit considerable variability between animals, with respect to both the 
time and location of metastatic progression (33).  
The ability to follow metastatic spread and its response to therapy in a 
single animal is an important experimental capability. Bioluminescence aims to 
accomplish this by providing sensitive whole-body information on locations of 
luciferase-expressing cancer cells, but we demonstrate that smaller cell 
populations can easily go undetected. Specifically, we show that initiated lymph 
node lesions and micro-metastases in separate organs are obscured by larger 
lesions throughout the metastatic process (Figure 3.3, Figure 3.4). Assuming 
that contrast enhanced voxels constituted entirely of Luc-1B3 cells, i.e. assuming 
no partial volume effects, and that 1 million cells correlate to a volume of 1-mm3, 
micro-metastases containing approximately 104 cells could be detected with 
Oatp1b3 post-administration of 1 mmol/kg of Gd-EOB-DTPA at 3 Tesla. 
However, the range of mean signal intensities exhibited amongst individual 
micro-metastases (Figure 3.3C) suggests that partial volume effects are in play, 
and that the detection limit of the Oatp1b3 reporter gene system may fall below 
this 10,000-cell threshold. Immediate next steps are focused on validating this 
measurement and accounting for partial volume effects.  
Bioluminescence measurements are often biased to detection of larger, 
more established lesions, that may not necessarily progress and respond to 
treatment in the same way as much smaller, recently-seeded metastases located 
in entirely different organ micro-environments. It may be that successful 
treatments for micro-metastases have been wrongly deemed ineffective simply 
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because much larger lesions dominated the measurements (34, 35). Oatp1b3 
mitigates these limitations of BLI for effective tracking of metastatic spread. We 
show that this reporter can dynamically track the metastatic process at its earliest 
stages, including small single lymph node lesions, even prior to BLI detection in 
some cases. At late stages, we demonstrate its superiority over BLI to track 
cancer spread to multiple lymph nodes and other organs such as the lungs. At 
this resolution, as demonstrated by others with endpoint analysis, we 
demonstrate that the metastatic process in this model starts when cells from the 
primary tumor travel to the ipsilateral axillary lymph node, subsequently spreads 
to the ipsilateral brachial lymph node or the contralateral axillary lymph node, and 
then the cancer cells appear to migrate down into the lungs. Although the sites of 
metastasis are in close agreement with previously published literature (36), and 
exhibit a pattern of metastasis similar to that observed in human breast cancer 
patients (37-39), imaging the dynamic migration of cancer cells in single animals 
from one location to the next has not previously been demonstrated. Oatp1b3 
fulfills a long-standing gap in our ability to accurately study metastatic disease 
over time and offers a path towards deep-tissue tracking of any Oatp1b3-
engineered cell type with combined high resolution, sensitivity, 3D spatial 
information, and surrounding anatomical context. 
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CHAPTER 4 Detection of Viable Cancer Lesions on Photoacoustic Imaging 
Rationale. We wanted to develop a photoacoustic imaging (PAI) reporter gene that has 
high translational potential. Previous research has shown that human Organic Anion-
Transporting Polypeptide 1b3 (Oatp1b3) promotes the uptake of the near-infrared 
fluorescent dye indocyanine green (ICG). Our objective in this study was to establish 
Oatp1b3 and ICG as a reporter gene–probe pair for in vivo PAI. Methods. Human breast 
cancer cells were engineered to express Oatp1b3. Control cells (not expressing Oatp1b3) 
or Oatp1b3-expressing cells were incubated with or without ICG, placed in a breast-
mimicking phantom, and imaged with PAI. Control (n = 6) or Oatp1b3-expressing (n = 5) 
cells were then implanted orthotopically into female mice. Full-spectrum PAI was performed 
before and 24 hours after ICG administration. One-way analysis of variance was 
performed, followed by Tukey post-hoc multiple comparisons, to assess statistical 
significance. Results. Oatp1b3-expressing cells incubated with ICG exhibited a 2.7-fold 
increase in contrast-to-noise ratio relative to all other controls in vitro (p<0.05). In mice, PAI 
signals after ICG administration were increased 2.3-fold in Oatp1b3 tumours relative to 
those in controls (p<0.05). Conclusions. Oatp1b3 operates as an in vivo PAI reporter gene 
based on its ability to promote the cellular uptake of ICG. Benefits include the human 
derivation of Oatp1b3, combined with the use of wavelengths in the near-infrared region, 
high extinction coefficient, low quantum yield, and clinical approval of ICG. We posit that 
this system will be useful for localized monitoring of emerging gene- and cell-based 
therapies in clinical applications. 
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4.1 Introduction 
Imaging reporter genes encode for proteins that can be used to visualize 
cellular and molecular processes in living systems (1). Unlike traditional contrast 
agents, reporter genes provide unique information on cellular viability as only living 
cells would express the reporter; and further, reporter expression can be linked to a 
gene of interest for dynamic tracking of its spatial and temporal expression patterns. 
Reporter genes for various imaging modalities have been developed, contributing 
extensively to monitoring the fates of various engineered cell types such as cancer, 
immune and stem cells in preclinical models (2-4). Moreover, clinical studies have 
applied reporter genes for monitoring of gene- (5) and cell-based (6) therapies in 
cancer patients via positron emission tomography (PET). While PET produces 
whole-body images with high sensitivity, it has limitations such as cost, availability, 
and ionizing radiation concerns for longitudinal studies. Reporter genes for 
affordable, portable, and safer imaging modalities are sought for continued localized 
monitoring of gene and cell therapies in humans.  
Photoacoustic imaging (PAI), or optoacoustic imaging, detects acoustic 
waves from optically-excited sources and is considerably more affordable than PET. 
Based on the photoacoustic effect, endogenous molecules such as deoxy- and 
oxyhemoglobin are able to absorb light and convert a fraction of that energy into 
heat. This heat energy leads to a transient thermoelastic expansion, resulting in 
emission of ultrasonic waves that can be detected by transducers to produce 
images. PAI thus combines the benefits of optical contrast with the resolution and 
depth-detection of ultrasound. Clinical PAI systems currently provide significant 
contrast at depths of several centimeters with resolutions of a few hundred microns 
 161 
(7, 8), and PAI is increasingly being applied to a growing number of biomedical 
applications, from sentinel lymph node imaging to vertebrae imaging for spinal 
surgery guidance (9-11). Reporter genes for PAI would allow for contrast 
enhancement of cell populations that would not otherwise produce PAI signals, thus 
potentially extending the utility of PAI for in vivo monitoring of gene- or cell-based 
therapies. PAI reporter genes that operate in the near-infrared (NIR) window are 
particularly desirable due to minimal endogenous photoacoustic molecules 
absorbing at these wavelengths (12).  
Though several PAI reporter genes have been developed and have shown 
significant value in preclinical studies, their clinical utility is potentially limited due to 
their non-human origin and/or undesirable toxicity (12). We sought to develop a PAI 
reporter gene system that overcomes these issues to increase the potential for 
clinical translation. As such, a member of the organic anion-transporting polypeptide 
(Oatp) family of proteins, namely OATP1B3, is endogenously expressed in the 
human liver and is responsible for hepatocyte uptake of the NIR fluorescent dye 
indocyanine green (ICG) during liver function tests. Previous work has also shown 
that OATP1B3 can take up ICG into cells that express it and can be used as a 
fluorescence reporter gene system (13, 14). Here we extended these previous 
studies to establish the combined use of OATP1B3 and ICG as a novel PAI human 
reporter gene. 
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4.2 Materials and Methods  
4.2.1 Cell Culture  
Human embryonic kidney cells (HEK 293T), human triple negative breast 
cancer cells (MDA-MB-231), and murine triple negative breast cancer cells (4T1) 
were obtained from a commercial supplier (American Type Culture Collection; 
ATCC, Manassas, Virginia, United States) and cultured in Dulbecco’s Modified 
Eagle Media (DMEM, Wisent Inc., Saint-Jean-Baptiste, Quebec, Canada) 
supplemented with 10% fetal bovine serum at 37°C and 5% CO2. Cells were 
routinely tested negative for mycoplasma using the MycoAlert mycoplasma 
detection kit (Lonza Group, Basel, Switzerland). 
 
4.2.2 Lentiviral Production and Generation of Stable Cells  
Genetic engineering of the reporter gene system involved third-generation 
packaging and envelope-expression plasmids (pMDLg/pRRE, pRSV-Rev, and 
pMD2.G, Addgene plasmids: #12251, #12253, and #12259, respectively; gifts from 
Didier Trono). A lentiviral transfer vector encoding the tdTomato (tdT) reporter gene 
for fluorescence, under regulation of the human elongation factor 1 alpha promoter 
(pEF1α) was obtained (15) along with a second lentiviral transfer plasmid encoding 
the zsGreen1 (zsG) reporter gene for fluorescence and the Organic anion 
transporting polypeptide 1a1 (Oatp1a1) reporter gene separated via a P2A self-
cleaving peptide, also under regulation of pEF1α (15). The sequence for Organic 
anion transporting polypeptide 1b3 (Oatp1b3) was acquired from the 
hOATP1B3/SLCO1B3 VersaClone cDNA Vector (Cat. RDC0870, R&D Systems, 
Minneapolis, Minnesota, United States). All cloning was performed using In-Fusion 
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HD Cloning (Takara Bio USA Inc, Madison, Wisconsin, United States). The Oatp1a1 
sequence in the second lentiviral transfer plasmid was replaced by the Oatp1b3 
sequence to obtain a resultant zsG/Oatp1b3 lentiviral transfer plasmid. The zsG 
fluorescent protein was utilized for fluorescence-activated cell sorting of Oatp1b3-
expressing cells, as it absorbs virtually no near-infrared light within the 680 to 970 
nm wavelength range and thus, will not confound signals generated during analysis 
of Oatp1b3 as a reporter gene for NIR-PAI (16).  
To produce tdT and zsG/Oatp1b3 lentiviruses (LV-tdT and LV-zsG/Oatp1b3), 
packaging, envelope and the relevant transfer plasmid were co-transfected into 
human embryonic kidney (HEK 293T) cells using Lipofectamine 3000 according to 
the manufacturer’s lentiviral production protocol (Thermo Fisher Scientific Inc., 
Waltham, Massachusetts, United States). Lentivirus-containing supernatants were 
harvested 24h and 48h post transfection, filtered through a 0.45-μm filter, and stored 
at -80°C prior to use. Human (MDA-MB-231) and murine (4T1) triple negative breast 
cancer cells were transduced with lentivirus encoding tdTomato fluorescent protein 
overnight in the presence of 4- to 8-μg/mL polybrene. Transduced cells were 
washed, collected, and sorted using a FACSAria III fluorescence-activated cell 
sorter (BD Biosciences, Mississauga, Ontario, Canada) for positive tdTomato 
fluorescence, generating tdTomato Control cells. A subset of these was then 
transduced with a second lentivirus co-encoding zsGreen fluorescent protein and 
OATP1B3 and sorted for equivalent tdTomato fluorescence intensity relative to the 
original tdTomato Control cells, as well as for positive zsGreen fluorescence. The 
resulting population was named tdTomato OATP1B3 cells. 
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4.2.3 Immunofluorescence Staining 
Cells were grown on glass coverslips, fixed with 4% paraformaldehyde (PFA) 
for 10 minutes, permeabilized via 0.02% Tween 20 for 20 minutes, and incubated 
overnight at 4°C with rabbit anti-SLCO1B3 (OATP1B3) primary antibody (2-µg/mL 
working concentration, HPA004943, Sigma-Aldrich Canada, Oakville, Ontario, 
Canada). Goat anti-rabbit AlexaFluor 647-conjugated secondary antibody was then 
applied (1:500 dilution; 4-µg/ml working concentration, ab150079, Lot E114795, 
Abcam, Cambridge, Massachusetts, United States). Cells on coverslips were 
counterstained with DAPI and imaged using an LSM Meta 510 microscope (Carl 
Zeiss AG, Oberkochen, Germany).  
 
4.2.4 Proliferation Assays  
Non-transduced, tdTomato Control, and tdTomato OATP1B3 cells (5×104) 
were seeded and cell proliferation was evaluated using a tetrazolium salt (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MTT) assay. Cells were 
incubated in phenol red-free DMEM (Cat. 319-051-CL, Wisent Inc., Saint-Jean-
Baptiste, Quebec, Canada) supplemented with 10% FBS that did or did not contain 
35-µg/ml ICG. Prior to optical measurements, wells were washed three times with 
PBS containing dimethyl sulfoxide (DMSO; 10% v/v). Absorbance measurements at 
590 nm were acquired with a spectrophotometer at 0, 24 and 48 hours after seeding. 
Proliferative measurements at 24 and 48 hours were normalized to absorption 
values obtained at seeding (0 hours).  
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4.2.5 In Vitro Fluorescence Imaging 
Human (MDA-MB-231) and murine (4T1) tdTomato Control and tdTomato 
OATP1B3 cells were incubated for 90 minutes at 37°C and 5% CO2 in media 
containing either 35-µg/ml ICG or an equivalent volume of DMSO solvent. Cells 
were then washed three times with DMSO-containing PBS (10% v/v), trypsinized, 
counted and 1x106 cells were pelleted and subsequently transferred into the wells 
of a custom-built 1% agarose, 0.5% intralipid phantom, designed to be asymmetrical 
in its distribution of wells. Additionally, a well containing 35-µg/ml ICG, and a well 
containing media without ICG were included as positive and negative controls, 
respectively. An IVIS Lumina XRMS In Vivo Imaging System (PerkinElmer, 
Waltham, Massachusetts, United States) was used to measure ICG fluorescence 
intensity using a 0.5-s exposure time, 780-nm excitation filter, and 845-nm emission 
filter. 
 
4.2.6 In Vitro Photoacoustic Imaging 
PAI of the cell phantoms was then performed using a custom-built 
photoacoustic tomography system. The PAI system consisted of a transducer array 
with 28 custom-built cylindrical unfocused transducers (2.7-MHz central frequency, 
~127% bandwidth, 4.5-mm diameter) mounted on two concentric circular rungs. All 
transducers were angled inwards to a point 25 mm below the array, providing a field-
of-view ~20 mm in diameter. 780-nm NIR illumination was provided by a tunable 
(680 – 950 nm) 10-Hz-pulsed laser (Phocus InLine, Opotek Inc., California, United 
States) injected into a four-legged fused-end fiber bundle (Lumen Dynamics Group 
Inc., Mississauga, Ontario, Canada). The output ends of the fiber bundle were 
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positioned at the centre of the circular transducer rings, pointing inwards towards 
the same focal point as the transducers. The transducer array with attached fiber 
bundles was mounted to an Epson SCARA robot (Epson C4, Suwa, Nagano 
Prefecture, Japan) for scanning. All transducers were connected to a custom 28-
channel, 50-MHz data acquisition system. The phantom was sealed with water in a 
modified Ziploc bag and submerged in a water tank along with the transducer array. 
The imaging array was raster scanned in three dimensions with 4-mm steps in the 
XY-plane, and 5-mm steps in the Z-direction to image the entire phantom. At each 
scan point, signal averaging was performed over 16 laser pulses to increase the 
signal-to-noise ratio. Following imaging, image reconstruction using universal back-
projection was performed (17). A maximum intensity projection (MIP) image of the 
3D stack was then acquired using ImageJ (18). Average signal intensity was 
measured from each well and the contrast-to-noise ratio (CNR) was calculated 
relative to an equal-sized ROI positioned at the centre of the MIP image.  
 
4.2.7 In Vivo Fluorescence Imaging 
All animal experiments were performed in compliance with an approved 
protocol of the University of Western Ontario’s Council on Animal Care (Animal Use 
Protocol 2016-026) and in accordance with the standards of the Canadian Council 
on Animal Care. tdTomato Control (n=6) or tdTomato OATP1B3 (n=5) MDA-MB-
231 cells (3×105) were implanted orthotopically into the right-bearing fourth 
mammary fat pad of immunocompromised (NU-Foxn1nu) 6-8-week-old female mice 
(Charles River Laboratories, Wilmington, Massachusetts, United States). FLI was 
performed on an IVIS Lumina XRMS In Vivo Imaging System (PerkinElmer, 
 167 
Waltham, Massachusetts, United States), starting 48h post cellular implantation. 
Mice were anesthetized with 1-2% isofluorane using a nose cone attached to an 
activated carbon charcoal filter for passive scavenging. FLI for tdTomato was 
performed using 520-nm excitation and 570-nm emission filters and images were 
acquired with a 5-minute exposure time. FLI for ICG was performed using 780-nm 
excitation and 845-nm emission filters and images were acquired with a 5-min 
exposure time. 
 
4.2.8 In Vivo Photoacoustic Imaging  
Mice were anesthetized as described above, and US and PAI were 
performed using the Vevo LAZR-X System (Fujifilm VisualSonics Inc., Toronto, 
Ontario, Canada). An LZ550 transducer was used to acquire US and PAI images 
with axial resolutions of 40 μm. Acoustic signals at each wavelength were measured 
ten times for signal averaging. The total acquisition time per wavelength was 2.0 s, 
and a total time of approximately 1.93 minutes was required to image each slice 
across all wavelengths.  US images of tumours were first acquired, followed by NIR 
spectrum (680-970 nm) PAI in 5-nm increments. For each tumour, a central slice, 
along with adjacent slices 800 µm on either side were acquired. Regions-of-interest 
(ROIs) around the perimeter of each tumour in US images were outlined and 
subsequently overlayed onto corresponding photoacoustic images. Tumour ROIs 
were processed through the software to generate a full-spectrum photoacoustic plot 
for each tumour both before and 24 hours following administration of ICG. Vevo Lab 
Image Software (Fujifilm VisualSonics Inc., Toronto, Ontario, Canada) was used to 
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spectrally unmix ICG signals from tumour data to generate ICG localization images 
within tumours, as previously described (19). 
 
4.2.9 Ex Vivo FLI and Histology 
Following in vivo imaging, mice were immediately sacrificed via isofluorane 
overdose, perfused with 4% paraformaldehyde through the left heart ventricle and 
tumours were excised from mammary fat pads. Tumours were subsequently frozen 
in Tissue-Tik Optimum Cutting Temperature (OCT) medium (Sakura Finetek, 
Maumee, Ohio, United States) and both 150-µm and 10-µm frozen sections were 
collected via the Leica CM350 Cryostat (Leica Microsystems, Wetzlar, Germany). 
The 150-µm sections were plated on glass slides and FLI images were collected 
using the IVIS Lumina XRMS In Vivo Imaging System (PerkinElmer, Waltham, 
Massachusetts, United States) for tdTomato expression (5-s exposure, 520-nm 
excitation filter, 570-nm emission filter), zsGreen expression (10-s exposure, 480-
nm excitation filter, 520-nm emission filter), and ICG uptake/retention (10-s 
exposure, 780-nm excitation filter, 845-nm emission filter). Microscopy images for 
tdTomato and zsGreen fluorescence were taken of the 10-µm sections using an 
EVOS FL Auto 2 Imaging System (Invitrogen, Thermo Fisher Scientific Inc., 
Waltham, Massachusetts, United States).     
 
4.2.10 Statistics 
One-way Analysis of Variance (ANOVA) was performed followed by Tukey’s 
post-hoc multiple comparisons using Graphpad Prism software (Version 7.00 for 
Mac OS X, GraphPad Software Inc., La Jolla, California, United States, 
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www.graphpad.com). For time-course experiments, repeated measures ANOVA 
was performed, followed by Tukey’s post-hoc multiple comparisons. For all tests, a 
nominal p-value less than 0.05 was considered statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 170 
4.3 Results 
4.3.1 Generation of breast cancer cells expressing reporter genes  
Human (MDA-MB-231) and murine (4T1) cells were transduced first with 
lentivirus encoding the fluorescence reporter tdTomato and were subsequently 
sorted for tdTomato fluorescence with >95% purity to generate tdTomato Control 
cells. A subset of these was then transduced with a second lentivirus co-encoding 
the fluorescence reporter zsGreen1 (zsG) and Oatp1b3 (Figure 4.1A). This second 
cell population was sorted for both tdTomato intensity equivalent to the tdTomato 
Control cell population, as well as zsGreen intensity with >95% purity to generate 
tdTomato OATP1B3 cells (Figure 4.1B). Immunofluorescence staining validated 
absence of Oatp1b3 expression in tdTomato Control cells, whereas positive staining 
was present in the tdTomato OATP1B3 cells (Figure 4.1C). Proliferation assays 
showed no significant difference in growth rates between non-transduced cells, 
tdTomato Control cells, and tdTomato OATP1B3 cells, or between cell populations 
incubated in 35-µg/ml ICG for 60 minutes (Figure 4.1D). 
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Figure 4.1. Cell Engineering and Characterization. A) Reporter gene constructs used to 
engineer cells, which include the fluorescence reporter tdTomato (top; tdTomato Control), 
or tdTomato in addition to the fluorescence reporter zsGreen (zsG) with Organic anion-
transporting polypeptide 1b3 (Oatp1b3) separated by the self-cleaving peptide (P2A) 
(bottom; tdTomato OATP1B3), each under control of the human elongation factor 1 
promoter (pEF1a). B) Fluorescence-activated cell sorting plots following lentivirus 
transduction of MDA-MB-231 cells with tdTomato Control transfer plasmids or tdTomato 
OATP1B3 transfer plasmids. C) Microscopy of engineered MDA-MB-231 cells for nuclear 
staining (DAPI; blue), tdTomato fluorescence (red), zsGreen fluorescence (green), and 
immunofluorescence staining for OATP1B3 expression (purple). Scale bar, 20 µm. D) 
Relative growth rates (arbitrary units, a.u.) of Non Transduced, tdTomato Control, and 
tdTomato OATP1B3 cells grown in the presence or absence of 35 µg/ml indocyanine green 
(ICG). Error bars represent one standard deviation. 
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4.3.2 In vitro ICG-enhanced FLI and PAI of breast cancer cells expressing Oatp1b3 
Next, we evaluated FLI and PAI contrast of both human and murine cells 
expressing Oatp1b3 incubated with or without ICG. Both MDA-MB-231 and 4T1 
tdTomato OATP1B3 cells incubated with 35-µg/ml ICG, and subsequently washed, 
exhibited significantly increased fluorescence radiance (p/s/cm2/sr) at ICG 
wavelengths relative to ICG-incubated tdTomato Control cells (4.0-fold, p<0.05; 
Figure 4.2A). Fluorescence radiance from ICG-incubated tdTomato OATP1B3 cells 
was also significantly increased relative to an equivalent volume of 35-µg/ml ICG 
alone as the positive control (2.6-fold; p<0.05). No significant difference in 
fluorescence radiance at ICG wavelengths was observed between tdTomato 
Control and tdTomato OATP1B3 cells not incubated with ICG, ruling out any 
contribution of zsGreen to signals at NIR wavelengths. PAI of the same phantom at 
780 nm was acquired using a custom-built PAI system. Photoacoustic CNR 
(arbitrary units, a.u.) was significantly increased for both MDA-MB-231 (2.7-fold; 
p<0.05) and 4T1 (2.4-fold; p<0.05) tdTomato OATP1B3 cells incubated with 35 
µg/ml-ICG, relative to CNR of ICG-incubated tdTomato Control cells and all 
untreated controls (Figure 4.2B). PAI of tdTomato Control cells incubated with ICG 
did not exhibit a significant difference in CNR relative to untreated Control cells. 
Additionally, it is important to note that both MDA-MB-231 and 4T1 treated control 
cells exhibited average fluorescence radiance that was greater than the 
fluorescence radiance from untreated controls, indicating that there was marginal 
uptake of ICG by control cells. However, on PAI, these same treated control cells 
did not demonstrate contrast enhancement greater than untreated controls, 
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suggesting that the threshold for detection for ICG using PAI is greater than that for 
ICG using fluorescence imaging. 
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Figure 4.2. In Vitro Fluorescence and Photoacoustic Imaging. A) Fluorescence 
imaging,  acquired with 780-nm excitation and 845-nm emission filters, of an asymmetrical 
phantom with wells: (1) 35-µg/ml indocyanine green (ICG); (2) media; (3) MDA-MB-231 
tdTomato Control cells; (4) MDA-MB-231 tdTomato Control cells incubated with 35 µg/ml 
ICG; (5) MDA-MB-231 tdTomato OATP1B3 cells; (6) MDA-MB-231 tdTomato OATP1B3 
cells incubated with 35-µg/ml ICG; (7) 4T1 tdTomato Control cells; (8) 4T1 tdTomato 
Control cells incubated with 35-µg/ml ICG; (9) 4T1 tdTomato OATP1B3 cells; and (10) 4T1 
tdTomato OATP1B3 cells incubated with 35-µg/ml ICG. Fluorescence radiance is 
measured in p/s/cm2/sr. B) Photoacoustic imaging (PAI) of the same phantom acquired 
with an optical excitation at 780 nm. Contrast-to-noise ratios (relative to the center of the 
phantom) were quantified (arbitrary units, a.u.). Numbers, 1-10, on graphs correspond to 
numbers on images. Scale bar, 1 cm. Error bars represent one standard deviation. 
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4.3.3 ICG-enhanced FLI signal from Oatp1b3-expressing tumours 
No significant difference in fluorescence radiance (p/s/cm2/sr) at tdTomato 
wavelengths was found between tdTomato Control (n=4) and tdTomato OATP1B3 
(n=4) tumours over time, suggesting comparable tumour growth rates (Figure 
4.3A). Longitudinal FLI for ICG fluorescence after intraperitoneal administration of 
8-mg/kg ICG determined that the largest significant difference in ICG signals 
between tdTomato Control and tdTomato OATP1B3 tumours occurred at 24 hours 
post-ICG (Figure 4.3B). Accordingly, a second cohort of animals was imaged prior 
to ICG administration and 24 hours post-ICG. Neither tdTomato Control (n=6) nor 
tdTomato OATP1B3 (n=5) tumours generated FLI radiance at ICG wavelengths 
prior to ICG administration, confirming no possible contribution by zsGreen (Figure 
4.3C, middle column). Prior to ICG administration, mean fluorescence radiance 
measures (± standard deviation) for ICG were not significantly different between 
tdTomato Control tumours (9.14 ± 3.49 x 106 p/s/cm2/sr) and tdTomato OATP1B3 
tumours (7.41 ± 1.86 x 106 p/s/cm2/sr). In contrast, twenty-four hours after ICG 
administration, tdTomato OATP1B3 tumours exhibited significantly increased (8.9-
fold) fluorescence (7.36 ± 1.77 x 108 p/s/cm2/sr) relative to tdTomato Control 
tumours (8.22 ± 0.527 x 107 p/s/cm2/sr; p<0.05; Figure 4.3D). FLI signals at ICG 
wavelengths were also detected from the abdomen of both tdTomato Control and 
tdTomato OATP1B3 tumours 24 hours following ICG administration, likely from 
physiological hepatobiliary clearance of ICG (20) (Figure 4.3C, last column).  
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Figure 4.3. In Vivo Fluorescence Imaging of Engineered Tumours. A) tdTomato 
fluorescence radiance (p/s/cm2/sr) of tdTomato Control (n=4) and tdTomato OATP1B3 
(n=4) tumours over time. B) ICG fluorescence radiance (p/s/cm2/sr) of tdTomato Control 
(n=4) and tdTomato OATP1B3 (n=4) tumours over time, up to 9 days, following 
administration of 8 mg/kg ICG. C) Fluorescence imaging (FLI) for tdTomato (first column) 
and indocyanine green (ICG) average radiance (p/s/cm2/sr) before (pre-ICG; second 
column) and 24 hours following administration of 8-mg/kg ICG (24h post ICG; third column) 
of a representative mouse burdened with a human breast cancer (MDA-MB-231) tdTomato 
Control tumour (top panel) or with a MDA-MB-231 tdTomato OATP1B3 tumour (bottom 
panel). Tumours are outlined with black dashed lines and/or pointed out via the “Tumour” 
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label. tdTomato signal (first column) is directly proportional to tumour size. D) Fluorescence 
radiance (p/s/cm2/sr) of tdTomato Control (n=6) and tdTomato OATP1B3 (n=5) tumours 
before administration of indocyanine green (ICG; pre-ICG), immediately following 
intraperitoneal injection of ICG (0h post ICG), and 24 hours following ICG administration 
(24h post ICG). Error bars represent one standard deviation. Whiskers on the box graph 
represent the range of observed values. 
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4.3.4 ICG-enhanced PAI signal from Oatp1b3-expressing tumours 
Prior to ICG administration, tdTomato Control and tdTomato OATP1B3 
tumour morphology was discernible via US, enabling acquisition of PAI baseline 
signals at field of views encompassing tumour boundaries (Figure 4.4A; i, iii). Since 
there was variance in tumour size, background signals, and tumour morphology 
within and across tdTomato Control and tdTomato OATP1B3 tumour groups, mean 
hemoglobin (HbO2) PA signals, measured via acoustic average (a.u.) as l ∈	(855, 
955); Dl=5nm, was calculated for each acquired spectrum and used to normalize 
the signal acquired at 805 nm. This ICG-to-HbO2 signal ratio, referred to as 
normalized PA signal (a.u.), was not statistically different between tdTomato Control 
(0.72 ± 0.09 a.u.) and tdTomato OATP1B3 (0.85 ± 0.16 a.u.) tumours prior to ICG 
injection. Normalized PA signal was also not significantly different between images 
of tdTomato Control tumours collected before and after ICG administration (0.75 ± 
0.13 a.u.; Figure 4.4C). In contrast, 24 hours post ICG, tdTomato OATP1B3 
tumours demonstrated significantly increased normalized PA signals (1.92 ± 0.40 
a.u.) relative to all other groups (p<0.05). Importantly, tdTomato OATP1B3 tumours 
exhibited increased PAI signal within a narrow absorption band spanning from 695 
to 855 nm, with a consensus maximum peak at 805 nm across all tdTomato 
OATP1B3 tumours 24 hours post-ICG.  
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Figure 4.4. In Vivo Near-Infrared Spectral Photoacoustic Imaging. A) Ultrasound image 
(top row), PAI image at 805 nm (second row), and a spectrally unmixed image of 
indocyanine green (ICG) distribution across all wavelengths (Unmixed; third row) of a 
representative human breast cancer (MDA-MB-231) tdTomato Control Tumour (left panel) 
and tdTomato OATP1B3 Tumour (right panel), both prior-to administration of ICG (i, iii; pre-
ICG) and 24 hours following administration of 8-mg/kg ICG (ii, iv; 24h post ICG). PAI 
contrast enhancement on PAI is exhibited by tdTomato OATP1B3 tumours 24 hours 
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following ICG administration, while tdTomato Control tumours do not exhibit increased 
signals 24 hours following ICG administration. B) Near-infrared PAI spectra of a 
representative tdTomato Control Tumour (top) and tdTomato OATP1B3 tumour (bottom), 
before administration of ICG (dashed-line plot) and 24 hours following administration of 8-
mg/kg ICG (solid-line plot), each labelled with hemoglobin (HbO2; red) and 
deoxyhemoblobin (Hb; blue) peaks. Increased photoacoustic signals are observed 
exclusively within tdTomato OATP1B3 tumours 24h post ICG, with a maximum at 805 nm 
(ICG peak). C) ICG-to-HbO2 ratio, referred to as the Normalized PA signal (arbitrary units, 
a.u.), across tumour and treatment groups. Scale bar, 1 mm. Error bars represent one 
standard deviation. Whiskers on the box graph represent the range of observed values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 181 
4.3.5 Ex vivo FLI confirms selective ICG retention in Oatp1b3-expressing tumours 
zsGreen fluorescence (10-s exposure, 480-nm excitation filter, 520-nm 
emission filter) was absent in tdTomato Control tumour sections but present in 
tdTomato OATP1B3 tumour sections. Importantly, ICG FLI signal (10-s exposure, 
780-nm excitation filter, 845-nm emission filter) was visible only in tdTomato 
OATP1B3 tumour sections. Fluorescence microscopy was also conducted, and 
further validated the presence and/or absence of tdTomato and zsGreen signals 
from FLI of tumours (Figure 4.5).  
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Figure 4.5. Ex Vivo Fluorescence Imaging. A) Fluorescence imaging (FLI) for tdTomato 
fluorescence (first column), zsGreen fluorescence (second column), and indocyanine 
green (ICG; third column) of tdTomato Control (top row) and tdTomato OATP1B3 (second 
row) tumour slices. Scale bar, 1 cm. B) Fluorescence microscopy for tdTomato (first 
column) and zsGreen (second column) of tdTomato Control (top row) and tdTomato 
OATP1B3 (second row) tumour slices. Scale bar, 100 µm. 
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4.4 Discussion 
In this study we establish Oatp1b3 and ICG as a novel reporter gene-probe 
system for in vivo PAI of engineered cell populations. We generated a novel lentiviral 
vector encoding Oatp1b3, allowing for engineering of cell lines to stably express this 
ICG transporter. Cells engineered to express Oatp1b3 demonstrated significantly 
increased fluorescence signals at NIR wavelengths following incubation with ICG, 
which was not observed in control cells. On PAI, Oatp1b3-expressing cells 
incubated with ICG exhibited significantly increased signals in vitro, while ICG-
incubated control cells were virtually undetectable. We also demonstrated that 
Oatp1b3-expressing breast cancer cells can be implanted to grow orthotopic 
tumours in vivo, and significantly increased FLI and PAI signal was seen in small 
tumours (<1mm3) 24 hours following administration of ICG. Importantly, we 
demonstrate that the increase in PAI detection was specific to the 695 to 855-nm 
wavelength range, with a consensus maximal peak at 805 nm, allowing for accurate 
in vivo identification of reporter gene-enhanced PAI signal. We further validate 
selective retention of ICG by Oatp1b3-expressing tumours.  
Our study extends previous work on Oatp1b3, establishing it as a 
multimodality reporter for numerous clinically-relevant modalities such as FLI, and 
now PAI, and also introduces potential for Oatp1b3 reporter gene imaging on a 
clinical 3-Tesla MR scanner. OATP1B3-enhanced PAI uniquely offers a non-ionizing 
and cost-effective method to detect engineered cell populations with sensitivity and 
relatively high resolution. Clinical PAI systems can image up to around 7 centimeters 
(21), and thus future work should establish how many Oatp1b3-expressing cells can 
be detected at specific depths in larger animal models. A caveat of this system is 
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that the engineered cells to be imaged on PAI should not be located beyond an 
optical-scattering material e.g., within the adult human skull, where the light needed 
to excite ICG would be largely reflected by bone before getting to the engineered 
cells. However, this issue may be solved through the use of more penetrative PAI 
systems that are being developed (22, 23). The ability to evaluate the status of a 
gene or cell population using whole-body (MRI) (24), localized (PAI) and 
microscopic (fluorescence) imaging techniques with a single reporter gene system 
could be broadly useful for many biomedical applications, such as tracking the 
viability and migration of therapeutic cells in patients (25, 26). Rat-derived Oatp1a1 
and the tracer 111Indium-EOB-DTPA have also been established as a reporter gene-
probe pair for single photon emission computed tomography (SPECT) (27). Studies 
evaluating human Oatp1b3 as a SPECT reporter gene are warranted to further 
extend the potential utility of this human reporter beyond FLI, PAI, and MRI, and 
improve cellular detectability via the higher probe sensitivity offered by SPECT.  
The ideal PAI reporter gene would be specific to the biological process of 
interest; exhibit an absorption maximum within the NIR window for deep tissue in 
vivo imaging; and, be nontoxic to the cell. Though other reporter genes for PAI have 
been described (e.g., NIR fluorescent proteins, photo-switchable fluorescent 
proteins), the PAI reporter gene arguably considered to have the highest 
translational potential is human tyrosinase, which initiates the conversion of 
endogenous tyrosine into detectable melanin (19, 28-30). Though tyrosinase 
presents desirable properties, including human origin, signal amplification due to 
enzymatic action, and a detectible product with high photostability, it is not without 
limitations (7). For instance, the melanin photoacoustic profile displays a broadband, 
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featureless absorption spectrum, making it difficult to distinguish ectopic melanin 
from other intrinsic signals with accuracy (12). Our Oatp1b3-ICG system, on the 
other hand, features a distinct band within the NIR region that is easy to identify and 
un-mix from hemoglobin and deoxyhemoglobin spectra, and from spectra of other 
PAI reporters added to the biological system for more complex functional imaging. 
It is also interesting to note that wells in the in vitro experiments containing a sample 
of ICG-incubated Oatp1b3-engineered cells exhibited greater fluorescence radiance 
(2.6-fold) and PAI signals (1.19-fold) relative to the positive-control well containing 
a sample of ICG at the treatment concentration. This suggests that uptake of ICG 
by OATP1B3 occurs in an active or active-coupled process, rather than simple 
diffusion, which is in agreement with current theories describing uptake mechanisms 
of the OATP1 family of transporters (31). While tyrosinase exhibits signal 
amplification due to enzymatic action, Oatp1b3 may provide signal amplification 
through active or active-coupled uptake of many ICG molecules. In addition, altered 
cell phenotype and toxicity associated with ectopic tyrosinase activity has been 
documented, (28, 32, 33) in so much that tyrosinase-encoding plasmid distributors 
(e.g., Imanis Life Sciences), recommend inducible promoters to minimize undesired 
biological effects during imaging studies. Though documented experiments are 
limited in number, ectopic Oatp1b3 overexpression has not been reported to cause 
cellular toxicity or confer observable phenotypic changes (14, 34), and we did not 
observe any quantitative or qualitative differences in cell proliferation rates and/or 
morphology in our own work, even when engineered cells were incubated in the 
presence of ICG. As we performed here, it was important to assess the effectiveness 
of this system at the preclinical stage using doses of ICG equivalent to current 
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clinical guidelines. Though ICG is safe to inject at these doses, further safety 
evaluation may be warranted on the intracellular toxicity of ICG once it is internalized 
by the OATP1B3 transporter. It should also be noted that detection of engineered 
cells near the hepatobiliary system would be difficult, as clearance of ICG within that 
pathway obscure the ability to detect OATP1B3-engineered cells retaining ICG.  
In the clinic, PET reporter genes have so far been used in patients for imaging 
of adenoviral gene therapy (5) and cytotoxic T cell immunotherapies (6) in cancer 
patients. These studies mark major milestones in reporter gene imaging, but limited 
access and costs due to associated infrastructure and operation, in combination with 
concerns over ionizing radiation may hinder broad applicability and longitudinal 
imaging via PET reporter genes. These limitations highlight the need for alternative 
reporter gene systems for safe, cost-effective, and accessible imaging modalities 
within the clinic. Although nuclear imaging (PET/SPECT) is capable of whole-body 
visualization, and photoacoustics is limited to localized imaging, reporter gene 
imaging with PAI should be applicable for a variety of clinical problems that only 
require imaging of specific tissues (35). For example, including the Oatp1b3 reporter 
gene to the genetic engineering protocol of chimeric antigen receptor (CAR) T cell 
therapies targeting prostate cancer stem cells (36) would allow for longitudinal 
monitoring of these cells in the prostate via an intraperitoneal laser/transrectal 
transducer system (37). We expect this technology to be particularly useful in clinical 
trials that involve localized injection of a gene or cellular therapy into a specific 
tissue, as it allows for real-time information on how a particular therapy is operating 
in the patient. Questions of interest include: is the therapy getting to the target site? 
Is it activating at the target site? For how long does it persist? Does reporter 
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expression correlate with patient response? However, until more gene and cell-
based therapeutics make their way into the clinic, we expect that this multimodality 
reporter system will be more rapidly utilized for tracking of gene expression and cell 
populations in preclinical animal models. 
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CHAPTER 5 Summary and Future Work  
This thesis presents work on Organic Anion-Transporting Polypeptide 1 (Oatp1) as a 
reporter gene for multimodality cell tracking in preclinical animal models with high 
sensitivity, high resolution, and surrounding anatomical context. At the start of this 
research, a single publication existed describing rat Oatp1a1 as a magnetic resonance 
reporter gene, using optimal parameters to prove its principle: high field strengths (7T, 
9.4T), large doses of Gd-EOB-DTPA, and xenografts in animal models. At that point in 
time, Oatp1 demonstrated great potential as a reporter gene, and provided a lot of 
excitement for future utility. In our work, we were first interested in assessing the 
feasibility of translating this system to the clinic. We showed that Oatp1a1 can be used 
to track cells at 3 Tesla, with clinically-feasible doses of the paired imaging probe Gd-
EOB-DTPA, and that these parameters allow for imaging high resolution distribution 
patterns of viable cells in 3-dimensional space. Next, we transitioned to a closely-related 
human transporter called Oatp1b3. We showed that Oatp1b3 can be used to track small 
populations of spontaneously metastasizing cancer cells longitudinally via MRI, and 
estimated its detection limit at about 104 cells. Finally, we demonstrated that Oatp1b3 
can be used as a photoacoustic imaging reporter gene, based on its ability to take up 
indocyanine green in vivo, allowing for rapid and cost-effective imaging of engineered 
cells in tissues. This thesis represents an important step in the development of a 
versatile imaging tool for tracking the location of viable engineered cells in preclinical 
animal models and lays groundwork for translating this technology for tracking of genes 
and/or cells in patients. The following sections outline a summary of the main findings in 
each study, as well as challenges and limitations, and future research avenues.  
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5.1 Discussion and Conclusions 
5.1.1 Chapter 2 - High Resolution Oatp1 Imaging using Clinical MR Parameters 
First, we tested the feasibility of using Oatp1a1 to track the growth of 
primary tumours over time on MRI, at clinical field strengths of 3 Tesla and 
clinically-feasible doses of 0.1-mmol/kg Gd-EOB-DTPA in mice. Using 
bioluminescence imaging as a reference modality, we observed continued 
growth in BLI signals from primary tumours over time at low resolutions. The 
main findings of this chapter were: 1) Oatp1a1 enhances bioluminescence 
imaging signals by mediating increased D-luciferin transport into engineered 
cells; 2) there is significant in vivo contrast enhancement by Oatp1a1-engineered 
cells on MRI at 3 Tesla, and 0.1-mmol/kg Gd-EOB-DTPA; and, 3) high resolution 
contrast enhancement patterns of engineered cells on MRI strongly correlated to 
distributions of viable cancer cells on matched histology.  
Ultimately, this initial set of observations established the multi-dimensional 
utility of using Oatp1a1 for tracking viable cells in vivo. Increased uptake of D-
luciferin resulted in increased sensitivity on bioluminescence imaging, allowing 
for detection of smaller and/or deeper populations of engineered cells, that would 
have otherwise gone undetected. MRI demonstrated that engineered cells 
appear enhanced at 3 Tesla, with relatively low doses of Gd-EOB-DTPA. Further, 
with longitudinal monitoring, we were able to dynamically observe architectural 
changes within primary tumours at high resolutions, including the emergence of 
necrotic centres and non-cancer cells within primary tumour boundaries, and 
were able to quantitatively validate these enhancement patterns at endpoint 
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using matched histology. In summary, this chapter established Oatp1a1 reporter 
gene imaging as a powerful tool to track viable engineered cells on MRI, with 
concomitant BLI enhancement. The multi-ligand nature of Oatp1a1, in its ability 
to take up D-luciferin and enhance BLI signals, as well as Gd-EOB-DTPA to 
enhance MR signals, warranted investigation towards other hepato-specific 
substrates, such as indocyanine green (ICG) for the enhancement of fluorescent 
and photoacoustic signals (1). However, we observed only modest uptake of ICG 
by Oatp1a1 in preliminary studies. At this point, we sought to investigate 
additional Oatp1 transporters, namely human Oatp1b1 and Oatp1b3, to 
characterize their uptake preferences for potential use in molecular imaging. 
Oatp1b3 proved to be very useful, and the sequential chapters highlight our 
major findings.  
 
5.1.2 Chapter 3 - Whole-Body Tracking of Spontaneous Metastases on MRI 
In the previous chapter, we initially planned to use Oatp1 as a tool to track 
bulk groups of cells on MRI and held conservative views on the sensitivity of this 
reporter gene technology. However, we were surprised to observe strong, 
positive quantitative correlations between enhancement patterns on MRI and 
matched histology at high resolutions in the previous chapter. As a result, we 
became increasingly interested in the potential of this technology for dynamic 
tracking of small populations of migrating cells. To this end, we used a 
spontaneous metastasis model of breast cancer in preclinical mice. Additionally, 
we were increasingly interested in studying the human Oatp1b3 transporter as a 
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reporter gene, for future applications of cell tracking in humanized mice models 
and clinical tracking of cell-based therapies in patients. The main findings of this 
chapter were: 1) there is significant contrast enhancement by Oatp1b3-
engineered cells on MRI at 3 Tesla, and 1-mmol/kg Gd-EOB-DTPA in preclinical 
animal models; 2) Oatp1b3 allows for longitudinal, whole-body tracking of 
migrating cells with high sensitivity and resolution; and, 3) the in vivo detection 
limit of Oatp1b3 is on the order of 104 cells, and sits on par with the detection 
limit of bioluminescence imaging.  
These findings were significant, as they offer a new approach for 
assessing metastatic burden with high resolution, sensitivity, and across the 
whole-body. With this technology, we were able to dynamically track the 
metastatic process in deep tissues on MRI, from early-stage metastasis at the 
single lymph-node level, to late-stage metastasis, when the cancer cells have 
invaded distant organs, such as the lungs. While tracking metastases non-
invasively with BLI allows for whole-body tracking of metastases, light scatter 
from larger lesions may obscure smaller metastases. Additionally, light scatter 
limits the resolution of imaging via bioluminescence, making it difficult to pinpoint 
the exact locations of engineered cells in 3-dimensional space. Further, light 
attenuation from surrounding signals make it difficult to distinguish between 
signals stemming from smaller populations of superficial cells or larger 
populations of deep-seated cells. In this way, light attenuation also contributes to 
the difficulty of pinpointing exact locations of engineered cells on BLI, and the 
capacity to quantify their signals on BLI. With Oatp1b3-MRI, we were able to 
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reveal the true locations of engineered cells in 3-dimensional space, with 
sensitivity comparable to that of bioluminescence. Notably, we were able to 
reveal smaller micro-metastases via Oatp1b3-MRI, which were indiscernible on 
BLI due to light scatter from larger lesions, allowing us to capture a “true picture” 
of how the cancer cells grow and migrate throughout the body.  
 
5.1.3 Chapter 4 - Photoacoustic Imaging with Oatp1 and Indocyanine Green 
Finally, in the final research chapter, we wanted to explore the potential of 
using Oatp1b3 as a multimodality reporter gene. Individual modalities present 
with inherent limitations, whereas combining multiple modalities with 
complementary advantages and limitations offers a more thorough understanding 
of the biological phenomenon being studied. The initial Oatp1a1 reporter gene 
paper introduced an indium-111 radionuclide analog of Gd-EOB-DTPA that was 
used for SPECT detection of Oatp1a1-expressing cells. While SPECT offers a 
clinical platform with increased sensitivity relative to MRI, it is far more limited in 
resolution and accessibility. Taking on a different direction, we discovered 
previous evidence suggesting that indocyanine green was a ligand for the 
Oatp1b3 transporter (2). Following this data, we sought to establish Oatp1b3 as 
a photoacoustic imaging reporter gene, as indocyanine green exhibits a high 
extinction coefficient, low quantum yield, and has previously been demonstrated 
as an effective photoacoustic contrast agent. The main findings of this chapter 
were: 1) there was significant contrast enhancement on PAI by Oatp1b3-
engineered cells in preclinical animal models, following administration of 8 
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mg/kg-ICG; 2) imaging was optimal at 24h post-intraperitoneal injection of ICG, 
at which point any non-specific ICG across the body was largely cleared; and, 3) 
specifically, broad increases in PAI signals within the NIR region (730-855 nm) 
were detected, with a consensus maximal peak at 805 nm.  
These findings provided support Oatp1b3 and ICG as a novel reporter 
gene system for photoacoustic imaging. While photoacoustic imaging is limited in 
its ability to capture whole-body images in non small animal models, largely due 
to the cumulative attenuation of the exciting light and/or optical scattering of the 
exciting light by materials like bone, there is still great utility for high-resolution 
localized imaging at depths of several centimeters. The ability to assess genetic 
and cellular information via the Oatp1b3-PAI reporter gene system paves the 
path towards cost-effective, and therefore, potentially widespread in vivo 
molecular imaging at the preclinical stage, and perhaps even for clinical 
applications. Longstanding clinical approval and commercial availability of the 
paired imaging probe, indocyanine green, may also facilitate the dissemination of 
this technology for use in the laboratory and for clinical tracking of gene- and cell-
based therapies in the clinic. Although more work is warranted, our initial studies 
demonstrate promising feasibility of this photoacoustic imaging approach for 
various applications requiring gene and/or cellular tracking.  
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5.2 Challenges and Limitations  
5.2.1 Sensitivity of Detection  
The ultimate goal of molecular imaging is to detect molecular events as 
they occur in a living organism. Several factors are important in assessing the 
effectiveness of an imaging strategy for detecting a biochemical feature. One of 
these is its sensitivity, defined as the detection threshold of the imaging 
approach, which can be measured in a number of ways, such as probe 
concentration, molecular events per second, or number of cells. Some imaging 
modalities are inherently more sensitive than others. A PET scanner, for 
instance, can detect probe concentrations between 10−11 mol/L to 10−12 mol/L, 
whereas proton MRI has a probe sensitivity of around 10−3 mol/L to 10−5 mol/L, 
which can be limiting (3). Due to the novelty of photoacoustic imaging, combined 
with the assortment of systems built and used for studies in the literature, it is 
somewhat challenging to estimate the sensitivity of photoacoustic imaging. 
However, specific studies can provide insight on its sensitivity: the blue product, 
5-bromo-4-chloro-indoxyl, generated by the β-galactosidase reporter gene has 
been detected at depths of several millimeters at 10−6 mol/L to 10−9 mol/L 
concentrations (4), which is more sensitive than MRI, but less sensitive than 
PET. Still, with increasing tissue depth, photoacoustic imaging becomes less 
sensitive and MRI more advantageous.  
Perhaps a more pertinent measure of sensitivity, especially for cell 
tracking purposes, is the minimal number of detectable cells. Some molecular 
imaging strategies have already permitted detection of single cells in vivo, such 
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as preloading of cells with iron oxide nanoparticles for detection on MRI (5). In 
this case, the single cell detection limit of iron oxide nanoparticles has repeatedly 
been validated at various field strengths, in a number of cell types including 
cancer cells directed to the brain for metastasis modelling (6, 7), mouse 
embryonic cells for tracking developmental cell migration (8), primary 
hepatocytes for transplant quality assurance (9), antigen-specific cytotoxic 
lymphocytes for targeting tumours (10), and mesenchymal stem cells for 
regenerative medicine (11). Although cellular pre-loading methods with PET have 
a limited timeframe due to radioactive decay, dynamic in vivo tracking of a single 
cell on PET was very recently demonstrated using 68Ga-labeled mesoporous 
silica nanoparticles: a single pre-labelled cancer cell was injected into the tail 
vein of a mouse, where its velocity in the bloodstream was tracked until its arrest 
in the lungs (12). The sensitivity of more traditional targeted probe methods for 
PET is highly variable and depends greatly on probe design, but the most well-
designed PET probes in recent years have exhibited detection thresholds on the 
order of 104 cells  (13-15).  
Reporter genes offer increased accuracy and sensitivity for monitoring of 
cell trafficking, proliferation, and persistence over long periods of time, relative to 
ex vivo cellular labelling methods (16). The sensitivity of a reporter gene in a 
particular experiment depends on a number of variables which may vary from 
study to study, including the efficiency of transfection or transduction, the 
promoter regulating its expression, and, in relevant cases, the bioavailability of 
the imaging probe to the reporter protein. Accordingly, studies employing 
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constitutive promoters and stable transfection or transduction methods would be 
able to provide information on sensitivity with optimized conditions. Recently, 
single cell bioluminescence imaging in vivo was demonstrated with a red-shifted 
luciferase-luciferin system (17). However, on more traditional luciferase systems, 
as few as 101 cells can be detected at the skin surface, whereas 106 cells would 
be required at depths of 2 cm due to light attenuation by surrounding tissues 
(18).  
With respect to clinically-relevant modalities, a comparative analysis of 
several established PET reporter genes, including the human sodium iodide 
symporter (hNIS), the human norepinephrine transporter (hNET), the human 
deoxycytidine kinase double mutant (hdCKDM), and the herpes simplex virus 
type 1 thymidine kinase (hsvTK), revealed detection limits between 105 to 106 
cells (19). With MRI, experimental evidence suggest that the detection limit of the 
ferritin reporter gene may fall above 105 cells in vitro at lower field strengths 
(4.7T) (20), but can go as low as 104 cells at high field (11.7T), as demonstrated 
in vivo by scientists from Carnegie Mellon University (21). In perspective, the 
estimated in vivo detection limit of 104 cells at 3T presented by Oatp1b3 in deep 
tissues is highly competitive, especially when combined with the positive 
contrast, high resolution, high specificity, and detailed anatomical information that 
are also provided by the system.   
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5.2.2 Unintended Effects on Biology by Reporter Genes 
The ideal reporter gene would provide detailed high resolution information, 
with biologically and statistically significant signal-to-noise, high specificity to the 
target of interest, and importantly, minimal effects on baseline physiological 
processes, so as not to alter, confound, and/or cause toxicity to the biology being 
studied (22). Two levels of reporter gene effects exist: 1) the method of reporter 
gene delivery, a necessary step in cellular engineering, that is relatively 
independent of the specific reporter gene used in a study; and, 2) any toxic or 
undesired biological effects caused directly by the reporter protein encoded by 
the gene introduced into the cell, which is highly dependent on the identity of the 
specific reporter system used in a study. The means of reporter gene delivery 
can be divided into methods that result in either transient expression of the 
reporter gene, i.e. extrachromosomal, or integrating methods that result in a 
stable cell line (23).  
The studies presented in this thesis use lentiviral methods to integrate the 
reporter gene into the host genome, which is a sub-class of retrovirus that can 
infect both proliferating and non-proliferating cells, and generates a relatively low 
immune response in target cells (24). This approach is efficient with respect to 
transporting the reporter gene to its final destination in the genome. However, its 
drawback is that integration occurs at preferentially-problematic positions in the 
genome e.g. near transcriptional start sites, within transcriptional units, (25) and 
has been previously been shown to result in disruption of important genes (26). 
Lentiviral gene delivery could potentially confound results, as any engineered 
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cells used in a study should ideally match the physiological behavior of the 
original cell population.  
Alternatively, the reporter gene product itself could potentially interfere 
with vital biochemical pathways and also lead to the generation of engineered 
cells with marked phenotypic differences relative to their ancestral cell 
population. For example, one study that focused on the toxic effects of GFP and 
LacZ revealed that engineered neuronal cells exhibited morphological differences 
in vitro relative to control cells, including long processes which eventually 
fragmented, smaller rounded cell bodies typical of dying cortical cells, as well as 
rapid decreases in fractions of viable engineered cells over passaging intervals 
(27). Although reporter gene-associated toxicity was observed in vitro, long term 
expression of reporter genes in vivo was more readily sustained, likely due to the 
presence of factors within the complex in vivo environment that provide support 
and protection to the engineered cells (27).  
In our own studies, in vitro proliferation rates of Oatp1a1- and Oatp1b3-
engineered cells were measured over time and found to not be significantly 
different from those of their parental cell counterparts. Additionally, qualitative 
observations of cell morphology did not indicate any biologically significant 
changes in cellular structure and in vivo growth rates of Oatp1-engineered breast 
cancer cells did not significantly differ from control tumours. Notably, the 
metastatic potential of the Oatp1b3-engineered MDA-MB-231 breast cancer cell 
line in mice was in close agreement with animals burdened with control MDA-
MB-231 luciferase control cells, as well as previously published timeframes of 
 205 
studies employing the same cell line and preclinical animal model (28). However, 
more thorough experiments may be warranted to study specific effects of 
Oatp1a1 and Oatp1b3 expression on baseline biochemical processes and 
phenotypes such as resting membrane potential. It is assuring that some Oatp1 
transporters with significant ligand overlap relative to Oatp1a1 and Oatp1b3, e.g. 
human Oatp1a2, have widespread tissue expression (29).  
 
5.2.3 Gadolinium Toxicity and Dose  
Another aspect to consider when using reporter genes is the potential 
toxicity of the reporter gene’s paired imaging probe. For our photoacoustic 
reporter gene system described in Chapter 4, indocyanine green is already a 
widely used contrast agent and has had longstanding approval for clinical use at 
comparable concentrations to those used in our preclinical Oatp1b3 study (1), 
and did not appear to have any effect on the proliferation rates of cells in vitro. 
Although gadolinium-based contrast agents have also been granted clinical 
approval for some time now, including the Gd-EOB-DTPA compound used as the 
imaging probe for Oatp1a1 and Oatp1b3, recent concerns over the biological 
effects of gadolinium have raised serious precautions over their utility in the clinic 
(30). These include long-term retention of gadolinium in brains of patients after 
single doses of gadolinium, the specific effects of which are not yet understood, 
as well as the phenomenon of nephrogenic system fibrosis (NSF), which 
manifests as scarring of the skin and internal organs as a direct result of 
exposure to gadolinium (31, 32).  
 206 
These are not substantial concerns for preclinical studies, like those 
investigated in this thesis: cells in vitro tolerated the gadolinium, as measured via 
viability and growth assays, and cells in vivo developed tumours and metastatic 
lesions at reasonable rates after repeated administration of gadolinium over 
several weeks. The doses of gadolinium used in this thesis (0.1-mmol/kg in 
Chapter 2, 1-mmol/kg in Chapter 4) also fell far below the median lethal dose for 
rodents, that is 10-mmol/kg (33). The challenge, however, lies in the translation 
of this system for clinical tracking of gene- and cell-based therapies in patients, 
which would require a cap on the administered dose of gadolinium. The main 
concern of chelated Gd constructs here comes from dissociation of free Gd3+ 
ions, which then go on to competitively inhibit Ca2+ in a number of physiologically 
important processes, including adenosine triphosphatase (ATPase) (34, 35).  
Under normal circumstances, the chelator allows sufficient clearance of 
Gd-EOB-DTPA (!! "⁄ =	1.8 ± 0.2 hours) before any biologically significant 
dissociation occurs (36). Yet, with Oatp1, Gd-EOB-DTPA remains within 
engineered cells, in the body, for several hours, and it is not yet known whether 
dissociation of free Gd3+ is negligible under these parameters. In Chapter 2, we 
successfully demonstrated that detailed intratumoral distributions of viable cells 
could be mapped out on MRI at a clinically feasible dose of 0.1 mmol/kg. 
However, the sensitivity of this system to track small populations of migrating 
cells at clinically-relevant doses has not yet been assessed. It will be important to 
maximize reporter expression and optimize imaging parameters for enhancing 
the conspicuity of engineered cells in order to minimize gadolinium dose. 
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5.3 Future Work 
5.3.1 Genetic Engineering Methods  
The studies presented in this thesis use lentiviral vectors to introduce the 
gene into the genome and constitutive promoters to express the protein product 
for basic cell tracking purposes. A translational bottleneck, however, is the 
necessity to engineer cells with randomly-integrating vectors. CRISPR (Clustered 
Regularly Interspaced Short Palindromic Repeats) and CRISPR-associated 
(Cas) targeted approaches for knock-in of reporter genes at a genomic safe 
harbor locus may overcome these safety concerns. To date, our group has built 
Homology Independent Targeted Integration (HITI) CRISPR/Cas9 plasmids for 
precise AAVS1-targeted simultaneous knock-in of the Oatp1a1 reporter gene, 
and observed increases in knock-in efficiency at the AAVS1 site using HITI 
vectors compared to traditional homology-directed repair donor vectors (37). 
Characterization of select HITI clones demonstrated significant Oatp1a1-
mediated uptake of Gd-EOB-DTPA, thereby supporting the feasibility of 
introducing Oatp1a1 via safer genetic engineering approaches (37). Further into 
the future, we are integrating the Oatp1b3 reporter gene into increasingly 
complex genetic circuits, so that its expression is activated in response to a 
specific stimulus, rather than having it simply expressed at all times (38, 39).  
 
5.3.2 Manganese Probe for MR Imaging of Oatp1b3 Expression 
With the goal of establishing human Oatp1b3 as a clinical-grade MR 
reporter gene, the pairing of a gadolinium-based contrast agent as its imaging 
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probe may considerably hinder its translation to the clinic, due to concerns over 
toxicity. With this in mind, future work on the Oatp1b3 reporter gene system will 
focus on developing a gadolinium-free manganese-based contrast agent as a 
ligand specific to Oatp1b3. To accomplish this goal, manganese porphyrin 
constructs offer a safe, sensitive, and versatile platform for molecular MRI, but 
little work has been performed to target these agents towards specific molecular 
biomarkers. We hypothesize that addition of an ethoxybenzyl (EOB) group to a 
manganese(III) porphyrin construct would allow for its uptake by cells expressing 
the Oatp1b3 transporter.  
Decreased toxicity of free manganese(III) relative to free gadolinium(III) in 
vivo (40), in combination with increased stability of the manganese(III) porphyrin 
structure relative to gadolinium chelates (41, 42) offer increased safety. 
Additionally, non-porphyrin manganese structures previously developed for MRI 
sacrifice relaxivity for safety (40), but the planar geometry of the porphyrin 
construct allows for water coordination both above and below the plane of the 
agent, leading to increased relaxivity, since relaxivity is directly proportional to 
the number of water molecules coordinated to the paramagnetic label and the 
residency time of the water molecules. In conjunction with the ability to “tune” the 
electron configuration at the paramagnetic center, these properties collectively 
contribute to increased relaxivity of Mn(III)-EOB-TriCP relative to Gd(III)-EOB-
DTPA. Further, the porphyrin backbone offers four locations onto which different 
functional groups may be added to alter important properties such as circulation 
half-life and ligand activity. Promising preliminary data poses the possibility of 
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replacing Gd-EOB-DTPA entirely with Mn-EOB-TriCP, pending future work 
focused on comparing enhancement of Oatp1b3-expressing cells in vivo 
between Mn-EOB-TriCP and Gd-EOB-DTPA in animals, as well as assessing in 
vivo biodistribution, demetallation and toxicity of Mn-EOB-TriCP. 
 
5.3.3 Syngeneic Reporter Gene Systems 
A separate issue is that introduction of a foreign protein into the preclinical 
animal model may elicit an immune reaction from the host, such that reporter 
gene expression becomes inconsistent, suppresses tumour growth, limits 
metastasis, and/or leads to therapeutic response misinterpretations (43). To 
circumvent this issue at the proof-of-principle stage, immune-compromised 
animal models were used to assess and characterize the Oatp1 reporter gene 
system in this thesis. In the future, however, we hope to develop a syngeneic 
reporter gene approach for cell tracking. In essence, we hope to develop mouse 
Oatp1a1 for murine cell tracking in immune-competent mouse models, rat 
Oatp1a1 for rat cell tracking in immune-competent rat models, and human 
Oatp1b3 for cell tracking in humanized animal models (44). In theory, any T cells 
that would have reacted to the reporter protein should have been negatively 
selected and eliminated during immune system development. Future work will 
focus on developing these systems and quantifying differences between reporter-
expressing cells relative to non-reporter expressing cells. In combination, with 
new genetic engineering methods (Section 5.3.1), a gadolinium-free manganese 
probe for imaging (Section 5.3.2) and a syngeneic reporter gene scheme 
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(Section 5.3.3), we hope to develop the Oatp1 reporter gene as a safe, 
sensitive, non-confounding imaging system for cell tracking in preclinical animal 
models, as well as cell tracking of gene- and cell-based therapies in human 
patients down the line.  
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